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Abstract
Mutations are common events in the human genome, arising by a variety of
mechanisms (i.e. slippage or mispairing during DNA replication, and via mutagens).
This is further complicated by the fact that there may be inherent sequence-specific
instability or genomic instability, and defective DNA repair may compound this.
APC is a key "gatekeeper" gene in colorectal tumourigenesis, with the majority of
cases harbouring inactivating mutations. To study the role of instability in colorectal
cancer, this project focussed on investigating any inherent sequence-specific
mutation frequency of the APC gene. I used an approach where clonal selective
advantage imparted by APC mutation is avoided, and have utilised a number of
cancer and non-cancer cell lines, and patient tissue samples. As deficient DNA repair
has been implicated in a number of CRC conditions, I have also investigated the
effect of defective DNA mismatch repair (MMR) and base excision repair (BER) on
APC mutation frequency and spectrum. In addition, I have also begun to develop a
novel technique for directly measuring BER activity in live cells.
I show elevation of mutation frequency in the APC gene compared to control gene
sequences. Polymorphism and evolutionary data indicate that APC is likely to be
subject to a high neutral mutation rate and purifying selection. Furthermore, detailed
analysis of de novo APC mutations has not implicated the involvement of any
alternative mutational mechanisms such as CpG island methylation. Additional work
is required to further characterise the possible sequence instability observed in these
normal cells.
In patient samples a striking effect of germline MUTYH mutation on APC mutation
spectrum was observed in tumour samples, and the consequence of bi-allelic
inactivation of MUTYH on somatic inactivating mutations in APC and K-ras was
clear.
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The findings presented in this thesis provide new understanding of early molecular
events during tumourigenesis, and how they are affected by defects in DNA repair
systems, in particular BER and MMR.
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I.1 Overview of colorectal cancer
In developed countries the incidence of colorectal cancer (CRC) is second only to
lung cancer (Pisani et al., 1999). Data from the American cancer society
(www.cancer.org) indicates that in the USA in 2006 there will be 148,610 new cases
of colorectal cancer and 55,170 deaths.
In the UK, the population lifetime risk of developing a large bowel malignancy is 1
in 25 (Dunlop, 1997). Each year CRC causes more than 20,000 deaths in the UK
(Farrington and Dunlop, 2004). Locally, in 2003 CRC was the third most frequently
diagnosed cancer in both sexes in Scotland, accounting for 14.7% of all male and
II.3% of all female cancers (www.isdscotland.org). CRC is associated with a
relatively poor survival rate; in the period 1997-2001 approximately 50% of patients
survived five years post-diagnosis (compared with -77% of breast cancer sufferers)
(Scottish Health Statistics, 2006).
Diet and lifestyle appear to have a large influence as to whether an individual
develops CRC, with industrialised countries having an incidence that is fifteen times
higher than in developing countries (Parkin et al., 1999). The majority of cases of
CRC are sporadic, but there is also a heritable component. A malignant tumour arises
as a result of multiple interactions between environmental factors and personal
genetic factors. Individuals with a first degree affected relative have been shown to
have a three fold increased risk of developing adenomatous polyps (pre-malignant
lesions) compared with a control population (Bonelli et al., 1988). Epidemiological
evidence of a genetic impact on CRC has also been provided by a large Scandinavian
twin study (Lichtenstein et al., 2000). A statistically significant effect from genetic
1
factors on the risk of acquiring CRC was observed, with heritability estimated at
35% (95% CI 10-48%).
CRC is clearly a major public health problem, with the estimated annual cost of
treating confirmed cases in Britain exceeding £200m (Dunlop, 1997). Research to
elucidate the causes of CRC, and potential preventative therapies are of the utmost
importance. There are a number of different areas of research that are thought to have
the potential to lead to future developments in the treatment of CRC. These include
the identification of new susceptibility/modifier genes, and genetic alterations in
tumours, peripheral blood, lymph nodes and bone marrow that will predict prognosis.
These will ultimately allow the development of drugs for treatment and prevention,
including the potential use of gene therapy to target treatment to tumour cells, and
the use of population based genetic screening to target high-risk individuals (Dunlop,
1997).
2
1.2 Environmental factors in Colorectal Cancer
The high incidence of CRC in western populations is believed to be primarily due to
diet and environment. In 1990 the area with the highest estimated rate of colorectal
cancer mortality was Australia and New Zealand (30.3 deaths per 100,000
population). Conversely, the area with the lowest estimated rate was middle Africa
(0.8 deaths per 100,000 population) (Pisani et al., 1999). Further evidence comes
from migrant populations from low incidence countries, who on adoption of the diet
of a high incidence country, soon (within one generation) develop the same rate of
CRC as natives of that country (Pisani et al., 1999). As such, CRC is a highly
preventable form of cancer, and much research has been earned out to deduce what
environmental (diet and lifestyle) factors might increase the risk of developing CRC;
reviewed in (Gertig and Hunter, 1998) and (Gatof and Ahnen, 2002). Comparisons of
diet and CRC incidence amongst different populations report a positive relationship
between the high consumption of meat, protein, and fat, and an inverse relationship
with the consumption of plant fibre. Table 1.1 provides a summary of the findings
from the most significant case-control and cohort studies into the effect of
environmental factors on CRC carried out to date.
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Table 1.1 Summary of case-control, and cohort studies investigating the relationship




Effect stronger in males, BMI>30 gives twofold increased
risk
Physical Activity Negative





Diet high in simple sugars may also be deficient in
protective nutrients.
Carbohydrate-
starch Negative Resistance may be due to fermentation in large bowel
Fat Positive Relative risk of 1.2 in patient's with highest fat intake
Meat Positive Carcinogenic heterocyclic amines may be formed during
cooking.
Fibre Negative Increases stool bulk and water, reducing gut transit time.
Fruits & Vegetables Negative Most consistently seen dietary relationship
Alcohol Positive Modest risk
Calcium & Vitamin D Negative
Selenium Negative May induce apoptosis in a similar way to Non steroidalanti-inflammatory drugs (NSAIDs)
Vitamin E Negative
Carotenoids Negative
Folic Acid Negative May counteract positive effect of alcohol
Vitamin C Inconclusive
Tobacco Positive 2 to 4 fold increase in risk
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There has been much evidence to suggest that long-term Non-steroidal anti¬
inflammatory drug (NSAID) intake can reduce the risk of developing CRC; reviewed
in (Williams et al., 1999). Additionally, adenomas have been shown to regress after
oral and rectal administration of NSAIDs (Giardiello et al., 1993). The anti¬
neoplastic effects of NSAIDs, including aspirin, may be due to their inhibition of
Cyclooxygenase (COX) enzymes (Williams et al., 1999). Cox-2 has been shown to
be over expressed in 80-85% of adenocarcinomas (Eberhart et al., 1994). An
alternative mechanism has been proposed that involves the NF-kB pathway.
Activation of NF-kB by aspirin is a pro-apoptotic event (Stark et al., 2001), mediated
by the sequestering of its p65 component within the nucleolus (Stark and Dunlop,
2005). Unfortunately, the long-term use of aspirin has side effects, including
gastrointestinal bleeding. Research is therefore currently looking into alternative
NSAIDs such as Sulindac (Matsumoto et al., 2006).
These dietary, lifestyle and chemopreventative factors play a role along side the
genetic pathways that lead to sporadic CRC (see section 1.3). The evidence for an
environmental basis for CRC is often unclear, with different studies of the same
factor showing contradictory affects. Therefore, gene-environment studies that
consider both variables may provide a better insight into the role of environmental
factors and how they effect different genetic states. For example, dietary factors that
have previously been shown to be associated with colorectal cancer risk have been
investigated to specifically determine their influence on the occurrence of somatic
inactivating mutations in the APC gene (Diergaarde et al., 2003). The study found
that vegetable consumption was protective against both APC mutation-positive and
mutation-negative CRC. On the other hand, alcohol consumption was inversely
associated with APC mutation-positive CRC, whilst meat, fish and fat consumption
were positively associated with mutation-positive CRC. Also, the effect of low
penetrance polymorphisms in enzymes involved in the metabolism of colon
carcinogens has been studied. N-Acetyltransferase (NAT) is involved in the
metabolism of cigarette-related carcinogens, and its activity is determined by
polymorphisms that cause people to be classified as either 'fast' or 'slow'
acetylators. Rapid acetylation at the NAT locus has been associated with an increased
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risk of developing CRC, due to the activation of substrates that are carcinogenic
specifically in the colonic epithelium during rapid, but not slow acetylation (Gertig
and Hunter, 1998).
Hereditary colorectal cancer syndromes (including FAP, MAP and HNPCC, see
sections 1.5 and 1.6) account for about 5% of all CRCs (Fearnhead et al., 2002).
Clearly, this falls significantly short of the estimated level of heritability (-35% as
indicated by an epidemiological twin study, (Lichtenstein et al., 2000)). As yet
undiscovered genetic susceptibility factors are therefore presumed to account for the
remaining 30% of cases caused by heritable factors. The remaining 65% of cases
arise as a result of the interplay between environmental factors (some of which have
already been identified) and the molecular events occurring within the cell. Lamlum
et al. estimate that -10% of individuals with multiple adenomas (but not a classical
FAP phenotype) have inherited APC variants (i.e. subpolymorphic missense
mutations, or mutations at the extreme 5' or 3' end of the gene) that may act alone, or
via interaction with other environmental/genetic factors to cause CRC (Lamlum et
al., 2000a). Even within individuals with the same CRC syndrome (genotype) great
differences can be seen in phenotype. This is due to the vast number of
environmental modifying factors involved, and the differences in underlying genetic
make-up between individuals (Ilyas et al., 1999). To help understand these
relationships further, mouse models can be useful, and these will be discussed in
detail in section 1.9.
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1.3 Selection and Mutation in Tumourigenesis
Colorectal cancer arises as the cumulative effect of mutations that inactivate tumour
suppressor genes and activate oncogenes within the cell, thus allowing it to escape
growth and regulatory control mechanisms (inactivation of genes can also occur via
epigenetic changes, this is discussed in section 1.8). This step-wise progression of
mutations facilitates the histological transition from normal mucosa to adenoma,
carcinoma and finally metastasis (Fearnhead et al., 2002).
A number of different models have been proposed to explain this accumulation of
mutations during tumourigenesis. The most frequently cited model is of clonal
evolution. As mutations occur largely in a random fashion, occasionally a mutation
will arise that confers a relative survival advantage to the cell (i.e. allows the cell to
evade growth controls or apoptosis). Clonal expansion follows, with a rapid increase
in the number of cells harbouring the selective advantage. At this early stage,
expansion of the developing clone depends on the rate of cell proliferation out¬
matching the rate of cell death. Therefore, the sequence of acquired mutations in the
developing tumour reflects the specific constraints that are rate limiting at different
stages during tumour evolution (i.e. rate of proliferation). Subsequently, when
another mutation occurs in one of the clones allowing it to escape additional
constraints, further clonal expansion can occur. Later mutations tend to have
different functions to those occurring early in the tumourigenic process, with a
similar order of mutations in most tumours.
An alternative idea to an ordered progression of mutations during the tumourigenic
process is the pre-tumour progression model (Calabrese et al., 2004a). It suggests
that the accumulation of mutations may in fact precede tumour progression,
occurring in normal appearing colonic crypt niche cells. Mutations are proposed to
accumulate within the stem cell population, evolving clonally as multiple stem cells
compete for dominance. Eventually, a mutation combination will convert a stem cell
into a tumour cell, and visible tumour progression ensues. Using the number of
microsatellite mutations present in tumour samples, Calabrese et al. calculated the
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age at which MMR loss had occurred in a series of patients (Calabrese et al., 2004b).
Controversially, they deduced that MMR loss was in fact a late (fifth or sixth) step in
the tumourigenic process, as opposed to an early event that leads to increased
mutation rate, and therefore subsequent oncogenic mutations.
Most recently a third model has been proposed. Using molecular evolutionary
methods to quantify diversity in oesophageal adenocarcinoma, Maley et al. provide
evidence for a multilineage persistence model (Maley et al., 2006). Showing that
lesions with greater clonal diversity are significantly more likely to progress to
cancer, the model states that variation is a pre-requisite for tumourigenic progression.
In the clonal evolution model, when a single lineage dominates a cell population due
to the acquisition of an advantageous mutation, clonal diversity is reduced. Thus,
diversity implies a lack of clonal evolution. In the multilineage persistence model
however, multiple lineages accumulate mutations (increasing diversity). This
increases the chance that one lineage will collect all the mutations required for
neoplastic transformation, compared with cells that are undergoing sequential
selection.
Within the colon, early mutations are presumed to occur within the stem cell
populations of the colonic crypts. It is assumed that mutations occurring in
differentiated epithelial cells would be lost due to the rapid turnover of cells within
the colon, before there is sufficient time for further mutations to accumulate
(Leedham et al., 2005). Work by Komarova et al. has disputed this idea (Komarova
and Wang, 2004). Using mathematical modelling they suggest a role for
differentiating cells in cancer initiation. Although differentiated migrating cells are
short-lived, there are a large number of them compared with the number of stem
cells. Therefore, it is likely that some will accumulate more than one relevant
mutation leading to tumourigenesis.
As discussed in more detail in sections 1.6 and 1.11 the loss of 'genomic stability'
can provide a permissive environment for mutations leading to tumourigenesis to
occur. For example, loss of mismatch repair or base excision repair dramatically
8
increases the cellular mutation rate of the genome. Microsatellite instability (MSI),
arising as a result of the loss of DNA mismatch repair is observed in -15% of all
colorectal cancers (Grady, 2004). MSI generates mutations in important genes that
contain microsatellite repeats, such as TGFJ3R2, BAX, IGFR2 and TAF1B
(Markowitz et al., 1995;Ouyang et al., 1997;Rampino et al., 1997b;Kim et al.,
2002;Woerner et al., 2005). If MSI is an early event in tumourigenesis it can
therefore alter the type and location of subsequent mutations (Olschwang et al.,
1997).
Selection pressure represents a major driving force in tumourigenesis. The genetic
pathway that a tumour develops along will be influenced by the selection pressures
of the tissue in which it develops. Likewise, different tumours in the same patient are
likely to grow at different rates because different oncogenic genotypes do not confer
identical selective advantages (Kinzler and Vogelstein, 1996).
There are many stages in the progression of CRC, from normal colonic epithelium to
metastasis. The first change is the formation of aberrant crypt foci (ACF's), small
areas of epithelium with irregular glandular architecture. Histologically, an
adenomatous polyp or adenoma is derived from an ACF. The presence of many
hundreds of polyps is characteristic of FAP (see section 1.5), where there are too
many to be removed surgically, and so typically the whole colon is removed. The
chance of developing polyps also increases with age in non-FAP individuals; by the
age of 70 years, approximately half of individuals living in western populations will
have developed polyps (Fodde et al., 2001b). If adenomatous polyps are left
untreated, cells show increasing levels of dysplasia, followed by a malignant change
that results in local invasion and eventually metastasis to distant sites (Vogelstein et
al., 1988). Figure 1.1 shows the simplified genetic model of multi-step
carcinogenesis within the colon.
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DCC
APC KRAS SMAD4 P53
Figure 1.1 Progression of colorectal cancer, with the predicted number of mutational 'hits'
required to progress from healthy intestinal tissue to a carcinoma/metastasis. APC mutations
are thought to initiate the neoplastic process, and are sufficient for colorectal tumours to
grow to at least 1cm in diameter (Lamlum et al., 2000b). KRAS oncogene mutation is an
important early genetic alteration (Vogelstein et al., 1988). Single base pair mutations in this
gene can transform cultured cell lines in vitro (Land et al., 1983). DNA repair deficiencies will
speed up the progression through each stage, by increasing the likelihood of mutations
occurring.
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1.4 Role of APC
As discussed in section 1.3 inactivation of the Adenomatous polyposis coli (APC)
gene is an early, rate-limiting event in colorectal cancer. This section will look in
more detail at the many functions of the APC protein. The APC gene was identified
as the gene responsible for FAP in 1991 (Groden et al., 1991). It is a large (8535 bp)
gene, located at chromosome 5q21, and coding for a 2843 amino acid
multifunctional protein. The gene consists of 15 main exons (21 if all alternative
exons are included), with exon 15 comprising over 75% of the coding sequence
(Bright-Thomas and Hargest, 2003) (Figure 1.2). APC is expressed in a variety of
epithelial and mesenchymal cells, including colon, breast, lung and lymphoid tissue
(Sieber et al., 2000). There is known tissue specific expression of alternative
transcripts, with at least five different forms of 5' non-coding sequences generated by
alternative splicing (Horii et al., 1993). Internal translation initiation is also possible
at codon 184 in genes mutated at the 5' end of the gene (such individuals often have
an attenuated FAP phenotype, see section 1.5) (Heppner et al., 2002).
The APC protein has roles in the control of WNT signalling (Figure 1.3), cell
adhesion and migration, apoptosis, and chromosome segregation at mitosis (Fodde et
al., 2001b)((Fodde et al., 2001a).
Exons 1-14 Exon 15
[
Oligomerization






amino acid repeats (green)




Figure 1.2 Schematic representation of the gene organisation and protein structure of APC.
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Figure.1.3 The Wnt signalling pathway. When the external signal WNT/Wingless binds to its
cell surface receptor frizzled, it causes inactivation of the protein kinase glycogen synthase
kinase 3p (GSK3P) (the WNT signal plays a role in intercellular communication, controlling
cell fate decisions). GSK3P, Axin, p-catenin and APC form a large protein complex within the
cytoplasm (shown in red). In the absence of WNT signalling, GSK3P phosphorylates APC
and p-catenin within the complex, signalling the ubiquitin mediated degradation of p-catenin.
APC acts as a scaffold protein for the complex, and when it is mutated, or when there is a
WNT signal, p-catenin is no longer down-regulated, and is free to translocate to the nucleus
and activate TCF-4 (Nathke, 1999). TCF-4 (T-cell factor-4) is a member of the high mobility
group (HMG) box transcription factors, activating genes involved in cell proliferation and
apoptosis, including those coding for Cyclin D1 and the oncogene C-myc. Activating
mutations in the oncogene CTNNB1, and AXIN also cause constitutively activated TCF-4,
but these occur very rarely in CRCs compared with APC mutations. APC and CTNNB1
mutations are thought to be mutually exclusive (Sparks et at., 1998).
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(3-catenin also has many roles in the cell, including those involved in tissue
architecture and polarity; (3-catenin provides the link between E-cadherin, and a-
catenin at adheren junctions, that form and maintain the contact between epithelial
cells. An increase in the free cytoplasmic pool of (3-catenin therefore also increases
cell migration.
Evidence suggests that APC has a role in the control of chromosome segregation, a
process that ensures that the correct numbers of chromosomes are present in each
daughter cell after mitosis. This is of interest because the majority of CRCs are
aneuploid (Giaretti et al., 2004;Cardoso et al., 2006). This role of APC in
chromosome segregation and stability, may therefore partly explain the aneuploid
phenotype in CRC. APC accumulates at the chromosome kinetochore where it
facilitates the binding of spindle microtubules (Fodde et al., 2001b). In the absence
of a functional C-terminal APC microtubule-binding domain (see Figure 1.2), often
lost due to truncating APC mutations, an aneuploid/CIN phenotype may occur
(Kaplan et al., 2001) (discussed in more detail in 1.11). Loss of microtubule spindle
structure due to truncating APC mutations can only be rescued by APC protein that
contains the missing microtubule binding domain (Dikovskaya et al., 2004). The
microtubule binding role of APC means that it also has a number of other important
links with the cytoskeleton. Lack of APC microtubule binding affects cell migration,
due to loss of interaction of APC and microtubules, and also because of the dominant
effects of isolated N-terminal fragments of APC on the F-actin cytoskeleton (Nathke,
2005). Disruption of the microtubule stabilising role has been offered as an
explanation for the role of APC in polyp formation in patients with truncating APC
mutations. Such cells would have compromised migration within the gut, and will
consequently be increasingly exposed to toxins for greater periods of time (Nathke,
1999). It is important to note that the cell adhesion and migration functions of APC
protein are closely related, and therefore extremely difficult to separate.
The role of APC in proliferation and apoptosis is under some debate, however a
number of studies indicate a role for mutant APC in the characteristic tumour traits
of increased cell proliferation, and decreased apoptosis. The APC/(3-catenin/TCF-4
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signalling pathway controls the expression of the anti-apoptotic protein Survivin.
Zhang et al. demonstrated that wild type (WT) APC down regulates Survivin
expression through TCF-4, allowing APC to regulate the size of stem cell
populations within intestinal crypts (Zhang et al., 2001). When APC is mutated,
control is lost, and stem cell populations are free to expand without control. It is
interesting to note that as a component of the multi-protein complex Cohesin,
Survivin also localises at centromeres. Sister chromatid cohesion until the
metaphase-anaphase transition is essential for post-replicative DNA repair by
homologous recombination and equal chromosome segregation. Unregulated
Survivin may therefore also contribute to genome instability observed during colon
tumourigenesis by disrupting the cohesin protein complex (Morrison et al., 2003).
The unregulated transcription of other genes such as MDR-1, C-myc, and Cyclin D1
in combination, have also been proposed to give rise to proliferating intestinal cell
lineages, where normal programmed cell death pathways are suppressed (Yamada et
al., 2000).
Over-expression of WT APC in fibroblasts has been shown to slow the progression
of the cell cycle (Baeg et al., 1995). Three possible explanations for this observation
have been offered. Firstly, it may be due to the binding of the carboxy terminal end
of APC to 'Discs Large Gene' (DLG) (Matsumine et al., 1996). DLG is a tumour
suppressor protein thought to be involved in cell cycling. Secondly, it has been
proposed that a role in cell cycle progression could be mediated by interaction with
both the cytoskeleton and DNA (via the (3-catenin/TCF-4 pathway) (Friedl et al.,
1996). Thirdly, control could be via the (3-catenin/TCF-4 pathway alone. TCF-4
drives transcription of Cyclin D1 which is over expressed in many colorectal cancers,
and is rate limiting for progression through the cell cycle (Arber et al., 1996).
The many different domains of APC, as demonstrated in Figure 1.2, result in a
diverse range of roles of the protein within the cell. As APC mutation is the first and
rate limiting event in colorectal tumourigenesis it is likely that the different roles of
APC within the cell contribute to colorectal cancer progression at many different
stages. APC's role in cell migration may be involved in early polyp formation, while
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the inability of mutant APC to decrease levels of intracellular (3-catenin is likely to
contribute to a variety of stages. Whilst all aspects of the multifunctional APC
protein are likely to contribute to colorectal tumour formation, and progression, it is
APC's tumour-suppressor role in the regulation of intracellular (3-catenin levels, that
is thought to be its most important function (Fodde, 2003), Figure 1.3.
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1.5 FAP
Familial adenomatous polyposis (FAP) (MIM175100) is an autosomal dominant
CRC condition with -100% penetrance. The frequency of the disease has been
estimated to be 1 in 13,528 births (Bisgaard et al., 1994). FAP is caused by a
germline inactivating mutation in the APC gene, and is characterised by the
development of hundreds to thousands of polyps within the colon. Due to this high
polyp burden, the age at diagnosis of CRC is 20-50 years, much earlier than in
sporadic CRC. Additionally, extra-colonic manifestations can include Congenital
Hypertrophy of the Retinal Pigment Epithelium (CHRPE), desmoid, adrenocortical
and upper gastrointestinal tumours (Miyaki et al., 1995). In addition to the classical
form of FAP, an attenuated form exists (AFAP), this is generally characterised by the
development of less than 100 adenomatous polyps, and delayed age at cancer onset
(Friedl et al., 1996).
An APC database of all published mutations was made available in 1996 (Beroud
and Soussi, 1996), with 700 germline and somatic mutations listed. 98% of mutations
within the database were either nonsense (30%) or frameshifts (68%) leading to
truncation of the APC protein. Germline mutations were scattered throughout the 5'
half of the gene, with two hotspots noted at codons 1061 and 1309. A search of the
most recent release of the APC database (Thierry Soussi, 2004) reveals that 978/999
(98%) of listed mutations leading to a FAP phenotype are either nonsense or
frameshifts that lead to premature termination. Mutations leading to AFAP tend to
occur at the extreme 5' end, i.e. the first four exons of the gene, facilitating internal
translation initiation, so that the 5' end of the protein remains intact (Heppner et al.,
2002). Mutations have also been reported towards the 3' end of the gene, where
desmoid disease is also associated with APC mutations (Eccles et al., 2001)
Generally the effects of germline missense mutations in APC are not well understood
and they are rarely believed to be causative in FAP patients. Germline missense
variants of the APC gene have however been studied to determine if they may
explain why some individuals are predisposed to colorectal adenomas, but don't have
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a clear FAP phenotype (Lamlum et al., 2000a). The APC variants I1307K (in Jewish
populations) and E1317Q (in Caucasian populations) have been found to be
significantly associated with multiple colorectal adenomas, and weakly with CRC.
I1307K acts as a pre-mutation, by creating a small, unstable segment of DNA,
indirectly causing cancer predisposition by facilitating the development of somatic
mutations (Laken et al., 1997;Zauber et al., 2003). Although some evidence suggests
that E1317Q has some direct pathogenic effect, how it exerts this effect is unclear.
The mutant amino acid may also be acting by increasing the selective advantage of
other APC mutations. Alternatively, the wild-type amino acid may play a role in
maintaining the structure of the f3-catenin binding and degradation repeats (Laken et
al., 1997;Lamlum et al., 2000a). No other germline missense changes in APC have
been shown to be positively associated with CRC.
As well as truncating mutations, FAP has also been shown to result from genomic
rearrangements/constitutive haploinsufficiency of APC (Su et al., 2000;Sieber et al.,
2002;Venesio et al., 2003). In 2002 two different genomic deletions that
encompassed the whole of APC exon 15 were described in two unrelated individuals
(Su et al., 2002). Interestingly, one patient had a classical FAP phenotype, whilst the
other presented with AFAP. This study underlines the complexities involved in
correlating APC mutation with FAP phenotype. A Belgian study in 2005 used
Multiplex Ligation-dependent Probe Amplification (MLPA) and Fluorescent In-Situ
Hybridisation (FISH) to examine patients with classical FAP in whom no truncating
APC mutation could be found (Michils et al., 2005). They found that 15% of patients
with classical FAP have a large deletion of the APC gene, accounting for a
significant proportion of those that were previously mutation-negative. There is
strong evidence therefore that genomic rearrangement is a common type of APC
mutation, and partly explains why conventional mutation screening of individual
exons by PCR cannot always identify a pathogenic mutation. Additionally, studies
have looked in more detail at the APC inactivating mutations in CRC; Bertario et al.
examined the relationship between the severity of FAP and the position of the
inherited mutation within the APC gene (Bertario et al., 2003). They revealed that
APC mutation sites can be grouped into three sequential subgroups, to identify FAP
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patients at high risk of major extra colonic disease. Their results confirmed previous
studies suggesting that the common 5bp deletion at position 1309 is associated with a
severe phenotype and early CRC development (Caspari et al., 1994).
The dosage effect, which results from having only one functional copy of APC
increases an individuals likelihood of developing polyps (Yan et al., 2002), but a
second, somatic event must occur for progression to CRC (see section 1.7). This
second, somatic event may be loss of heterozygosity (LOH), consistent with
Knudson's 2-hit model; the remaining wild-type APC allele is lost, and so only 1
mutant APC allele remains, or a secondary mutation in the remaining APC allele is
possible. A third possibility is that mitotic non-disjunction can occur, so that
daughter cells become hemizygous for the mutant copy of APC. Somatic APC
mutations will be looked at in more detail in section 1.7.
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1.6 Cancers associated with DNA repair defects
As well as mutations in oncogenes (i.e. KRAS, BRAF and C-Myc) and tumour-
suppressor genes (i.e. APC and p53), a third class of genes, involved in DNA repair
and maintaining genomic stability can also contribute to tumourigenesis and
susceptibility. Germline mutations in APC account for <0.1% of CRC's, although
85% of tumours have somatic APC mutation. In contrast, cancers associated with
loss of DNA repair systems account for -15% of all cancers, and are therefore much
more prevalent than APC in the germline (>5%).
1.6.1 Mismatch repair
Hereditary non-polyposis colorectal cancer (HNPCC) (MIM120435) accounts for 5-
8% of CRC cases (Lynch and de la Chapelle, 1999). HNPCC is an autosomal
dominant CRC condition caused by a deficiency in post-replicative mismatch repair
(MMR). Affected individuals carry one mutant copy of a MMR gene, and as with
FAP (section 1.5) further somatic events induce early onset cancer (Zhang et al.,
2006), most frequently of the colon, but without the characteristic polyps of FAP.
HNPCC is associated with an 80% lifetime risk of developing CRC, and 60% risk of
developing endometrial cancer (Dunlop et al., 1996;Aarnio et al., 1999). In addition,
HNPCC patients are susceptible to other extra-colonic cancers such as endometrial,
ovarian, small bowel, sebaceous, central nervous system, ureter and renal pelvis
cancer (Watson and Lynch, 1993).
MMR was first described in Escherichia coli, where three proteins; MutS, MutL and
MutH act together in a complex to identify DNA mismatches, and initiate repair
(Kolodner, 1996). Much of what is understood about MMR mechanisms in
eukaryotes is based on studies of the prokaryotic system. MutS is an ATPase that
drives mismatch recognition. MutL is also an ATPase, that couples mismatch
recognition to MutS by downstream processing steps and MutH (a methylation
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sensitive endonuclease) is involved in targeting MMR to the newly synthesised













Figure 1.4 Model for mismatch repair of DNA replication errors in E.coli. Adapted from
(Harfe and Jinks-Robertson, 2000). MutS is a 95kD ATPase that acts as a homodimer to
bind base:base mismatches or small insertion:deletion loops (Su and Modrich, 1986). The
25kD endonuclease MutH protein cleaves the unmethylated strand of a hemi-methylated
GATC dam methylation site, thereby introducing a nick in the nascent strand for
exonucieolytic removal and resynthesis (Modrich, 1991a). The precise role of MutL is less
well defined than that of MutS and MutH, however a number of studies have indicated that it
serves as a molecular matchmaker, coupling mismatch recognition and downstream MMR
events, forming a complex with MutS and enhancing ATP hydrolysis (Modrich and Lahue,
1996;Galio ef a/., 1999).
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The function of eukaryotic MMR is best understood in the budding yeast S.
cerevisiae. The human MMR system shares genetic and functional similarities with
this system. In humans there are now known to be 6 MutS homologs (MSH1-MSH6)
and 4 MutL homologs (MLH1, MLH3, PMS1 and PMS2), no MutH homologues have
been identified (Harfe and Jinks-Robertson, 2000). Heterodimers form between
MSH2 and either MSH3 or MSH6, these are known as MutS(3 and MutSa
respectively (Acharya et al., 1996). MutSp is specific for insertiomdeletion
mismatches whereas MutSa binds preferentially to base substitutions and small
insertiomdeletion mismatches (Figure 1.5) (Palombo et al., 1996;Umar et al., 1998).
The redundancy between MSH3 and MSH6 in the repair of insertiomdeletion loops
is suggested to explain the prevalence of MSH2 mutations in HNPCC CRCs over
mutations in the other two MSH proteins.
In S. cerivisae and humans MLH1 is the major MutL homologue and has been
demonstrated to form heterodimers with three other MutL proteins (Figure 1.5)
(Prolla et al., 1994;Li and Modrich, 1995;Lipkin et al., 2000). Interactions between
the MLH1-PMS2 complex and MSH2 complexes have been demonstrated,
suggesting that MLH1-PMS2 acts as a molecular matchmaker, co-ordinating
activities between MSH complexes and downstream MMR events in role similar to
that of MLH1 in bacteria (Figure 1.5) (Prolla et al., 1994;Kolodner and Marsischky,
1999). MLH1-PMS1 heterodimers are referred to as MutL(3, whose role in MMR has
not yet been demonstrated. MLH3 interacts with MLH1 (Lipkin et al., 2000) and its
homology to the yeast MLH3 protein suggests that it is involved in the repair of a
subset of insertiomdeletion mispairs recognised by the MSH2-MSH3 complex
(Flores-Rozas and Kolodner, 1998). The role of the human MLH1-MLH3 complex
remains to be elucidated.
The assembly of MLH and MSH complexes subsequently recruits a number of other
proteins that are not specific to MMR activity but are involved in completing the
later stages of MMR. These include DNA polymerase 5, replication protein A,
proliferating cell nuclear antigen (PCNA), replication factor C (RFC), exonuclease 1,
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Fen 1 and the DNA polymerase 5 and e associated exonucleases (Kolodner and
Marsischky, 1999).
5' - TAGCTGCTA - 3'




5' - GTAGCACACACACACACACACTACG - 3'
3' - CATCGTGTGTGTGTGTGTGTGTTGC - 5'
Insertiorrdeletion loop repair
Figure 1.5 Interaction of human MMR proteins in the repair of base:base mispairs and
insertion:deletion loops. Adapted from references (Kolodner and Marsischky, 1999;Harfe and
Jinks-Robertson, 2000).
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The genetic basis for HNPCC was initially reported by Peltomaki et al. in 1993, who
mapped the first locus to 2pl5-16 (Peltomaki et al., 1993). MMR deficiency in
sporadic and heritable cancer is usually caused by inactivating mutations (or
promoter hypermethylation) mainly in the MLH1 (-50%), MSH2 (-40%), or MSH6
(-10%) genes (Peltomaki, 2001), as these are directly involved in post-replication
repair. MSH3 plays a role in sporadic, whilst PMS2 and PMS1 play a minor role in
both sporadic and hereditary CRC. The other proteins have different roles i.e. MSH4
and MSH5 function in meiosis.
MMR is important in maintaining the fidelity of replication, as well as targeting
repair of mispaired bases from replication errors, homologous replication and DNA
damage. MMR deficiency increases the rate of mutations in tumour cells by 100 to
1000 times over normal cells (Modrich, 1991b). This is highlighted by the
observation of a high frequency of mutations in non-coding microsatellites where
there is no apparent selection pressure (Hienonen et al., 2005). A deficient MMR
system leads to the accumulation of mutations (base-base mismatches, and insertion,
deletion loops) and instability of short tandem repeats (microsatellite instability
(MSI)) within the genome. MSI is a consequence of DNA polymerase slippage and
consequently strand misalignment at repetitive sequences during DNA replication. If
uncorrected, these errors become fixed as a mutation. If post-replicative errors occur
within tumour suppressors or oncogenes they significantly increase an individual's
risk of developing cancer. In addition MMR deficient cells are hyper-
recombinogenic. This is because the MMR system usually imposes a barrier to
recombination, enabling the repair of DNA damage caused by agents such as UV
radiation, reactive oxygen species, and alkylating agents (Schofield and Hsieh,
2003).
MSI is used as an indicator of MMR deficiency in CRC, with >90% HNPCC cases,
and -15% of sporadic CRC's displaying MSI (Liu et al., 1995;Fearnhead et al.,
2002). Inactivating mutations in MMR genes are identified in less than 30% of
sporadic CRC's displaying MSI, in the rest, a role of epigenetic silencing of MLH1
is regarded as more important (Oda et al., 2005). Sporadic tumours with a very high
24
frequency of methylation at the CpG islands in the MLH1 promoter, and at other
sites are known as CIMP (CpG Island Methylator Phenotype) positive (Issa, 2004a).
In HNPCC and sporadic disease repetitive sequences are found within the important
growth control genes TGFJ3R2 (Transforming growth factor (3-receptor 2) and IGFR2
(Insulin growth factor-receptor 2), and genes associated with apoptosis i.e. BAX (Bcl-
2-associated X protein gene) and Caspase5. These are useful indicators of MSI (Oda
et al., 2005). Some genes show a high frequency of frameshift mutations even at the
early adenoma stage of MSI tumourigenesis; 72% of MSI adenomas and 90% of MSI
carcinomas show mutations at a TGFJ3R2 poly(A) tract (Markowitz et al.,
1995;Woerner et al., 2005). BAX is a pro-apoptotic gene containing a poly(G)g tract
in exon 3 (Ouyang et al., 1998). The balance between BAX and Bcl-2 (the antagonist
of BAX) regulates the apoptotic response of the cell to apoptotic stimuli (Pawlowski
and Kraft, 2000). Around 50% of CRCs with MSI have frameshift mutations at the
polyG(8) tract of BAX, creating a diminished ability to trigger apoptosis upon
receiving a death signal (Rampino et al., 1997a). The loss of these apoptotic response
genes in MMR deficient tumours is further compounded by the fact that the MMR
proteins also have their own role in the initiation of apoptosis in response to the
detection to DNA damage (Zhang et al., 1999). Additionally, MMR deficiency
influences subsequent gene mutations during the progression of tumourigenesis.
TCF-4 (see section 1.4) has been shown to be a target gene for frameshift mutations
in MMR deficient colon cancers (mostly sporadic cases), due to its sequence
structure and role in oncogenesis (Peltomaki, 2001). The BRAF V599E missense
change is also associated with MSI colorectal carcinomas (Rajagopalan et al., 2002).
BRAF is a downstream actor of KRAS in the MAPK pathway, and plays a key role
in the oncogenesis of melanoma and CRC (Davies et al., 2002). Despite the fact that
the V599E BRAF alteration occurs only in CIMP tumours with MSI, it does not arise
as a direct consequence of deficient MMR. This indicates that MSI caused by
epigenetic MLFI1 silencing creates a distinct mutational background from that
caused by genetic loss of MMR (Lubomierski et al., 2005).
A better prognosis is associated with MMR deficient colorectal cancer, compared
with cancers that retain MMR activity (Jass, 2000), although this may be associated
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with sporadic MMR deficiency only, as two reports from our own lab indicate that
germline MMR gene carriers do not have a survival advantage (Farrington et al.,
2002;Barnetson et al., 2006). A micro array study of 12,625 probes revealed that
MMR inactivation produces distinct changes in the cellular mRNA pool of tumours
and colorectal cancer cell lines, when compared with tumours and cell lines with
intact MMR (di Pietro et al., 2005). MMR deficient cancers had reduced transcript
levels of several genes that favour tumour progression and increased levels of factors
believed to inhibit tumour growth, progression and invasiveness (i.e. Caspase2 and
SMAD4). The authors propose that reduced levels of transcription may be due to
microsatellite sequences in the 5'UTR (affecting transcription efficiency) or coding
region (leading to nonsense mediated decay). In contrast, shortened microsatellite
sequences in the 3'UTR of genes that showed increased levels of transcription in
MMR deficient cancers were observed, suggesting a possible effect on RNA
stability, processing and translation efficiency.
The type of APC mutations observed in CRC tumours can differ, depending on
whether or not there are defective DNA repair pathways present. There is some
evidence to suggest that the APC mutation spectrum is affected by the loss of MMR
(Huang et al., 1996), with deficient tumours having a higher rate of APC frameshift
mutations than MMR proficient tumours, and a tendency towards them occurring
within mononucleotide repeats. A coupled in vitro synthesised protein test was used
to look at the truncating mutations occurring at APC in patients with MSI tumours
(Huang et al., 2004). They found that 58% of cases had APC mutations; 69% of
which were frameshifts (mostly at mononucleotide repeats) and 31% nonsense
(missense mutations were not investigated). They concluded that most mutations
arose directly as a result of deficient MMR, and therefore that defective MMR was
occurring earlier than APC mutation in these patients. Previous reports have however
produced conflicting results (Lamlum et al., 2000b), and are discussed further in
section 1.7.
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BER deficient tumours also show a specificity for APC mutation with a propensity
for G to T transversions (A1 Tassan et al., 2002;Jones et al., 2002), as described in
further detail below.
1.6.2 Base excision repair
Heritable mutations in the genes involved with the BER system have recently been
implicated in CRC. BER protects cells against the deleterious effects of DNA
oxidation, specifically the removal of 8-oxo7,8-dihydro2'deoxyguanine (8-oxoG/8-
hydroxyguanine), the most stable and mutagenic product of oxidative DNA damage
(Hayashi et al., 2002) (Figure 1.6)
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Figure 1.6 A model of base-excision repair in mammalian cells, adapted from (Slupphaug et
al., 2003). MTH (£. coli mutT homolog) is the first line of defence, acting by removing 8-oxoG
from the nucleotide pool via hydrolysation (Fortini et at., 2003). If 8-oxoG escapes this
sanitation of the nucleotide pool, it may be incorporated into DNA by polymerases. During
DNA replication 8-oxoG can become incorporated opposite C residues in place of G. 8-oxoG
may then pair with A at the next round of replication, leading to a G:C to T:A transversion
mutation. OGG1 (a specific DNA glycosylase) can remove 8-oxoG from the template strand
prior to DNA replication. In cases where 8-oxoG:C lesions are not repaired before the next
round of replication, the lesion will become 8-oxoG:A. In these cases the MYH glycosylase
protein (the E. coli MutY homolog) will then excise the A residue that has become mis-
incorporated opposite 8-oxoG during replication, allowing the 8-oxoG:C lesion to be repaired
by OGG1. The importance of these repair systems in humans is supported by the finding
that inherited variants of MYH at conserved amino acid residues are associated with
increased somatic G:C to T:A transversions in colorectal tumours (Al Tassan et al., 2002).
Oxidative DNA damage is particularly prevalent in the gut, which is why mutations in the
BER genes are thought to be specifically important in colorectal tumours.
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Individuals with inactivating mutations in the BER gene MUTYH, coding for MYH,
have a higher rate of G:C to T:A transversions within the APC gene than those with
intact MUTYH (A1 Tassan et al., 2002). Inherited biallelic mutations in MUTYH,
cause an autosomal recessive trait (lMYH-associated polyposis', MAP) that
predisposes individuals to the formation of colonic polyps (Sampson et al., 2003)
due to an increased mutation rate, and specific mutations in APC, KRAS (Lipton et
al., 2003;Jones et al., 2004) and potentially other, as yet unidentified genes involved
in the pathogenesis of colorectal tumours (Halford et al., 2003). Individuals with
MAP typically have an attenuated or atypical adenomatous polyposis phenotype
(Aretz et al., 2006b). Age at diagnosis is later (-50 years), and patients present with
less polyps and without the severe extra-intestinal manifestations associated with
typical polyposis (FAP) (Aretz et al., 2006a). There may also be a small increase in
risk of developing colorectal cancer for individuals with heterozygous MYH
mutations (Farrington et al., 2005;Jenkins et al., 2006;Tenesa et al., 2006).
MYH enhances the fidelity of DNA replication and genetic recombination via
physical association with replicative proteins, and mismatch repair proteins (Gu et
al., 2002). While MMR mutations are seen in -10-15% of sporadic CRCs, mutations
in MUTYH do not appear to have a significant affect on sporadic disease. However,
allelic loss of lp loci has been described as an early event in colorectal
tumourigenesis (Fothe et al., 1995), and FOH of the remaining allele in MUTYH
heterozygotes may provide an explanation for the increased risk of developing CRC
in these patients (Croitoru et al., 2004b). It has been suggested that the lack of
somatic MUTYH mutations may indicate that MMR and oxidative repair genes
predispose to bowel tumours through fundamentally different mechanisms (Halford
et al., 2003). Nonetheless, there is interaction between the MMR and BER pathways.
For example, oxidative DNA damage can contribute to frameshift mutations, due to
8-oxoG becoming incorporated opposite C and A residues in repetitive DNA
sequences (Macpherson et al., 2005). In turn, MMR reduces the burden of DNA 8-
oxoG, since MutSa (a heterodimer of Msh2 and Msh6) is able to recognise 8-oxoG
mispairs, and initiate MMR (Farson et al., 2003). Fevels of steady-state and H202-
induced DNA 8-oxoG were shown to be increased in msh2~'~ mouse embryonic
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fibroblasts (Colussi et al., 2002;Gu et al., 2002). Thus, deficient MMR contributes to
the defective processing of oxidative DNA damage. Cancers showing both MMR
and BER deficiency have not been described (although patients carrying both a
MMR gene mutation and a heterozygote MUTYH mutation have been demonstrated
(Niessen et al., 2006)), this is possibly due to the fact that a double deficiency is
simply not required for genomic instability, or that cells could not cope with two
defective pathways (Lipton et al., 2003).
The protein products of many of the genes discussed above, have been linked to
DNA damage-induced cell-cycle arrest, and apoptosis (Heinen et al., 2002). This
indicates that as well as causing the primary genomic instability pathway to
tumourigenesis, DNA repair mutations also give a second selective advantage to the
cell, as was also seen for APC mutations (section 1.4). This goes some way to
explain why, in mouse models, the MMR deficient Msh6_/" embryonic stem cells, but
not Msh3_/" cells display resistance to the mutagen N-Methyl-N'-Nitro-N-
Nitrosoguanidine (MNNG). While the heterodimer MSH2-MSH6 is involved in
DNA damage recognition, MSH2-MSH3 is not (de Wind et al., 1999), so the Msh6
knockout is unable to detect mutagen induced damage, but the Msh3 knockout
retains DNA damage recognition.
The elevated mutation rates observed in cells with deficient DNA repair systems is
often referred to as a mutator phenotype, and has been recognised as an early genetic
event in sporadic and hereditary cancers (Loeb, 2001). A mutator phenotype
(discussed in more detail in section 1.11), combined with selection pressure (as
discussed in section 1.3) is believed to facilitate the accumulation of mutations in
important regulatory genes, that ultimately leads to the initiation and progression of
tumourigenesis.
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1.7 Somatic and sporadic APC mutations
As discussed in section 1.5, in FAP patients, tumours are initiated by additional
somatic mutations affecting the wild-type APC allele. The majority (>85%) of
somatic APC mutations are known to occur within the mutation cluster region
(MCR), a region of exon 15 from codons 1286 to 1513, containing the (3-catenin
binding amino acid repeats (Figure 1.5). In contrast, only 29% of germline mutations
are found within the MCR (Miyaki et al., 1995). (3-catenin levels have been proposed
to be important in deciding where in the gene a second APC mutation occurs.
Retention of one of the (3-catenin down-regulating 20-amino-acid repeats in either of
the two APC alleles appears to be advantageous during tumourigenesis. This
suggests that there is some optimal level of (3-catenin signalling that is required for
tumour formation, and is termed the 'just-right' signalling model (Albuquerque et
al., 2002).
Within the context of cancer biology somatic cell genetics generally refers to the
molecular events that occur in cells before and during neoplastic transformation. It is
thought that increased knowledge of somatic cell genetics will greatly affect the
prognosis of sporadic cancer. To identify common alterations involved in tumour
pathogenesis and progression Blaker et al. looked for second somatic mutations, and
the corresponding immunohistologic phenotype of (3-catenin, that followed a known
germline mutation in ten different adenomatous polyps from a single FAP patient
(Blaker et al., 2003). All polyps had a second somatic mutation; eight frameshifts
(three of which were identical), one nonsense mutation, and one missense mutation,
six also had chromosomal imbalances. All polyps had enhanced membranous and
cytoplasmic (3-catenin staining, although only 1 showed nuclear translocation of (3-
catenin. It is widely accepted that biallelic APC inactivation is an early event in
tumourigenesis that is necessary, and sufficient for adenoma development (Lamlum
et al., 2000b;Fodde et al., 2001b). However, whilst loss of APC function may be a
prerequisite, it is not the sole cause of nuclear translocation of (3-catenin. Likewise,
chromosomal alterations are not required for adenoma development, but are often a
consequence of it (Fodde et al., 2001a).
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As mentioned previously, -30-35% of all colorectal cancers are thought to have a
hereditary component (Lichtenstein et al., 2000;Fearnhead et al., 2002). The
remaining cases are likely to arise as a result of purely sporadic mutations. These
occur in the somatic cells of the affected individual, or can occur in the germline of a
parent and are subsequently inherited as a de novo mutation, as in the case of some
sporadic and also potentially de novo FAP cases (Farrington and Dunlop, 1999). The
majority of sporadic colorectal cancer cases also have inactivating mutations on both
APC alleles (Nagase and Nakamura, 1993).
Due to a lack of detectable parental origin bias, or parental age effect Ripa et al.
propose that de novo APC germline mutations arise during meiotic division,
compared with somatic mutations (and mutations in mosaic individuals) that arise
during mitosis (Ripa et al., 2002). However, there is conflicting evidence of a
parental origin for de novo APC mutations (Ripa et al., 2002;Aretz et al., 2004), with
small sample sizes hindering significant conclusions.
The difference in distribution between somatic and germline mutations within the
APC gene alongside other evidence may suggest that APC is susceptible to genetic
changes during meiosis, compared with most other genes where changes occurring at
meiosis are not observed. A specific role for polymerase (3 in repair synthesis during
the early stages of meiosis rather than mitosis has been proposed (Plug et al., 1997).
Additionally, the replication error spectrum of polymerase (3 has also been shown to
contain a significant subset of the APC hotspots seen in colorectal cancer
(Muniappan and Thilly, 2002). These include a 5bp deletion at codon 1309
(delAAAGA), found to be over-represented in patients with de novo mutations
(45%) compared with familial mutations (5%) (Aretz et al., 2004). This provides
good evidence for a mechanism involving polymerase (3 errors arising during meiosis
to explain how de novo germline mutations arise in APC. With the possibility that the
sequence context of the APC gene is increasing its susceptibility to errors arising
during polymerase (3 repair synthesis. An alternative argument could also be that a
wide spectrum of germline mutations are occurring, but that are permissive for only a
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limited spectrum of somatic second mutations, thus leading to the differences
observed in the distributions of somatic and germline mutations.
Further analysis of somatic mutations in the APC gene has been performed by
Luchtenborg et al., who examined the MCR of APC in a Dutch cohort of sporadic
colorectal carcinomas (Luchtenborg et al., 2004). They observed that the majority of
mutations (61%) were missense point mutations. The relevance of missense
mutations in APC are not well understood, and more investigation is required to
determine which, if any, have a pathogenic effect. Truncating APC mutations were
seen in 37% of cases - 52% of which also had a missense mutation. Multiple
mutations (between 2 and 8) were seen in 55% of cases, and underline the existence
of tumour heterogeneity in sporadic CRC. Heterogeneity in sporadic cancers is
expected to arise as the result of sub clones harbouring different mutations (Maley et
al., 2006), but may also indicate a defect in DNA repair. The presence of a truncating
and missense mutation in the tumour DNA of a single patient, if they are biallelic,
may indicate pathogenicity of missense mutations, but whether mutations were
present on the same allele was not investigated in this study.
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1.8 Epigenetic changes in CRC
Epigenetics is an alternative mechanism in carcinogenesis, with most colorectal
cancers having some epigenetic abnormalities (Kondo and Issa, 2004). As mentioned
previously (section 1.6.1), promoter CpG island methylation, is the most common
form of epigenetic change, and results in irreversible inhibition of gene expression. A
subset of colorectal tumours have an exceptionally high frequency of methylation of
some CpG islands, and are referred to as CIMP positive/high (Issa, 2004b). CIMP
positive tumours are associated with a variety of clinical, histopathological and
epidemiological characteristics (Samowitz et al., 2005), most notably MSI.
MMR deficiency in sporadic colorectal cancer is known to be caused largely by
epigenetic mechanisms. A number of studies have shown that the most common
mechanism causing MSI in sporadic colorectal cancer is transcriptional silencing of
the MLH1 gene by methylation of the MLH1 gene promoter (Lei et al., 2004). Veigl
et al. also showed that 5 out of 6 MSI cell lines with no detectable MLH1 protein,
but wild type coding sequences had promoter hypermethylation of the gene promoter
from both parental alleles (Veigl et al., 1998).
As well as the better-documented MLH1 case, the APC gene is also known to be
silenced by epigenetic mechanisms. Work by Esteller et al. in 2000 highlighted the
fact that in some non-familial tumours with APC mutations there is no second
identifiable event, and up to 20% of tumours have no APC mutation (Esteller et al.,
2000). They showed that the APC promoter 1A is hypermethylated, and unexpressed
in 18% of sporadic colorectal carcinomas and adenomas. Hypermethylation appears
to occur early in colon tumourigenesis, and usually affects intact copies of APC.
The APC gene contains two promoters, 1A and IB. The main APC transcript is
initiated from 1A, and a minor transcript from IB. Hypermethylation of promoter 1A
has been demonstrated in melanoma cell lines, that did not show increased WNT
signalling (Worm et al., 2004). It is suggested that this may be due to residual
activity from promoter IB, causing a promotion of cell proliferation, without
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compromising invasive capacity. Indeed, promoter 1A hypermethylation is a normal
event in the stomach (but not the colon), here virtually all APC transcripts result from
promoter IB (Tsuchiya et al, 2000).
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1.9 Mouse models
Mouse models are used in the study of CRC to further dissect complicated genotype-
phenotype relationships, to look at the interplay between different genotypes, and as
preclinical models for the testing of preventative, and therapeutic agents (Fodde and
Smits, 2001). Whilst useful, it is important to be aware of the limitations of mouse
models. Differences in phenotype and disease progression are often seen between
humans and mice with similar genotypes, and so any conclusions drawn from these
models must account for these differences.
The multiple intestinal neoplasia (Min) mouse has a nonsense mutation at codon 850
of Ape, resulting in truncation of the protein product (Moser et al., 1990;Su et al.,
1992). Heterozygous Apc+/ApcMm mice have a severe phenotype, developing over
100 intestinal tumours (but not polyps), and rarely surviving past 140 days. Tumours
tend to appear in the small intestine, rather than the colon, and due to the severity of
disease, and lack of polyps, early events in tumourigenesis are difficult to study in
the Min mouse. In the majority of cases, loss of the WT Ape allele is the result of the
entire loss of mouse chromosome 18 (Luongo et al., 1994), syntenic to human
chromosome 5, but ultimately very different to the situation observed in humans.
The Min mouse has been useful in a large number of in vivo studies into
chemopreventative and therapeutic strategies for colorectal cancer, where the
suppression of intestinal adenoma development can be monitored and compared
under a variety of conditions. The ability of PEG-3500 (a polyethene formulation) to
stimulate apoptosis as a potential chemopreventative treatment was examined by Roy
et al. They found that clinically relevant levels of PEG-3500 in drinking water could
reduce tumour burden and resulted in a 2-3 fold increase in colonic mucosal
apoptosis (Roy et al., 2004). Likewise, Sale et al. detected a 24% decrease in
adenoma load following the administration of the synthetic resveratol analog DMU-
212 to ApcMm mice (Sale et al., 2005).
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The Min mouse was used to identify a modifier locus, 'modifier-of-Min' (Mom-1)
(Dietrich et al., 1993). Mom-1 encodes a secretory phospholipase A2, a gene
involved in lipid metabolism and prostaglandin production (MacPhee et al., 1995). In
mice it reduces the number of tumours seen in the Apc+/ApcMm mice, and lies in a
region of the mouse genome syntenic to human chromosome lp35-36. This region is
known to be lost in many human cancers, including colorectal cancer. However, no
correlation has been established for phospholipase A2 gene mutation and the FAP
phenotype therefore, there is no evidence in humans that this region acts as a
modifier (Farrington and Dunlop, 2004).
The Ape protein in the Apc1638T mouse is truncated at codon 1638, and so retains all
(3-catenin binding repeats, 3 of the 7 (3-catenin down regulating repeats, and one
axin/conductin binding domain, but lacks all the C-terminal interaction domains
(Smits et al., 1999). Heterozygous, and indeed homozygous ApcI638T mice, show no
increase in tumour susceptibility, indicating that the C-terminal end of Ape is not
required for tumour suppression (in mice). However, homozygous embryonic stem
(ES) cells do show a high degree of chromosomal instability. It is proposed that this
indicates that Ape is directly involved in chromosomal stability, but that while
chromosomal instability is necessary, it is not sufficient to trigger tumour formation
(Fodde et al., 2001a).
The Apc,638N mouse has a 'leaky' allele, producing 1-2% of the truncated protein
product. A/7C+/1638N mice, like Min mice have a distribution of tumours that is
different to that seen in humans, with the majority being in the upper GI tract,
between the stomach and small intestine (Fodde and Smits, 2001). On a B6
background, 1638N mice are particularly prone to developing extra-intestinal lesions,
similar to FAP patients. These include desmoid tumours, cutaneous cysts and a
CHRPE-like retinal abnormality (van der, 98 A.D.). The two mouse models, ApcI638T
and ApcI638N provide strong evidence that there is haploinsufficiency of the mutant
Ape protein, so the leaky allele at 1-2% of normal expression creates a detectable
phenotype that is not seen when the same mutant allele is expressed at 'normal',
higher levels.
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The importance of somatic loss of APC in sporadic CRC has been underlined in the
Apc580S mouse (Shibata et al., 1997). In this model the LoxP/Cre system is used to
somatically inactivate both Ape alleles (by deleting exon 14, creating a frameshift),
inducing tumour formation within the colorectum extremely rapidly, within 4 weeks
of conditional targeting of Ape.
The synergistic interaction between the Ape gene and defective MMR has also been
explored in mice; Msh2 and Mlhl deficiencies have been shown to cause somatic
Ape mutations in the normal mucosa of Apc+/-Msh2+I-and Apc,638NMlhl-/- mice
respectively (Sohn et al., 2003) (Kuraguchi et al., 2000). In Min mice inactivation of
the second Ape allele is usually the result of LOH (Shoemaker et al., 1997), instead
in the Apc+/-Msh2+I- and Apc'638NMlhl-/- mice, a mutator phenotype caused by
deficient Msh2/Mlhl resulted in inactivation of the second allele by a somatic
inactivating mutation. A high proportion of mutations observed within Apc+I-
Msh2+I- adenomas were missense (56%) and this further underlines the importance
of analysis into their role in tumourigenesis. In contrast, the vast majority of tumour
Apc mutations from the Apc1638NMlhl-/- mouse were truncating mutations.
The DNA repair and DNA damage-induced apoptosis roles of Msh6 and Msh2 (de
Wind et al., 1999;Zhang et al., 1999) have been successfully uncoupled using two
mouse models harbouring missense mutations. The Msh2G674A and Msh61I217D mice
show loss of DNA MMR, without an affect on their apoptotic response to DNA
damaging agents (Lin et al., 2004;Yang et al., 2004). These studies indicate that
genotype-phenotype correlations can provide valuable information for cancer
treatment. As tumours lacking MMR as a result of missense mutations may not have
resistance to chemotherapeutic agents. Mouse models for HNPCC have been used to
determine the effect of single MMR gene loss, and combinations of MMR genes on
genomic mutation frequency (Hegan et al., 2006). However, as mentioned
previously, due to fundamental differences between humans and mice all results
must be interpreted with caution. Whilst Mlhl-/- mice spontaneously develop
gastrointestinal tumours by 48 weeks, to provide a good model for HNPCC (Tokairin
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et al., 2006), mice defective in Msh2 show increased predisposition to skin cancer
(Meira et al., 2002).
Mouse models have been used to look at the interactions between the Myh and Oggl
proteins, and it is suggested that in mice they act synergistically (Xie et al., 2004). A
deficiency in either Myh or Oggl appeared to be compensated for by the presence of
the other. Only in the double knockouts was the 50% survival age significantly
decreased, and tumour incidence significantly increased. On the Apc+/min
background, Sieber et al. show that Myh deficiency {Myh-/-, but not Myh+/-)
enhances intestinal tumourigenesis, providing a model for MAP (Sieber et al., 2004).
Inactivating Ape G-T transversion mutations were observed in 10% of adenomas,
however no K-ras mutations were observed, as is seen in human MAP. Likewise,
whilst a significant increase in ACF number was observed in the Myh-/- mice
compared with the Myh+/- and Myh+/+ mice, these did not appear to progress to
carcinomas. These mouse models again highlight the problems with using mice to
model human conditions. Not only do Myh and Oggl proteins have different
properties, they are also able to substitute for one another. Additionally, in the double
knockout the mice do not develop CRC, but instead develop lung tumours (Xie et al.,
2004), and in human MYH mutation is not thought to predispose to lung carcinoma
(Al-Tassan et al., 2004).
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1.10 Sequence Context of Genes, and its Role in Tumourigenesis
The APC mutation spectrum is known to be affected by the loss of MMR (Huang et
al., 1996;Otsuka et al., 2003), and BER (base excision repair) (Al Tassan et al.,
2002;Jones et al, 2002). Likewise, as discussed in section 1.7, DNA polymerases
and sequence context may also play a role in influencing the type and location of
mutations in APC.
Evidence suggests that sequence context may play a significant role in mutation
susceptibility and tumourigenesis; Bacon et al. have shown that the sequence context
of a microsatellite influences the mutation rate that is observed in MMR deficient
cells (Bacon et al., 2000). It was found that, when the D2S123 locus (CA repeats)
was interrupted it was more stable than when the microsatellite was 'perfect'. 80% of
mutations at D2S123 were derived from the shorter allele, as these contained
uninterrupted CA repeats. Various oncogenes have been shown to have mutational
hotspots, including KRAS codons 12 and 13 in CRC, but this, as with many such
observed 'hot-spots' is likely to be due to ascertainment bias, as mutations at this
codon seriously disrupt the functionality of the KRAS protein.
Further understanding of mutation rates and what influences them is required to be
able to address how sequence context affects mutation. Neutral mutation rates are
calculated either at 'four-fold' sites; for example the third codon position changes
where any of the four bases could code for the same amino acid, i.e. Serine is coded
for by TCT, TCC, TCA and TCG, or at ancestral repeat sequences which are areas
where transposable elements were inserted and fixed before two organisms diverged.
Neutral sites are often used to determine how fast a sequence is evolving, since they
are not subject to the usual selection pressures. The Mouse Genome Sequencing
Consortium (Waterston et al., 2002) used alignments of the human and mouse
genomes to study neutral mutation rates. They reported variation in the substitution
rate across the human genome, that indicated "substantial regional fluctuation",
which they suggest may be caused by long-range factors that affect mutation rate.
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In addition to long-range factors, studies have shown sequence context effects at
short ranges (Ellegren et al., 2003). Silva and Kondrashov used human-baboon
genomic alignments to study mutation rates, and found that nucleotide substitutions
are clumped together at scales of <10, and 1000-10,000 nucleotides, indicating two
different factors at work. Potentially, sequence context effects work at the shorter
scale (<10bp) and regional differences in mutation rate at the longer scale (l-10Kb)
(Silva and Kondrashov, 2002).
It is important to use new bioinformatics tools i.e. comparisons between complete
genome sequences, to gain further understanding of mutation rates and the influence
of sequence context. Such analysis will begin to highlight areas of the genome with
potential mutational hot-spots, or that are mutating faster than expected. These
regions can subsequently be investigated to determine if they correlate with genes
and genome regions that are known to be involved in cancer.
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1.11 Mutator phenotype and Genomic Instability
Genomic instability, and the role that it plays in tumourigenesis has been discussed
widely in many reviews (Lengauer et al., 1998;Strauss, 1998;Cahill et al.,
1999;Coleman and Tsongalis, 1999;Loeb, 2001;Charames and Bapat, 2003;Grady,
2004). It is largely agreed that instability is the 'engine' of tumour progression,
causing no two tumours to be the same, and allowing them to adapt effectively to a
changing environment. The widely held view is that an increase in mutation rate is
required for the initiation and progression of cancer.
The genetic changes induced in CRC, whether heritable or sporadic can be explained
by the mutator model of tumourigenesis (Loeb, 2001). This model states that
mutations arising in genes that ensure the stability of the genome (i.e. MMR genes
and DNA polymerases) generate mutant cells that are selected for because they are
able to escape the regulatory mechanisms that control cell replication, invasion and
metastasis. This model explains the enormous differences seen in the numbers of
mutations in normal and cancerous cells. Stoler et al. used inter- (simple sequence
repeat) PCR on pre-malignant polyp DNA to estimate that there are at least 11,000
genomic events per carcinoma cell in sporadic cancers (Stoler et al., 1999). Although
this technique only detects fairly large changes that alter the sizes of PCR products, it
does suggest that genomic destabilisation is an early step, and a cause rather than
effect in sporadic tumour development. There is a trade-off between the selective
advantage of accumulating many mutations that allow a cell to evade constraints in
growth and regulation, and the disadvantage of reaching the threshold for cell
replication and viability, resulting in cell death.
The alternative to the mutator model is that pre-cancerous cells are mutating at the
normal rate, estimated to be approximately 1.4 x 10"10 nucleotides/cell/division
(Loeb, 2001), and that clonal expansion (or efficient selection) causes the outgrowth
of those cells that randomly acquire advantageous mutations (Lengauer et al., 1998).
Evidence against the mutator model includes the fact that such high levels of
mutation as proposed by the mutator model are likely to induce apoptosis, the fact
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that tumours are dynamic and take decades to develop, and that despite being a
universal process, the loss of MMR in HNPCC patients only causes a limited set of
cancers (Strauss, 1998). So, heightened mutability is not necessarily accompanied by
a general increase in tumourigenesis, but instead affects only a subset of specific
types. In his p53 review, Strauss notes that the mutation process in some genes is
different to other genes, and hypothesises that it may be likened to the generation of
antibodies, where a limited portion of the genome becomes hypermutable for a
limited time (Strauss, 1998).
These hypotheses indicate the enormity of trying to understand mutation rate and
selection advantages, however it is important to remember that the presence of
mutations within a tumour, gives no information of mutation rate, nor does it prove
that a tumour is genetically unstable. It is possible that the early mutations found in
human tumours provide both a selective advantage as well as an increased mutation
rate (Fishel, 2001). Elucidating what is actually going on during the tumourigenie
process has proven extremely difficult.
Direct examples of genetic instability include work from Bacon et al.(Bacon et al.,
2001) showing that a poly(A)io tract in TGF/3R2 is hypermutable in MMR deficient
cells derived from a normal lineage. This leads the authors to conclude that "exon 3
of TGF/3R2 is inherently mutable and predilection for instability at (this) poly(A)io
tract contributes to the frequent observation of TGF/3R2 mutations in MMR deficient
tumours". Another example of increased mutation rate preceding tumourigenesis
comes from the novel polymorphism described at codon 1307 of APC (Laken et al.,
1997). The T to A transversion at nucleotide 3920 is observed in 6% of Ashkenazi
Jews and creates an A8 tract that is hypermutable, and so, indirectly causes a cancer
predisposition. Approximately 50% of tumours arising in patients with this
polymorphism have insertion/deletion mutations in this hypermutable run of 8
nucleotides.
The 'stable gene hypothesis' (Frei, 1990;Frei, 1995) suggests a stabilising
mechanism for genes (coined as a putative 'comparase' enzyme system in the paper)
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to reduce mutation rate. This hypothetical system is proposed to correct mutations
occurring in any gene that appears within the genome in multiple copies (i.e.
pseudogenes, and developmentally or differentially expressed copies). It follows
therefore that unstable genes are likely to be those that occur in only a single copy
within the genome, and are as such not protected by the comparase system. APC is
given as an example in this paper of such an unstable gene. At present this is just an
idea needing experimental evidence to support it.
Chromosomal instability is a major form of instability in the genome (detected in
>85% of CRC) and arises when the cell loses its ability to ensure that the correct
number of intact chromosomes are passed to each daughter cell before cytokinesis.
This results in aneuploidy (a change in chromosome number) that is seen frequently
in tumours. As discussed in section 1.4, CIN can be caused by truncating mutations
in APC (Fodde et al., 2001a). CIN has been detected as an early event in a significant
proportion of FAP and MAP adenomas (Cardoso et al., 2006). There are also an
excess of 100 candidate genes that have the potential to cause a CIN phenotype
(Grady, 2004), some of which may act synergistically with APC, further enhancing
the CIN phenotype. One group of candidate genes contains the mitotic checkpoint
regulators. Cahill et al. showed that in some colorectal cancers displaying CIN, loss
of the mitotic checkpoint was associated with inactivation of the human homolog of
yeast BUB1 (hBUBl) (Cahill et al., 1998). BUB1 controls mitotic checkpoints and
chromosome segregation in yeast, by binding to the kinetochore, and is required for
mitotic delay in response to spindle disruption (Roberts et al., 1994;Pangilinan and
Spencer, 1996). Other chromosome changes include LOH, which is caused by
translocations that result in the loss of the maternal or paternal allele during
recombination. This can be accompanied by the gain of the opposite allele, leaving a
normal appearing karyotype, but abnormal 'allelotype' (Lengauer et al., 1998). Gene
amplification is another form of instability, eg. N-myc oncogene amplification in
Neuroblastoma (Kohl et al., 1983). Gene amplification is often seen to occur late in
tumourigenesis, and it is likely therefore that cancer cells, unlike normal cells, may
be able to survive gene amplifications (because the normal signals for apoptosis are
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disrupted) making them an effect of tumourigenesis, rather than a cause in some
cases.
Under normal cellular conditions the combination of repair processes and apoptosis
ensures that genetic material is transmitted precisely. It has been proposed (Cahill et
al., 1999) that if the accumulated damage from cell division rises above the threshold
for viability, cellular apoptotic pathways are activated and cell death ensues.
However, if the ability for a cell to undergo apoptosis in response to DNA damage is
lost, then the cell is left unchecked to accumulate mutations, and tumourigenesis is
likely. Some MMR-dependent apoptosis may be mediated through MBD4, a thymine
DNA glycosylase involved in reducing the mutability of methyl-CpG sites in the
genome. It interacts with MLH1, and deficiency has been shown to reduce the
apoptotic response following exposure to cytotoxic agents (Sansom et al., 2003).
Conversely, over expression of MLH1 induces an apoptotic response in both repair-
proficient and -deficient cell lines (Zhang et al., 1999). APC is also likely to have a
role in apoptosis, i.e. through disruption of Survivin expression, as mentioned in
section 1.4. There is likely to be an inverse relationship between MIN and CIN in
CRC, as the two conditions are rarely found to co-exist in the same tumour. This is
likely to be due to the fact that the presence of just one condition is sufficient for
tumourigenesis, but may also indicate that the mutational load created by both
conditions exceeds the threshold for cell replication and viability, and becomes a
selective disadvantage initiating apoptosis
The specific factors that can affect the propensity to mutation, such as loss of DNA
repair, have been discussed in detail already. An inherent instability is also believed
to be an important influence in tumourigenesis, affecting the frequency with which
one gene might accumulate mutations. The specific consequences and relative
contribution of this 'inherent instability' is also not well understood. With respect to
APC, we know that it plays a pivotal role in deciding cell fate. The gene also appears
to be hypermutable. This is underlined by the high rate of new germline APC
mutations that are seen in sporadic cases of FAP. 25% of all FAP cases are sporadic
(new mutants) (Bisgaard et al., 1994) i.e. instead of the APC mutation being
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inherited from one or other of the parents, in this situation germline mutations occur
de novo during oogenesis, spermatogenesis, or early embryogenesis. It should be
noted however that early estimates of the proportion of cases of FAP due to new
mutations is likely to be artificially elevated by MAP cases and other as yet
undefined genetic conditions. Parental APC mutational mosaicism has been proposed
to explain a proportion of the high rate of sporadic, apparently new germline APC
mutations (Farrington and Dunlop, 1999). Farrington and Dunlop hypothesise that
passage through the germline of instability-prone individuals may represent a
mechanism by which new APC mutations might arise. However, this phenomenon
has only been shown in two cases, and is unlikely to account for more than a small
proportion of the sporadic APC mutations. Whilst being equally vital in the WNT
signalling pathway, mutations in CTNNB1 and Axin are seen at just a fraction of the
frequency of APC mutations. Inactivation of APC is seen in virtually all CRC cases,
and has been shown to be an early event.
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1.12 Research aims
The central premise for this project was to investigate the hypothesis that the APC
gene is inherently unstable. In particular to determine the influence that DNA repair
plays in APC mutation, and how the presence or absence of DNA repair might affect
mutations in individual cells and genetic alterations in whole tumours.
In view of the evidence from published literature, it was hypothesised that a number
of de novo APC mutations and the presence of inactivating mutations in the vast
majority of colorectal cancers (whether familial or sporadic) could indicate that the
APC gene is inherently prone to mutation. The work presented in this thesis forms a
body of evidence to test this hypothesis against the alternative argument that
numerous mutations in the APC gene are seen because APC mutation is the most
direct route to CRC. A previous investigation from the lab provided preliminary
evidence that a region of the APC gene appeared to be hypermutable in normal cells,
when compared with another gene involved in tumourigenesis (Bacon, 2001).
Inherent instability is predicted to increase mutation frequency above that which is
normally expected. This would explain why mutations in other vital genes such as
those involved in Wnt signalling are seen at a much lower frequency than APC. APC
has been shown to be susceptible to the mutagenic effect of MMR and BER
deficiency, and we propose that this is also due to inherent mutability and possibly
the sequence context of the gene.
I specifically aimed to investigate the inherent instability of the APC gene in both the
in vivo and in vitro situations. Therefore, cell lines and patient samples with a variety
of DNA repair process mutations were utilised. In parallel with the analysis of the
underlying frequency with which mutations arise in the APC gene, it was deemed
important to determine which of these mutations were ultimately selected during the
tumourigenic process, and how selection was affected by DNA repair processes. It
was predicted that evolutionary and polymorphism data would give insights into the
influences that the APC gene is under. Alongside a detailed comparison of de novo
mutations and mutation rates, it was aimed to use in silico techniques to further our
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understanding of how inherent instability of APC might contribute to tumour
progression. The final aim of the project was to look in more detail at how the loss of
the DNA repair affects mutation frequency, and begin to develop other techniques
that would enable this to be directly measured and compared.
Loss of APC is associated with the vast majority of colorectal cancers, and
understanding the molecular basis with which these mutations arise and what
influences them is clinically important in terms of identifying genetic alterations that
might predict prognosis. Furthermore, as cancers with DNA repair defects influence
genetic alterations, elucidation of how they exert their effect may provide new
insight into the contribution of DNA repair defects in colon carcinogenesis. This may
shed light on the interaction between selection and inherent instability involved in
the initiation and progression of cancer.
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1.13 Experimental approach
The research presented in this thesis utilises 12 different cell lines and 38 patient
samples. The cell lines included lymphoblastoid, epithelial colorectal carcinoma and
fibroblast cell lines that harbour defects in either MMR or BER genes, as well as
wild-type cells. The patient samples were normal and tumour colonic material from
individuals with sporadic colorectal cancer, or germline mutations in either MMR or
BER.
We have determined the mutation frequency of APC using an approach where clonal
selective advantage imparted by APC mutation was excluded. By cloning individual
alleles, APC mutation frequency was compared between the samples, and mutation
spectrum investigated.
The data presented in Chapter 3 of this thesis focuses on determining the mutation
frequency and spectrum of the APC gene in cell lines (in vitro) and in patient
samples (in vivo). The in vitro work compares the mutation frequency in a region of
APC exon 15 with similar sized regions of the TGF/3R2 and GPD1 genes. This was
carried out in two WT lymphoblastoid cell lines, a MMR heterozygote
lymphoblastoid cell line, 2 homozygote MMR cell lines (one lymphoblastoid and
one colorectal cancer cell line), and two BER null cell lines (one fibroblast and one
colorectal cancer cell line). The TGFJ3R2 gene (MIM 190182) belongs to the serine-
threonine kinase family of receptors. It acts by transducing the transforming growth
factor-beta inhibitory signal, a signalling pathway disrupted in most colorectal
cancers. As mentioned previously, (section 1.6.1) TGF/3R2 is found to be inactivated
in a subset of colon cancer cell lines with MSI (Parsons et al., 1995). Additionally,
there is a single report of a germline mutation event in familial CRC (Lu et al.,
1998). GPD1 (Glycerol 3-phosphate dehydrogenase, MIM 138420), is a house¬
keeping gene expressed in the colon, and used previously as a control gene in studies
of MMR as it is not implicated in any disease or cancer (Geisler et al., 2003). The in
vivo work also compares mutation frequencies observed in a region of APC exon 15,
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and GPD1 using DNA derived from in vivo patient samples to deduce if selection
pressures and clonal evolution might influence the mutation frequencies observed.
In Chapter 4 somatic inactivating mutations in the APC and KRAS genes are
investigated in the patient samples to identify the selected mutations. The influence
of DNA repair deficiency on the APC and KRAS somatic inactivating mutations
could therefore be determined. The potential for using KRAS codon 12 mutation as a
screening tool for biallelic MUTYPI inactivation in the Scottish population is
discussed.
Chapter 5 focuses on using in silico techniques to further corroborate the hypothesis
of instability in the APC gene. Polymorphism and evolutionary data presented in
Chapter 5 are discussed alongside the experimental results presented in Chapter 3.
Here we investigated whether APC is subject to a high neutral mutation rate and
whether purifying or negative selection is acting. The de novo mutation rate of APC
is compared with a number of genes associated with other dominant traits, and the
type and location of de novo APC mutations is compared to those arising in other
similar genes.
Finally, in Chapter 6 a novel technique based on EGFP fluorescence and cell sorting
has been developed for directly measuring and comparing the effect of BER
deficiency on the mutation frequency in live cells. Initial stages of the optimisation
of the assay are described.
A detailed discussion of the results for each section of work is provided in the
relevant chapter. Chapter 7 then summarises the main themes and conclusions that




The following chapter documents the methods used during the course of this thesis.
Where appropriate, specific details are included in the relevant chapter. Standard
protocols are cited, and any adjustments have been documented. Stock solutions and
media marked with an asterisk (*) were prepared by the solution and media
preparation service at the MRC Human Genetics Unit, and sterilised by autoclaving.
Procedures carried out by the technical services department at the MRC HGU are
attributed to the relevant member of staff, or for general procedures, marked with a
hash (#). Risk assessments (including COSHH regulations) were carried out for all
procedures, and adhered to throughout.
2.1 Biological Material
2.1.1 Summary of cell lines
The following cell lines were used during the course of this PhD, outlined in table
2.1. Epstein-Barr virus (EBV) transformed lymphoblast cell lines ConC, ConA and
lbl-c5 were established by Sheila Mcbeath (MRC, Human Genetics Unit, Edinburgh)
from healthy anonymous individuals, and are maintained as laboratory stocks. Cell
lines lbl-1260 and lbl-1261 were a donation from Prof. Vogelstein (John Hopkins
Oncology Centre, Maryland). The colorectal carcinoma cell lines, HCT116, HCT116
+ C3 and SW480 are available from American/European Type culture collections
(ATCC/ECACC). The colorectal carcinoma cell line VAC0425 was a donation from
Dr. James Willson (Case Western Reserve University, Ohio, USA).
Prof. M. Dunlop and Dr. S. Farrington have collected a panel of samples (blood,
tissue and cell lines) from patients with CRC, and these were available as a
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laboratory resource. The fibroblast cell lines 2630, 439 and 825 are untransformed
primary cell lines, cultured from the skin of patients with and without CRC, bearing
the same MD laboratory identification number.
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Table 2.1 Details of all cell lines used within this thesis, including cell type, genotype, and
reference to original source.
Name Cell Type Genotype Reference
ConC LCL EBV WT Lab stock
ConA LCL EBV WT Lab stock
Ibl-c5 LCL EBV WT Lab stock
lbl-1261 LCL EBV PMS2 deficient Parsons et al., 1995
lbl-1260 LCL EBV MLH1 heterozygote Parsons et al., 1995
HCT116 CRC MLH1 deficient Papadopoulous et
WT (restoration of MMR
al., 1994
HCT116 + C3 CRC activity by introduction of Koi et al., 1994WT allele on
chromosome 3)
VAC0425 CRC MYH deficient Parker et al., 2002
SW480 CRC WT Leibovitz et al.,1976
MD2630 Fib MYH deficient Lab stock
MD439 Fib WT Lab stock
MD825 Fib MSH2 heterozygote Lab stock
Key: LCL Lymphoblastoid Cell Line
CRC Epithelial Colorectal Carcinoma Cell Line
Fib Fibroblast
EBV Epstein-Barr virus transformed
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2.1.2 Maintenance of cell lines
The following describes the procedures used to grow and maintain all cell lines for
DNA and protein extraction, transfection, apoptosis assays and FACs (fluorescence
activated cell sorting) analysis:
Tissue Culture Medium
RPMI or L-15 (HCT116 only) (Gibco BRL)
10% w/v Foetal bovine serum (FBS) (Gibco BRL)
1 x Antibiotic, antimycotic solution (Sigma-Aldrich, Irvine, UK)








8% w/v Dimethyl Sulfoxide (DMSO) in FBS
Maintenance of all cell lines was carried out by myself, under sterile conditions in a
category 2 containment hood in a category 2 laboratory. Long-term storage of all cell
lines takes place in the liquid nitrogen facility at the MRC Human Genetics Unit.
Cells are raised from liquid nitrogen by rapidly thawing in warm water, then placed
into appropriate media as soon as possible, and washed twice with media, in between
centrifugation steps (1200rpm in a Wifug 500E centrifuge). Cells are fed with media
as required, and passaged by washing with PBS, and incubating with TV (5 min) for
the adherent cell lines, and then, as for all cell lines by aliquoting 1/2 to 1/10 of cell
suspension into fresh media. To maintain cell lines as a renewable stock, at least 3 x
106 were split from the main culture at regular intervals, centrifuged as above, and
the pellet re-suspended in freezing media. Stocks are first frozen at -70°C before




1 x Tris EDTA (TE)
lMTris (pH7.7)
0.5M Na2EDTA (pH8.0)
3M Sodium Acetate NaOAc
3M NaOAc-3H20
pH4
2.2.1 Estimation of DNA concentration
Optical densitometry on a GeneQuant Pro RNA/DNA calculator UV
spectrophotometer (Amersham Pharmacia biotech, Cambridge, UK) was used to
estimate the concentration of DNA obtained from the protocols listed below. DNA
samples were diluted 1 in 100 and the DNA program used to measure absorbency at
260nm and 280nm, giving a concentration in jUg/ml. Stock samples were then diluted
to a working stock of 100ng//xl in TE, or where starting concentration was less than
this (in the case of paraffin embedded samples), to an appropriate concentration for
handling.
2.2.2 Purification of DNA from bacterial plasmids
Bacterial plasmid DNA was extracted on a small scale, using a QIAprep miniprep kit
(QIAGEN Ltd, Crawley, UK) according to manufacturers instructions. For DNA
extraction of plasmids in a 96 well plate format a BioMek© 2000 workstation robot
was used, operated by Stephen Brown (MRC, Human Genetics Unit, Edinburgh)
according to manufacturers instructions.
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2.2.3 Purification of DNA from paraffin embedded archival material
Prof. M. Dunlop and Dr. S. Farrington have collected a panel of blocks of tumour
and adjacent normal colon mucosa samples from patients with CRC. Samples were
formalin-fixed, and paraffin embedded, and are available as a laboratory resource.
10|Um slides are cut from the paraffin blocks using a Shandon AS325 Retraction
microtome (Anglia Scientific Instruments, Cambridge, UK), and Haemotoxylin &
Eosin (H&E) stained by Naila Haq (Colon Cancer Genetics Group, Edinburgh
University, UK) to identify normal and tumour tissue. Approximately 5-10 ng of
tissue (normal and tumour separately) is scraped from the slides using a razor blade,
and DNA extracted using a QIAamp DNA mini kit (Tissue protocol) as per
manufacturers instructions (QIAGEN Ltd), with lysis performed over-night at 56°C,
and the final elution step carried out twice with 50/xl buffer AE and 5 min incubation
to insure maximum DNA yield.
2.2.4 Colorectal blood, tumour and normal mucosal DNA
The following (Table 2.2) were obtained by Prof. M. Dunlop and Dr. S Farrington as
part of an ongoing collection of DNA samples from individuals with CRC. All were
extracted from blood or fresh normal and tumour colon mucosa, using a QIAamp
DNA mini kit, or mini blood kit, as appropriate, and tissue extracted as described
above (QIAGEN Ltd).
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Table 2.2 Details of all normal and tumour samples used within this thesis, including unique
sample ID number, sample source and genotype details.
Sample ID Sample Type Genotype
1946 NM/T Germline MLH1 carrier
2116 NM/T Germline MLH1 carrier
533 NM/T Germline MLH1 carrier
1974 NB/T Germline MSH2 carrier
2486 NM/T MSS, BER+
2490 NM/T MSS, BER+
2491 NM/T MSS, BER+
2494 NB/T MSS, BER+
1184 NM/T MYH: Germline G382D Heterozygote
1574 NM/T MYH: Germline G382D Heterozygote
1677 NM/T MYH: Germline G382D Heterozygote
2564 NM/T MYH: Germline G382D Heterozygote
2596 NM/T MYH: Germline G382D Heterozygote
3603 NM/T MYH: Germline G382D Heterozygote
2574 NM/T MYH: Germline G382D Homozygote
2650 NM/T MYH: Germline G382D Homozygote
3044 NM/T MYH: Germline G382D Homozygote









MYH: Germline Y165C Heterozygote
2009 NM/T MYH: Germline Y165C Heterozygote
3116 NM/T MYH: Germline Y165C Heterozygote
6121 NM/T MYH: Germline Y165C Heterozygote
1010 NM/T MYH: Germline Y165C Homozygote
1283 NM/T MYH: Germline Y165C Homozygote
1299 NM/T MYH: Germline Y165C Homozygote
1960 NB/T MYH: Germline Y165C/P391L
Compound Heterozygote




2.2.5 Precipitation and clean-up of DNA
DNA was concentrated and purified using a QIAquick PCR purification kit
(QIAGEN Ltd) according to manufacturers instructions, or by ethanol precipitation.
For ethanol precipitation, a 1:10 volume of 3M NaOAc (pH4) was added to the DNA
solution along with 2-3 volumes of 100% ethanol. The solution was incubated for 30
min at -70°C and then centrifuged for 15 min at 2000rpm in a Biofuge pico Heraeus
centrifuge (Kendro Laboratory products). The DNA pellet was re-suspended in an
appropriate volume of TE.
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2.3 PCR Protocols
2.3.1 Oligonucleotides for PCR
Primers were supplied by Invitrogen lyophillised and re-suspended in dH20 to a
stock concentration of ljiig/pd. Working stock solutions were made to 100ng//xl with
dH20. PCR amplification was performed on a Peltier PCT225 thermal cycler (MJ
Research, Waltham USA) under the following reaction conditions, unless stated
otherwise: 94°C - 3min, (94°C - 45secs, 55°C - 45secs, 72°C - 45 sees) x 35, Final
extension 72°C - lOmin. Primers were designed either by eye, or using the Primer3
web based design program at www://frodo.wi .mit.edu/cgi-
bin/primer3/primer3 www.cgi. Primers are listed in table 2.3, F and R refer to
forward and reverse respectively.
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Table 2.3 Details of all primers used within this thesis, including sequence, cycling
conditions and reference where appropriate.














































All PCR reactions were earned out in 25/rl reaction volumes, with either the Expand
High Fidelity PCR system (Roche Diagnostics, Lewes, UK) or AmpliTaq (Roche
Diagnostics). For the Expand High Fidelity system each reaction contained lOOng of
each primer, 2.5/rl dNTPs (lOmM) (Invitrogen, Paisley, UK), lx Expand buffer
containing 15mM MgCl2, 1 unit (0.25/xl) Taq Expand, lOOng DNA and 16.75/xl
dH20. For the AmpliTaq system, each reaction contained lOOng of each primer,
2.5/xl dNTPs (lOmM) (Invitrogen), 1 x AmpliTaq buffer, 2.5/xl MgCl2 (2.5mM),
0.25/xl AmpliTaq, lOOng DNA and 14.25/xl dH20. Where PCR analysis was directly
from a bacterial plasmid, colonies were stabbed into the PCR reactions using a sterile
pipette tip, in place of lOOng DNA. The colony was then stabbed into a storage 96
well culture plate (see 2.7)
2.3.3 Gel Electrophoresis
Solutions
10 x Tris-Acetate EDTA(TAE)*
2M Tris




0.25% w/v Bromophenol blue
30% w/v Sucrose
For resolving standard size PCR products (100-1000 base pairs) 2% agarose gels
were prepared using routine grade agarose (Biogene, Kimbolton, UK) and lx TAE,
3/u.l of ethidium bromide (BDH, Electran, Poole, England), per 100ml gel was added
prior to pouring. 5/xl PCR product was loaded into the gel with loading buffer (lpl
per 4pl product). A 1Kb DNA ladder (Invitrogen,) was also loaded into each gel to
determine the size of the PCR products. DNA was electrophoresed at 30-80V for
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30min, or until the dye front was 1cm from the end of the gel, depending on the size
of products being resolved. PCR products were visualized using a BioRad Chemi




2.4.1 Purification of PCR products
PCR products were purified for sequencing analysis using a combination of
exonuclease I (USB, Ohio, USA) and shrimp alkaline phosphatase (SAP; USB). 5pl
of PCR amplification mixture was added to lpl exonuclease I (lOU/pl) and 2pi SAP
(lU/pl). The mixture was incubated in a Peltier PCT225 thermal cycler (MJ
Research) for 15min at 37°C and then exonuclease and phosphatase inactivated by
heating to 80°C for 15min.
2.4.2 DNA Sequencing
All sequencing reactions were performed using ABI PRISM Ready Big Dye
Terminator cycle sequencing kit with AmpliTaq DNA polymerase FS (Applied
Biosystems, Cheshire, UK).
Sequencing of purified PCR products was earned out in lOpl reactions using lOOng
of purified DNA, 40ng primer (forward and reverse separately) and 4pl Big Dye
Version 3.1 (Applied Biosystems). Amplification was performed in a Peltier PCT225
thermal cycler (MJ Research) under the following reaction conditions: (96°C -
30secs, 50°C - 15secs, 60°C - 4 min) x 25.
Sequencing of plasmid DNA was carried out in 22pl reactions using approximately
lOOng plasmid DNA, lOOng primer, 4pl Big Dye Version 3.1 (Applied Biosystems)
and 0.36mM MgCl. Amplification was performed in a Peltier PCT225 thermal cycler
(MJ Research) under the following reaction conditions: 96°C - 5min, (96°C -
30secs, 50°C - 15secs, 60°C - 4 min) x 25 #.
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All sequencing reactions were carried out in either eppendorf tubes or in 96 well
plates.
2.4.3 Precipitation of DNA from sequencing reactions
Following amplification, precipitation of sequenced DNA was performed by adding
55pl of 95% ethanol and 2ql 3M NaOAC (pH4) to the sequencing reaction mix, and
incubated at room temperature for 30 min. Samples were then spun at 1500rpm in a
Biofuge pico Heraeus centrifuge for 30 min, and the DNA pellet washed in 70%
ethanol, and dried in a hot-block (60°C) to allow complete evaporation of ethanol.
DNA pellets were stored at -20°C prior to re-suspension.
For precipitation of DNA in a 96 well format the same procedure as above was
carried out, except that plates were spun in a Sorvell RT6000 centrifuge at 2000 rpm
for 30 min, and supernatant removed by flicking the plate, and then pulse spinning
the upturned plates on paper towels at 800 rpm. 70% ethanol was used to wash the
DNA pellets, by pipetting down the side of the wells, and rapidly inverting the plate
immediately. Pellets were finally dried by a further pulse spin.
Ethanol precipitated reaction products were re-suspended in Hi-Di™ (Applied
Biosystems) and heated to 90°C for 2 min by Agnes Gallacher (MRC, Human
Genetics Unit, Edinburgh). Samples were resolved on the ABI PRISM© 3100 or
3730 genetic analysers, according to manufacturers instructions.
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2.4.4 Analysis of sequence data
Raw sequence data was analysed using Sequencing Analysis Version 3.7 or 5.2 (for
3100 and 3730 respectively) (Applied Biosystems). The alignment of multiple
sequences of the same fragment was carried out by importing all sequence data, as a
project into the Consed program. Sequencing traces were read, aligned and viewed
using the Phred/Phrap/Consed packages respectively
(www.phrap.org/phredphrapconsed.html). The consensus sequence for each project
was exported and aligned with the known sequence of each fragment using the
general purpose multiple sequence alignment program ClustalW at
http://www.ebi.ac.uk/clustalw, to obtain accurate mutation positions. Individual base
pairs highlighted by Consed as showing mutation, deletion, insertion or ambiguous
sequence were then manually curated, and mutation status confirmed as required.
65
2.5 Cell Analysis
2.5.1 Annexin V Apoptosis Assay
The Annexin V-FITC kit (Oncogene Research Products, San Diego, USA) was used
to determine the levels of apoptosis taking place in the cell lines. As a positive
control, apoptosis was induced in lymphoblastoid cells by pre-treating with lOpM
Cyclohexamide (Sigma) for 1 hour, and then an overnight treatment with lOng/ml
Tumour Necrosis Factor (R&D Systems, Minneapolis, USA).
Each cell line (apoptosis induced and untreated) was split into four, and used in the
Annexin V-FITC assay as described below with either FITC and Propidium Iodide
(PI), FITC only, PI only, or no FITC or PI.
Cell concentration was adjusted to 1 x 106 cells/ml, 0.5ml cell suspension was
transferred to an eppendorf, and 10pl media binding reagent (Oncogene Research
Products) added. 1.25|xl Annexin V-FITC (Oncogene Research Products) was added
to the appropriate tubes, and incubated for 15 min at room temperature in the dark.
Tubes were spun at 1300 rpm for 5 min in a Biofuge pico Heraeus, and supernatant
was removed. The cell pellets were re-suspended in 0.5ml cold lx binding buffer
(Oncogene Research Products), and 10pl PI (Oncogene Research Products) added to
the appropriate samples. All samples were placed on ice until analysis by flow
cytometry.
2.5.2 Flow Cytometry
Assistance with Flow Cytometry was given by Kay Samuel (John Hughes Benett
Laboratory, Dept. Oncology, Western General Hospital, Edinburgh), using a
FACSCaliber cytometer with CellQuest software (Becton Dickinson Biosciences,
Franklin Lakes, USA). The Annexin V-FITC signal was quantified at 518nm, and the
Propidium Iodide signal at 620nm. The flow cytometer was set up using the
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cyclohexamide/TNF apoptosis induced cells stained with FITC only, and PI only.
Output data was obtained for 20,000 cells in each treatment group, and showed the
log of the annexin V-FITC fluorescence on the X axis, and the log of the PI
fluorescence on the Y axis
2.5.3 Transfection of cell lines
Transfection of cell lines with DNA plasmids was carried out using Lipofectamine™
2000 (Invitrogen) in a 6 well format according to manufacturers instructions.
2.5.4 B-gal assay for transfection efficiency
A (3-Galactosidase enzyme assay system (Promega, Madison, USA) was used to
control for transfection efficiency in all transfection experiments. Cells were co-
transfected with the pSV-(3-Galactosidase control vector (Promega) and vector of
interest, and fUGalactosidase activity measured in cell aliquots according to
manufacturers instructions for a 96 well plate assay. Absorbance was read at 420nm
using a Multiskan MS plate reader (Labsystems, Basingstoke, UK).
2.5.5 FACs analysis of GFP transfected cells
Assistance with FACs analysis was giving by Eric Miller (CR UK Cancer Research
Centre, Edinburgh) using a FACSCaliber cytometer with CellQuest software (Becton
Dickinson Biosciences). For the analysis of levels of green fluorescent protein
expressed by transfected cell lines, cells were harvested using TV, spun at 1200 rpm
in a Wifug 500E, washed, and re-suspended in 1ml PBS. The GFP signal was
quantified at 507nm, and data for 5000 cells in three separate experiments (total of
15,000 cells) of each cell type, in each treatment group was acquired.
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2.6 Site Directed Mutagenesis
Site directed mutagenesis was carried out on the pEGFP-Cl vector (Becton
Dickinson Biosciences) using a QuikChange® site directed mutagenesis kit
(Stratagene, La Jolla, USA), using the primers listed below. See chapter 5 for further
details.
2.6.1 Oligonucleotides
Oligonucleotides for site directed mutagenesis were designed using a web-based
primer design software program, specifically for designing optimal mutagenic
primers for use with the QuikChange site directed mutagenesis kit. The program
incorporates all relevant design guidelines for use with the kit, and is accessed at
http://labtools.stratagene.com/OC.
The oligonucleotide sequences used are:
L45T-1 Forward 5' -TACGGCAAGCTGACCTGAAAGTTCATCTGCACC-3'
L45T-1 Reverse 5' -GGTGCAGATGAACTTTCAGGTCAGCTTGCCGTA-3'
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2.7 Cloning and Bacterial Culture
Media
Luria Broth (L-Broth)*
0.1% w/v Tryptone (Difco)
0.05% w/v Yeast extract (Difco)
171mM NaCl
Luria Agar (L-Agar)*
0.1% w/v Tryptone (Difco)
0.05% w/v Yeast extract (Difco)
171mM NaCl
0.15% w/v Agar (Oxoid Ltd)
Terrific Broth (Ter-Broth)*
0.12% Tryptone (Difco)
0.24% w/v Yeast extract (Difco)
0.04% Glycerol
1 x TB phosphate







40mg/ml X-gal (Sigma) in Dimethylformamide (DMF)
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2.7.1 TA Cloning and transformation
Individual alleles were cloned using a TOPO TA kit, version Q (Invitrogen).
Genomic DNA was PCR amplified as described above (2.3.2) using the Expand
High Fidelity PCR system (Roche), and purified using exonuclease I (USB) and
Shrimp Alkaline Phosphatase (USB), as described above (2.4.1). Post-amplification
addition of 3' deoxyadenosine (A) overhangs to the PCR products was carried out
prior to ligation into the cloning vector, to ensure cloning efficiency; lp.1 Taq
Expand, lpl Expand Buffer (Roche), lpl dATP (Invitrogen) and 2pl dHiO were
added to 5p,l PCR product, and incubated at 72°C for 15 min in a Peltier PCT225
thermal cycler (MJ Research). PCR products were cloned into pCR 2.1-TOPO
vectors (Invitrogen) according to manufacturers instructions. Clones were then
chemically transformed into TOPIO E.coli strains (Invitrogen) according to
manufacturers instructions. 50pl of each transformation was spread onto selective L-
agar plates containing ampicillin (50p,g/pl) and X-gal (40pg/ml). Plates were
incubated, upside down overnight at 37°C. This enabled light blue/white screening of
transformants; dark blue colonies contain the vector without the insert.
2.7.2 Colony selection and storage
White and light blue bacterial colonies were picked using sterile pipette tips.
Colonies were stabbed into a 96 well stock plate containing 200|il L-Broth
containing ampicillin (50pg/ml), and then into the corresponding well of a 96 well
PCR plate containing 24pl mastermix with M13F and M13R primers as described
above (2.3.2). A PCR hot start of 94°C for 6 min was used to burst the bacterial walls
prior to amplification of plasmid DNA. PCR analysis of clones indicated those that
contained the correct length insert, and these were then cultured for DNA
purification. Stock plates were incubated at 37°C and shaken at 1601pm overnight,
long-term storage of these plates was at -70°C after the addition of 25pl glycerol to
each well. DNA was purified from stock plates, by thawing on ice, and inoculation
into an additional 96 well plate containing 1.2mls/well Ter-broth with 50|ig/ml
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ampicillin, these plates were incubated at 37°C for 18 hours shaking at 300rpm #.




A SALSA P043 APC Multiplex Ligation-dependent Probe Amplification (MLPA)
kit (MRC-Holland, Amsterdam, Netherlands) was used to quantify APC nucleic acid
levels in a series of 51 unrelated individuals clinically diagnosed with a multiple
polyp phenotype in whom no germline APC mutation had been identified. Blood
DNA from these patients was collected and extracted by Prof. M Dunlop and Dr S.
Farrington as part of an ongoing panel of samples from individuals with CRC, DNA
had been extracted previously as described above (2.2.4). The MLPA technique
allows DNA samples to be screened for exonic deletions and duplications that are not
detectable by other mutation detection techniques, such as PCR and sequencing, as
well as the most frequent small deletions at codons 1061 and 1309. 50ng of DNA
from each patient, and 3 controls with known APC deletions were analysed
according to manufacturers instructions using a Hybaid Touchdown thermal cycler.
2.8.2 Fragment size analysis using the ABI310 genetic analyser
Following the PCR reaction, 0.75pl of each product was mixed with 0.75pl dFLO,
0.5pl Genescan 400HD ROX (Applied Biosystems) as an internal standard, and 12pl
deionised formamide (Applied Biosystems). Products were denatured by heating to
94°C for 2 min, and then separated on an ABI310 genetic analyser (Applied
Biosystems) according to manufacturers instructions, using POP-4 polymer (Applied
Biosystems), 10 second injections at 15kV, and a run time of 40 min per sample at
60°C and 15kV, with filter set C.
To analyse the output data from the Genescan 350 data collection software version
1.0.4 (Applied Biosystems), peak size and areas were exported to an Excel
spreadsheet, available from www.mrc-holland.com. For normalisation, relative probe
signals were calculated by dividing each measured peak area by the sum of all peak
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areas for that sample. Normalised peak areas are compared to the average results
obtained on all samples. Samples with a reduction in relative peak area of 30% or
greater were repeated to verify results.
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2.9 In Silico Database Comparisons and Mutation Analysis
2.9.1 APC Mutation Databases
The latest version of the APC database, containing over 2000 mutations and the
corresponding reference list, was obtained from Prof. Thierry Soussi (Laboratoire de
Genotoxicologie des tumeurs, Paris) on 27th February 2004 (T. Soussi, personal
communication). The database was searched to identify all germline mutations
arising in FAP patients, and the corresponding references were obtained to
extrapolate whether they were familial or new (de novo) mutations. These references
are listed in Appendix C. Likewise, the Scottish APC database compiled by Dr Susan
Farrington (S. Farrington, personal communication) was searched to identify all de
novo germline mutations arising in FAP patients. These de novo APC mutations were
then analysed for any patterns emerging in their spectrum (type, location etc.).
2.9.2 Mutation Analysis
The de novo mutation frequencies of the APC, NF1, FGFR2, VHL, /3-globin and a-
globin genes were obtained from published literature. Analysis and comparisons
were carried out to determine how the new mutation rate of the APC gene compared
with other genes involved in disease.
The spectrum of de novo mutations (2.9.1) of the APC gene was compared with the
published database for the PAX6 gene, and the known de novo mutations from the fd-
globin gene.
Polymorphism data from (Bustamante et al., 2005) was obtained for the APC gene.
The rates of synonymous and nonsynonymous substitutions were also calculated for
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2.10.1 Preparation of nuclear extracts
Western analysis was used to determine nuclear levels of the MMR proteins MLH1,
MSH2, MSH6, and PMS2, and the BER protein MYH by western blotting. Cells were
scraped in PBS from two confluent T25 flasks for each extract. Cells were spun at
1200 rpm in a Biofuge pico Heraeus centrifuge for 5 min, and re-suspended in 5mls
PBS. Cells were then lysed in approximately 3x cell volume of lysis buffer (~80pl)
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containing Complete™ protease inhibitor cocktail at 1:1250 dilution (Roche
Diagnostics), ImM pepstatin A (Sigma) and lOOmM PEFA block (Roche
Diagnostics). Cytoplasmic extract was removed by centrifugation at 6000rpm at 4°C
for 20 min in a Micromax RF IEC centrifuge and discarding the supernatant. Nuclei
were then lysed by re-suspending the pellet in approximately 1.5x cell volume
(~30pi) hypertonic buffer containing Complete™ protease inhibitor cocktail at
1:1250 dilution (Roche Diagnostics), ImM pepstatin A (Sigma) and lOOmM PEFA
block (Roche Diagnostics), and incubated on ice for 20 min. Debris was cleared by
centrifugation at 13000rpm at 4°C for 5 min in a Micromax RF IEC centrifuge.
Total protein concentration was determined by Bradford assays (Biorad, Hercules,
USA), read on a Multiskan MS plate reader (Fabsystems), and nuclear extracts
adjusted to 20pg by adding PBS.
2.10.2 Western analysis
Nuclear extract was added to a 1:6 dilution of sample buffer, boiled in a hot block for
5 min, and placed on ice. Samples were resolved by denaturing SDS-PAGE on a 7%
polyacrylamide gel in 1 x running buffer at 100 volts for approximately 1 hour. Pre-
stained molecular weight markers (Biorad) were run on each gel. Prior to transfer,
gels were pre-soaked in semi-dry transfer buffer and the nitrocellulose membrane
prepared by coating first in 100% methanol and then also in transfer buffer. Proteins
were transferred to the nitro-cellulose membrane using a Biorad mini Trans-blot
semi-dry Transfer cell for 35 min at 20 volts.
Blots were blocked in 5% dried milk (Marvel) and 0.3% Tween (Sigma) in PBS,
overnight at 4°C. Blots were incubated for 1 hour with primary monoclonal
antibodies (see table 2.4 below), washed in 5% dried milk (Marvel) and 0.3% Tween
(Sigma) in PBS for 3 x 10 min, and then incubated for 1 hour with horseradish
peroxidase conjugated sheep antirabbit IgG secondary antibody (for all primary
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antibodies) (Amersham), and washed as before. (3-actin was used as a loading control
for all blots.
Protein bands were detected using ECL western blotting protocol (Santa Cruz
Biotechnology, Buckinghamshire, UK) according to manufacturers instructions.
Blots were stripped prior to re-probing with an antibody raised in the same animal by
adding to a glass staining jar containing 50ml strip buffer, this was heated to 60°C
using a heat block and 400pl (3-mercaptoethanol added. After incubation for 40min,
strip buffer was removed, blots washed in 5% dried milk (Marvel) and 0.3% Tween
(Sigma) in PBS and then blocked overnight as before.
Densitometry was performed on blots to quantify protein levels. Gel pictures were
scanned using a Hp Scanjet 7400c scanner and saved as .tiff files. These were used to
create a volume report using QuantityOne (BioRad) software, this was opened in an
Excel file, and protein band volumes normalised using the (3-actin loading controls.
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Table 2.4 Antibodies used in this thesis, details of manufacturer, and working concentration.
Antibody Manufacturer Dilution Used
MSH6 BD Biosciences 1 500
PMS2 BD Biosciences 1 500
MSH2 BD Biosciences 1 500
MLH1 BD Biosciences 1 500
MYH Alpha Diagnostic Intl. Inc. 1 400
p-ACTIN BD Biosciences 1 1000
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2.11 Calculations and Statistics
2.11.1 Statistical Analysis
Statistical advice, in the form of confirming the most appropriate statistical test to
employ for any given null hypothesis was provided by Andrew Carothers (MRC,
Human Genetics Unit, Edinburgh). Chi squared (Minitab. V14) was used to
determine whether the frequency of a given event was observed more often than
would be expected by chance. Critical values for the Chi squared distribution were
obtained from www.psvchstat.smsu.edu/introbook/chisq.htm and the null hypothesis
was rejected if the Chi squared statistic exceeded this value at the 95% significance
level. Specific statistical calculations and methodology of data analysis is described
in more detail in the relevant results chapters.
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Chapter 3
Analysis of the Instability of APC Gene Sequences
and the Influence of Defective DNA Repair
3.1 Introduction
It is apparent that the APC gene is mutated in the majority of colorectal cancers
(Powell et al., 1992;Nagase and Nakamura, 1993;Huang et al., 1996;Fodde et al.,
2001b) however, the specific mechanisms by which these mutations are arising is not
clear. One potential mechanism is that selection pressures are acting on this vital
gate-keeper gene allowing advantageous mutations to become fixed. Another
hypothesis is that mutations are arising spontaneously as a consequence of genomic
instability. Genomic instability within multiple lineages would subsequently lead to
greater clonal diversity, increasing the chances of progression to carcinogenesis
(Maley et al., 2006). Alternatively, an interplay between clonal selection and
genomic instability is also a possibility.
Defects in DNA repair processes that maintain genomic stability provide an
environment in which mutations can remain undetected, becoming fixed in
subsequent cellular populations and contributing themselves to clonal expansion.
Genome instability is now recognised as an important factor contributing to the
initiation and progression of cancer, and in this chapter I have utilised a number of
cell lines and in vivo patient samples to explore the hypothesis that the APC gene
may be inherently unstable.
Our hypothesis that the APC gene may be inherently unstable is supported by two
observations. Firstly, the rate of new germline APC mutations; approximately 25% of
all FAP cases are thought to be due to de novo mutations (Bisgaard et al., 1994). It
should be noted however that a small number of these de novo mutations have been
shown to be a result of mosaicism (Farrington and Dunlop, 1999), and another
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unknown proportion of this 25% of cases are likely to be due to other genetic
predisposing conditions, unknown at the time of the Bisgaard study, such as MAP.
The second observation is the apparent susceptibility of APC to the mutagenic effect
of DNA repair deficiencies. Lack of activity in both the MMR (Huang et al., 1996)
and BER (Al Tassan et al., 2002;Jones et al., 2002) pathways leads to hereditary
colorectal cancer syndromes, in which APC inactivation, dysregulated Wnt
signalling, and silencing of EPHB2 expression (Batlle et al., 2005) are thought to be
the first pathogenic events in tumour progression.
I have employed a cloning based approach to detect the underlying genomic
variation arising spontaneously during cell replication and division in individual
alleles. This strategy has been used effectively before to examine the effect of
defective MMR on repetitive regions of the TGF/3R2 and BAX genes, selective
advantage imparted by mutation is excluded and therefore, unbiased reporting of true
mutation frequencies is possible (Bacon et al., 2001).
To address the question of whether the APC gene is inherently unstable I have
compared the frequency of mutations arising in a specific region of APC (B1D2, see
3.2.1) with the frequency of mutations arising in similar sized regions from two
control genes. The TGFJ3R2 gene (MIM 190182) is involved in carcinogenesis, it
belongs to the serine-threonine kinase family of receptors, and transduces the
transforming growth factor-beta inhibitory signal; the loss of this negative regulation
can contribute to tumour development. TGF/3R2 is found to be inactivated in a subset
of colon cancer cell lines with MSI (Parsons et al., 1995), there is one report of a
germline mutation event in familial CRC (Lu et al., 1998) and the signalling pathway
is disrupted in most colorectal cancers. GPD1 (Glycerol 3-phosphate dehydrogenase,
MIM 138420), is a house-keeping gene expressed in the colon, and used previously
as a control gene in studies of MMR as it is not implicated in any disease or cancer
(Geisler et al., 2003).
82
3.2 Methodological Overview
3.2.1 Amplification of APC, TGF/3R2 and GPD1 gene fragments
A 955bp region from nt 2202 to nt 3157 upstream of the mutation cluster region in
exon 15 was amplified from the APC gene (Ace. No. BC111591), using
combinations of the primers listed in Table 2.3. A 883bp region of exon 4 of the
TGFJ3R2 gene from nt 65100 to nt 65983 (Ace. No. AY675319) was amplified using
primers TGFBR2ex4F and TGFBR2ex4R (2.3.1). A 700bp region of the GPD1 gene
from nt 3505 to nt 4205 (ENSG00000167588), encompassing exons 6 and 7 was
amplified using primers GPDlex6+7F and GPDlex6+7R (2.3.1). The sequence of
GPD1 intron 6 was excluded from our analysis, to prevent the possibility of different
constraints on non-coding sequence affecting comparisons between the 3 gene
regions. In each case lOOng DNA template was used for amplification, with the
Expand High Fidelity PCR system, as described in 2.3.2.
3.2.2 Cloning of Individual APC, TGF0R2 and GPD1 alleles
Individual alleles were cloned from PCR products obtained above (3.2.1), into PCR
cloning TA overhang vectors as described in 2.7.1. All clones were PCR amplified to
ensure the presence of an insert of the appropriate size, by direct PCR analysis from
each bacterial colony using M13F and M13R primers as described in 2.3.1. Insert
positive bacterial clones were subsequently grown and plasmid DNA harvested as
described in 2.7.2.
3.2.3 Sequencing of cloned alleles
Individual alleles were sequenced from plasmid DNA as described in 2.4. Each insert
was sequenced directly from the positive insert clones using M13F and M13R vector
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specific primers (2.3.1). Sequence data was analysed as described in 2.4.4, for the
presence of mutations.
3.2.4 Statistical Analysis
The mutation frequency for each cell line was calculated at each locus analysed. The
total number of mutations observed was divided by the total amount of high quality
sequence analysed (in kilobases) to give a mutation frequency/Kb. It is assumed that
a mutation is equally likely to occur at any individual base pair by chance.
Differences in the number of nucleotides found to be mutated, out of the total
number of nucleotides analysed at any given locus from different DNA templates
were then evaluated for significance using a Chi-squared analysis as described in
2.11.1. The cut-off for significant p values was taken as 1%.
3.2.5 Cell lines
Epstein-Barr virus (EBV) transformed lymphoblast cell lines ConC, ConA, lbl-1260,
lbl-1261 and colorectal cancer cell lines HCT116, VAC0425 and the primary
fibroblast cell line 2630 (2.1.1) were used. Cells were cultured as described in 2.1.2
and DNA extracted from them as described in 2.2. ConC and ConA cell lines are
derived from healthy individuals with no family history of colorectal cancer. Cell
line lbl-1261 is derived from patient 6 referred to by Parsons et al. and displays a
mutator phenotype due to what was originally thought to be a dominant negative
mutation in PMS2 (Parsons et al., 1995;Hamilton et al., 1995;Bacon et al., 2001), but
has subsequently been demonstrated to be a compound heterozygote (De Vos et al.,
2004). Cell line lbl-1260 is derived from patient 4 (Parsons et al., 1995) and displays
a mutator phenotype at microsatellite sequences, but not gene sequences (Bacon et
al., 2001) due to an MLH1 mutation. VAC0425 has been characterised as having
severely reduced levels of MYH mRNA, a complete absence of detectable MYH
protein, and no 8-Oxo-G repair activity (Parker et al., 2002). 2630 is a fibroblast cell
84
line derived from the abdominal skin of a patient with germline bi-allelic inactivation
of the MUTYH gene.
3.2.6 Patient Samples
Normal mucosa/blood (NM/NB) and tumour (T) patient samples used in this chapter
are listed in Table 2.2. The patients with sporadic CRC have been screened
extensively for MMR and BER defects, and none have been found (Susan
Farrington, personal communication). DNA was purified from formalin fixed,
paraffin embedded samples as described in 2.2.3. DNA was purified from fresh
normal and tumour colonic samples, and blood as described in 2.2.4. Due to the large
numbers of patient samples analysed, the TGF/3R2 gene region was not included in
the in vivo analysis of mutation frequencies.
3.2.7 Characterisation of cell lines by western blot analysis
Nuclear extracts were prepared from cultured cells as described in 2.10.1. Western
analysis was used to determine nuclear levels of MMR and MYH proteins, as
described in 2.10.2, using antibodies listed in Table 2.4.
3.2.8 Apoptosis Assay
Annexin V apoptosis assays (Oncogene Research Products, San Diego, USA) were
carried out on cell lines lbl-1260, lbl-1261, ConA and ConC as described in 2.5.1.
For each assay apoptosis induced cells (treated with cyclohexamide and TNF) and
untreated cells were analysed for levels of early and late apoptosis. Results from the
untreated cells of 3 separate assays (20,000 cells per assay) carried out on successive
weeks were used to determine the basal levels of apoptosis in each cell line. Standard
errors were calculated for each cell line.
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3.3 Results
3.3.1 Mutation frequencies and spectra of cell lines
A detailed analysis of all mutations detected from all cell lines and genes analysed,
including mutation type and location is presented in Appendix A. To address whether
the APC gene is inherently unstable in the presence of normal DNA repair the level
of spontaneous mitotic mutations arising in the B1D2 region was assessed in 2
normal (DNA repair proficient) control cell lines, ConC and ConA (Table 3.1).
These frequencies were compared with those observed for ConC and ConA in two
control gene regions from TGF/3R2 and GPD1 (Table 3.1). Analysis of the observed
mutation frequencies in the ConC and ConA cell lines reveals significantly higher
mutation frequencies in the APC gene, compared to the 2 control genes TGFJ3R2 and
GPDL ConC; %2=19.3, p<0.0001, ConA; x2=14.728, p=0.001. The vast majority of
mutations detected in ConC and ConA at all three genes were transition mutations,
with a single T:A-G:C transversion mutation detected in the APC gene from ConA
DNA.
To further address whether the APC gene is inherently unstable, and understand
whether mutations might arise in APC that are usually repaired by MMR, we have
analysed the mutation frequencies of our three genes in three cell lines with MMR
defects. Individual alleles from the 3 gene regions were cloned from the MMR null
lymphoblastoid cell line lbl-1261, MMR null colorectal cancer cell line HCT116, and
the MMR heterozygote lymphoblastoid cell line lbl-1260 (3.2.5). In contrast to the
control cell lines, in all three MMR defective cell lines, no significant difference was
seen between the mutation frequencies of the three genes studied (Table 3.1).
However, lbl-1260 had elevated mutation frequencies at all gene sequences
compared with lbl-1261 and HCT116. The mutations arising in these MMR defective
cell lines displayed a similar spectrum to those observed in the control
lymphoblastoid cell lines (see above). The possibility that changes in the rate of
apoptosis are affecting the observed raised mutation frequency of lbl-1260 have been
initially addressed using Annexin V assays (see section 2.5.1). However, neither lbl-
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1260 or lbl-1261 cell lines demonstrated any increase in levels of apoptosis over
control cells (data not shown).
To determine how instability in the APC gene might be influenced by other DNA
repair deficiencies we examined two cell lines with BER deficiencies. The mutation
frequencies for all genes in the 2630 and VAC0425 cell lines were significantly
higher than those observed in the MMR deficient cell lines, lbl-1261 and HCT116;
%2=90.066, p<0.0001. The APC frequencies of the BER null cell lines were also
higher, but not significantly, than the elevated mutation frequencies observed in the
normal lymphoblastoid cell lines, ConC and ConA and the MMR heterozygote cell
line, lbl-1260. Overall, the propensity for transition mutations that is seen in the
control and MMR deficient cell lines is also seen in the BER defective cell lines.
Interestingly however, both BER null cell lines also have a number of transversion
mutations present at the APC gene, 2 of 76 in VAC0425 and 3 of 82 in 2630,
representing 2.6% and 3.7% respectively. At the GPD1 gene a single transversion
mutation was identified in VAC0425 DNA, representing 3.7% of total mutations. In
all cell lines the spectrum of transition mutations at all genes shows an increase in the
frequency of T:A-C:G and A:T-G:C changes compared with C:G-T:A and G:C-A:T
changes.
Western blotting was carried out to confirm the DNA repair status of each cell line,
previously inferred from the mutations harboured by the individuals from which the
cell lines were derived (data not shown). The data confirmed that cell lines lbl-1260,
lbl-1261 and HCT116 do indeed have MMR defects resulting from known gene
mutations, and likewise that ConC and ConA are MMR proficient. Levels of MYH
protein were also significantly reduced in cell lines 2630 and VAC0425.
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Table 3.1 Mutational analysis of APC exon 15 B1D2 region, TGF/3R2 exon 4 and GPD1
exons 6 & 7 in 7 cell lines.









ConC 80 65.586 38 0.58
ConA 71 62.159 39 0.63
lbl-1260 134 117.514 74 0.63
APC lbl-1261 154 129.68 24 0.19
HCT116 96 85.497 20 0.23
VAC0425 91 86.663 76 0.88
2630 94 89.864 82 0.91
ConC 56 49.594 12 0.24
ConA 26 25.086 3 0.12
lbl-1260 30 27.545 12 0.44
TGFBR2 lbl-1261 69 67.024 10 0.15
HCT116 41 38.014 2 0.05
VAC0425 47 39.088 24 0.61
2630 26 22.958 19 0.83
ConC 70 23.857 0 Undetectable
ConA 74 25.086 5 0.2
lbl-1260 46 15.118 5 0.33
GPD1 lbl-1261 20 6.674 0 Undetectable
HCT116 26 8.602 0 Undetectable
VAC0425 109 25.397 27 1.06
2630 69 16.077 9 0.56
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3.3.2 Mutation frequencies and spectra of patient samples
To determine whether or not it is possible to detect instability of the APC gene in
vivo, normal and tumour DNA's from 18 patients (3.2.6) were analysed in a similar
way to the cell line DNA. Details of all mutations detected in the in vivo samples are
listed in Appendix B.
Comparison of mutation frequencies from patients with sporadic CRC and the data
obtained for MUTYH heterozygote and homozygote patients shows that mutation
frequencies in both the APC and GPD1 genes in MUTYH heterozygotes are generally
higher than in MUTYH wild-type (sporadic) individuals (Figure 3.1). Additionally,
MUTYH homozygote mutation frequencies tend to be higher than in both the
sporadic and MUTYH heterozygotes. No significant differences were seen between
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Figure 3.1 Comparison of mutation frequencies in all 36 in vivo samples. MUTYH compound
heterozygotes, homozygotes and heterozygotes were compared with HNPCC and sporadic
CRC patients for mutation frequencies at the APC and GPD1 genes.
Overall there was an increase in transversion mutations observed in the tumour
samples of MUTYH heterozygotes and homozygotes in contrast to the spectrums
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observed in the sporadic and HNPCC individuals. No significant difference was seen
in the occurrence of transversions between normal and tumour samples in sporadic
and HNPCC patients. However, there was a difference in the proportion of
transversion mutations present in the APC tumour DNA of the MUTYH
heterozygotes, compared with the sporadic samples (p=0.014). This suggests that as
a general trend there may be a heterozygous effect on mutation spectrum of having a
single inactivated copy of MUTYH. Interestingly, G:C-T:A transversions were seen
in the in the APC gene, but not in the GPD1 gene in any samples studied.
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3.3.3 Comparison of mutations detected in cell lines and patient
samples, with known synonymous changes in APC
To determine whether or not the mutations detected in our cloning based assay were
indeed 'real' mutations and not artefacts from the initial PCR amplification of
sample DNA^s, a comparison was set up between the mutations presented in 3.3.1
and 3.3.2 (and listed in Appendices A and B) and synonymous changes in the
equivalent portion of the APC gene that have been reported in human material.
No synonymous changes are reported between codons 736 and 1054 (B1D2 portion)
of the APC mutation database (Thierry Soussi, 2004) or the HGMD database (March
2007). A single SNP is reported in this region in the ensembl database
http://www.ensembl.org/index.html. A human-mouse alignment of APC (see section
6.2.3) revealed 40 synonymous changes between the two sequences. Using the
Xenopus gene sequence (see section 6.3.3), 14 synonymous changes were found to
have occurred in the mouse lineage and 11 in the human lineage. The lineage of the
remaining 15 synonymous changes could not be determined. These 11 synonymous
changes, the single emsembl SNP and a single synonymous change in the human
lineage detected in the human-chimp alignment (Table 6.12) were compared with the
1720 mutations detected in the B1D2 APC region in cell lines and patient DNA
(Table 3.2 and Appendices A and B).
The synonymous mutations in Table 3.2 represent 'real' mutations, that is, mutations
that have occurred naturally in the B1D2 region of APC, and are not under any
selection pressure. If the mutations detected in cell lines and patient samples by our
assay are also 'real' mutations and not PCR artefacts one would expect a comparison
of the spectra of the two groups to be similar. However, despite only 13 'real'






































































Table 3.2 Synonymous changes in the B1D2 region of APC that have been reported in
human material are compared with mutations detected in patient samples and cell lines
using our cloning based assay.
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3.4 Discussion
Data presented in this chapter demonstrates that a region of the APC gene may be
hypermutable in control (MMR and BER proficient) cell lines derived from normal
tissue (lymphocytes), when compared with sequence from regions in the TGFJ3R2
gene, and a control gene GPD1 (ConA, p=0.001, and ConC, p<0.0001) (3.3.1).
These cells do not possess an increased mutational load from a defective DNA repair
system, and a significantly high APC mutation frequency is revealed, whilst no such
increase in mutation frequency in the TGF/3R2 or GPD1 genes is observed. Few
studies have looked at mutation frequencies in non-repetitive sequences (Takenoshita
et al., 1997), however, this finding is consistent with previous work showing that
normal control cells can display detectable mutations (Bacon et al., 2001).
This observation suggests that there may be an inherent susceptibility to mutation
within the APC gene, which might contribute to the frequency of mutations found
early in sporadic tumourigenesis. This is the first demonstration that the APC gene
has the ability to be hypermutable in normal cells, and may also go some way to
explaining why APC is mutated somatically in 85% of CRCs (Powell et al.,
1992;Miyaki et al., 1994) and how certain regions of APC, such as the mutation
cluster region are specifically affected (Miyoshi et al., 1992).
The BER defective cell lines VAC0425 and 2630 appear to be associated with a
similar increase in mutational load as is seen in the MMR heterozygote lbl-1260 cell
line, with mutation frequencies being elevated in all three genes studied (3.3.1). In
the heterozygote MMR cell line lbl-1260 this may demonstrate that 'normal' cells
with a heterozygote MLH1 defect show a subtle mutator phenotype that might
explain the propensity for disease progression at an earlier age. Alternatively, there
may have been other events occurring in this cell line that are affecting repair that we
are not aware of. When compared to the mutation frequency increase in APC seen in
normal lymphoblastoid cells the mutation frequency increases at VAC0425 and
2630 appear modest, and therefore this increase alone cannot account for the large
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increase in tumour number seen in MAP patients (typically 10's to 100's adenomas
compared to normal individuals of the same age with 0 to 1 adenoma).
The statistically significant increase in APC mutation frequencies compared with
control genes in the both normal cell lines, provides evidence to support the majority
of mutations detected by this assay being genuine and suggests that PCR error does
not significantly bias the results obtained. However, the possibility that many of the
mutations observed have been generated during PCR amplification cannot be ruled
out. To go some way to addressing this issue the expected number of PCR errors was
estimated for all cell lines and patient samples using the published error rate for the
Expand High Fidelity PCR system (Boheringer Mannheim). These figures showed
that the raised mutation frequencies observed at the APC gene in ConC and ConA
were indeed significantly higher than expected due to Taq polymerase error
(p<0.0001). In addition, repeat sequencing and re-isolation of plasmid stocks
confirmed mutations in all cases. Nevertheless, this cannot counter the effect of
mutations occurring in early clones during the culture of the cell lines (see below),
during the initial PCR amplification step, or due to a property of the APC gene that
might itself induce Taq polymerase errors (i.e. local DNA conformation). To
determine whether or not PCR errors are having a significant impact on these results
it would be useful to try and induce/prevent errors in the initial PCR amplification
step, by using low fidelity conditions or altering DNA confirmation by cloning the
sequence into a vector prior to PCR amplification. If a further increase/decrease in
similar types of mutations were seen, then this would provide good evidence that
these mutations are PCR induced errors and not 'real' mutations. Although this assay
has been used previously (Bacon et al., 2001), this study concentrated on repetitive
regions where the mutation frequency is several fold higher than at non-repetitive
regions, and therefore errors induced by PCR amplification made up a much less
significant proportion of the errors observed.
Generally, mutation frequencies calculated from populations of cells in culture are
inadequate indicators of spontaneous mutation rates. This is because the population
of mutants in a culture of cells is composed of clones, each of which arose from an
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individual cell that sustained a mutation. The size of a given mutant clone will
depend on when during the growth of the population the mutation occurred. This is
the fundamental property of spontaneous mutation that was exploited by the famous
Luria Delbrtick fluctuation test (Luria and Delbruck, 1943). The model was
expanded in 1949 by Lea and Coulson (Lea and Coulson, 1949) to create 'The model
of expansion of mutant clones'. This states that when a population is growing
exponentially, as in a cell culture, the appearance of new mutants, plus the
proliferation of pre-existing mutants results in a constant increase in the mutant
fraction each generation. The mutation rate is this increase and can be determined by
measuring the change in the mutant fraction over time. A population of cells must be
of a sufficient size so that the probability that mutations occur each generation is the
same. However, by the time the population reaches a sufficient size, some mutations
will have already occurred. These will produce clones of mutants that make it
impossible to accurately measure the accumulation of new mutants. To address the
effect that the expansion ofmutant clones might have had on the results presented in
this chapter, an early passage of the lbl-1260 cell line was analysed for mutation
frequency. No significant difference was detected between the early and late
passages (early; 20 mutations in 39.933Kb sequence - 0.501 mutations/Kb Vs later
passage; 0.63 mutations/Kb x2=0.83, p=0.362). Based upon the theory of expansion
of mutant clones, one would expect a higher mutation frequency from the later
passage, therefore this data provides further weight to the argument that the results
observed in this chapter are largely due to PCR error. In addition, the data from the
patient samples (3.3.2) is much more variable than that from the cell line data (3.3.1),
and this is likely to be due to the vast number of highly complex selection barriers
that are acting upon the in vivo colon during the clonal process of tumourigenesis,
compared with the cell line situation (Cahill et al., 1999c).
The analysis of mutation spectrums has been used previously to uncover the
mechanism by which mutations are being created (Al Tassan et al., 2002f), for this
reason the mutation spectrums of all genes, cell lines and patient samples were
examined. Previously, C:G-T:A transitions have been reported as the most common
somatic APC point mutations in colorectal tumours (Nagase and Nakamura,
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1993;Laurent-Puig et al., 1998a). Here we have shown a predominance for T:A-C:G
and A:T-G:C transitions, although due to small numbers significance has not been
able to be tested in many cases. A slight increase in transversion mutations was
detected in the VAC0425 and 2630 cell lines and MUTYH homozygote and
heterozygote patients. However, no G:C-T:A transversions were detected in the BER
null cell lines by our assay, although a small number were seen in the patient
samples. There were significantly more transversion mutations in the tumour DNA
of the homozygote MUTYH patients than in the normal DNA (p=0.011). It is
interesting that significantly more transversions, and specifically G:C-T:A changes
have accumulated in the APC gene from tumour tissue compared with the normal
tissue. A similar, but more highly significant effect on mutation spectrum was seen in
the MUTYH heterozygotes, suggesting that there may be a heterozygous effect of
having one inactivated copy of the MYH protein. The heterozygotes appear to show
a BER defect that may not be entirely dependent on MYH, possibly implicating other
BER gene involvement. Alternatively, MYH may have a role other than BER
damage removal that is causing this signature of increased transversions mutations,
or it could be due to ascertainment; if one assumes that the heterozygous MUTYH
mutations are not having an affect then these patients may have other predisposing
problems with DNA repair. One would expect more G:C-T:A mutations to be
observed, and their absence suggests that our assay is not representative of the in vivo
situation (oxidative damage in the colon). Infact, the overall spectrum of mutations
observed, possibly with the exception of the few transversion mutations in MUTYH
mutant patients is largely consistent with PCR derived mutations. The mutations
observed in the cell line lbl-1260 and the MMR defective patient samples (1974 and
533) are also not consistent with the inactivating mutations that have been reported in
APC in HNPCC individuals (Huang et al., 1996;Huang et al., 2004). These include
insertions/deletions at (A)n tracts, and C:G-T:A transitions at CpG dinucleotides.
We have examined polymorphism (Bustamante et al., 2005), divergence
(www.ensembl.org), and chromatin environment data (J. Prendergast, personal
communication) for our 3 genes of interest, and find conflicting results for which
gene is predicted to be the most 'mutable'. This is discussed further in Chapter 6.
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Within our data we observe similar frequencies of synonymous and non-synonymous
changes occurring within the gene sequences studied, supporting the argument that
what we are observing are mutations under non-selective conditions that can be used
to deduce the true mutability of a sequence. In contrast to this, despite only 13
synonymous 'real' mutations being available for comparison with the 1720
mutations detected by our assay (3.3.3) we have observed that the spectrum of
mutations is completely different between the two groups. This provides further
evidence to support the theory that that our assay may be severely compromised by
the initial PCR amplification step.
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Chapter 4
The Influence of Defective DNA Repair on Somatic
Inactivating Mutations in APC and KRAS
4.1 Introduction
APC inactivation is a key, early event in tumourigenesis and was thought to be
necessary, and sufficient for adenoma development in all colorectal cancers (Powell
et al., 1992;Nagase and Nakamura, 1993). Most pathogenic APC mutations
(germline and somatic) cause the loss or disruption of the central p-catenin binding
region of the APC protein. These mutations are strongly selected for, because the
subsequent nuclear translocation of p-catenin provides the cell with a selective
advantage allowing for initial clonal expansion (Fodde et al., 2001b). Selection for
the 'second hit' in APC (inactivating mutation, allelic loss or promoter
hypermethylation (Esteller et al., 2000)) is widely believed to be dependent on the
first pathogenic event (Rowan et al., 2000;Albuquerque et al., 2002;Cheadle et al.,
2002). Two truncating mutations in the MCR have been shown to be the most likely
combination of events selected for, followed by one truncating mutation in the MCR
with the other event either allelic loss, or a truncating mutation out with the MCR.
Selection is lowest when neither event is a truncating mutation within the MCR
(Cheadle et al., 2002). Nevertheless, retention of one P-catenin down-regulating 20
amino acid repeat in either of the two APC alleles appears to be advantageous,
suggesting that there is an optimal level of P-catenin signalling required for tumour
formation (Albuquerque et al., 2002).
In normal cells the level of cytoplasmic P-catenin is maintained at a low level by
APC mediated degradation, but if APC is not functional, P-catenin is left unchecked,
levels rise and the protein is free to enter the nucleus. Within the nucleus, P-catenin
binds to the T-cell transcription factor 4 (TCF-4), enhancing the transcription of
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many oncogenes including c-Myc, and cell cycle regulators such as cyclin D1
(Bright-Thomas and Hargest, 2003). Nonetheless, whilst constitutive activation of
the Wnt signalling pathway is required for progression from normal epithelium to
adenoma, not all the pathway's target genes promote further neoplastic changes, and
they must be consequently modified. EphB receptors are Wnt signalling target genes,
despite the fact that they suppress colorectal cancer progression (Clevers and Batlle,
2006). In crypt progenitor cells they control cell compartmentalization along the
crypt axis through repulsive interactions with EphrinB ligands. However, during
tumour progression, when activation of (3-catenin/Tcf-4 causes the initiation of
tumourigenesis, selection acts against the expression of EPHB genes (Batlle et al.,
2005).
The KRAS oncogene codes for a small membrane attached GTP-bound protein that
plays a key role in the transduction of extra cellular mitogenic signals. Mutations in
KRAS result in the loss of GTPase activity, causing the cell to be continuously
activated and locked into proliferation. Mutations are present in a significant number
of different tumour types, including colorectal adenomas and carcinomas (Capella et
al., 1991). Between 35 and 41% of sporadic colorectal cancers are reported to
harbour activating missense mutations at either KRAS codon 12 or 13 (Tortola et al.,
1999; Kambara et al., 2004; Hsieh et al., 2005). More recently, G:C-T:A
transversion mutations at KRAS codon 12 have been described in the tumours of
MAP patients, with variable frequencies (Lipton et al., 2003; Jones et al., 2004), and
in MUTYH heterozygotes (Kambara et al., 2004).
Both the KRAS and APC genes are targets for mutation in colorectal cancer, and are
influenced by DNA repair defects. MAP, HNPCC and sporadic CRC patients have
no inherited APC or KRAS mutations, so it is possible to compare normal and tumour
material to detect the pathogenic mutations leading to a CRC phenotype. The
consequence of the absence of BER or MMR on the mutation spectrum at the APC
and KRAS loci can thus be elucidated. Previously, it has been shown that virtually all
APC truncating mutations in MAP patients are G:C-T:A transversions, and almost all
occur upstream of the di-nucleotide AA (Jones et al., 2002; Lipton et al., 2003).
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However, the consequence of carrying a heterozygote MUTYH mutation is much less
clear.
In this chapter, to further consolidate our findings from Chapter 3 we have examined
the APC and KRAS genes to deduce how DNA repair affects the mutations that are
selected for during carcinogenesis, and whether this tallies with the previous results.
In addition, we have determined whether such mutations might be useful tools for
predicting DNA repair status in Scottish colorectal cancer patients in a prognostic
setting. We describe the analysis of a 2850bp region of APC exon 15 (codons 744-
1671) that contains 8/11 of its (3-catenin binding sites, and KRAS codons 12 and 13.
Both normal and tumour tissue were amplified and sequenced, to establish somatic
mutations that were present in the tumour DNA only. We have examined 4 sporadic,
3 HNPCC, 7 MUTYH homozygotes and 11 heterozygous MUTYH colorectal cancer
patients from the Scottish population.
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4.2 Methodological Overview
4.2.1 PCR of overlapping APC fragments and KRAS exons 12 & 13
A 2.85 Kb region of APC from codon 744 to codon 1671 was PCR amplified as 9
overlapping fragments BIB2 to J1J2. PCR primers are listed on Table 2.3. KRAS
exons 12 and 13 were PCR amplified using primers KRAScodonl2F and
KRAScodonl2R (Table 2.3). In each case ~100ng of normal and tumour DNA was
amplified using AmpliTaq polymerase, as described in 2.3.2.
4.2.3 Sequencing of APC Fragments
PCR products were resolved on 2% agarose gels as described in 2.3.3. PCR products
of the correct size were then purified using exonuclease and shrimp alkaline
phosphatase as described in 2.4.1. Following purification, PCR products were
sequenced using the same primers as for the amplification step, and analysed as
outlined in 2.4.
4.2.4 DNA Samples
Normal mucosa/blood and tumour patient samples used in this chapter are listed in
Table 2.2 (individuals 533 and 1299 were not included in the analysis in this
chapter). DNA was purified from formalin fixed, paraffin embedded samples as
described in 2.2.3, or from fresh normal and tumour colonic samples, and blood as
described in 2.2.4.
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4.2.5 Cloning of Individual alleles from sample 2650
The PCR primers APCexl6Gl and APCexl5G2 were used to amplify the G1I2
fragment from the tumour sample of individual 2650. This was cloned into a TA
vector as described in 2.7.1/2.7.2. Sequencing of plasmid DNA was carried out as
described in 2.4. Each insert was sequenced using M13F and M13R vector specific
primers (2.3.1). Sequence data was analysed as described in 2.4.4 to determine if the
two truncating mutations (listed on Table 5.1) occurred on the same or different
alleles.
4.2.6 Statistical analysis
Differences in the number of patients with mutations in either APC or KRAS were
evaluated for significance using a Chi-squared analysis as described in 2.11.1. The
cut-off for significant p values was taken as 1%.
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4.3 Results
Analysis of 26 archival colorectal tumours identified nine (35%) APC mutations and
six KRAS mutations that are predicted to alter protein function. In none of these cases
was the variant present in the constitutional DNA. Table 2.2 gives details of the
genotype and samples used for the 26 patients screened for APC and KRAS
mutations.
4.3.1 Somatic KRAS and inactivating APC mutations reflect bi-
allelic MUTYH mutation status
Six of the seven (86%) individuals with biallelic inactivation of the MYH protein
{MUTYH homozygotes), had a tumour specific G:C-T:A transversion at codon 12 of
KRAS (Table 4.1). This was compared with none of the eighteen individuals with at
least one functioning copy ofMYH (p<0.0001), Table 5.2.
The MCR of APC was mutated in three of five (60%) MUTYH homozygotes for
whom good quality sequencing was available for analysis. One patient demonstrated
double inactivation of the APC gene (sample 2650). Two G:C-T:A transversions
were identified in the tumour DNA of patient 2650, leading to nonsense changes at
codons 1306 and 1554 (Table 4.1). Subsequent cloning, as described in 5.2.5,
confirmed that these two mutations are on separate alleles (data not shown).
All detected lesions in the MUTYH homozygote individuals were G:C-T:A
transversions, as expected to occur from unrepaired 8-oxoG lesions. All APC
mutations occurred upstream of AA dinucleotides, and 2 are believed to be novel, i.e.
they have not been previously reported in the APC mutation database (Feb 05
version) (Laurent-Puig et al., 1998b) or HGMD (Feb 06), these are highlighted in
Table 4.1.
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Table 4.1 Somatic inactivating mutations detected in the tumour DNA (none of the mutations
are present in constitutional DNA) of seven MUTYH homozygotes. Highlighted mutations are
believed to be novel.
APC B-J KRAS Codons 12 & 13
Genotype Sample ID Nucleotide Amino-acid Sequence Nucleotide Amino-acid Sequence
Change change Context Change change Context
G382D/G382D 2574 ND 34G-T Gly12Cys TGGTGGC
2650 3916G-T Glu1306X AGAAATA 34G-T Gly12Cys TGGTGGC
4660G-T Glu1554X AGAAAAA
3044 Not Screened 34G-T Gly12Cys TGGTGGC
G382D/Splice 2395 ND 34G-T Gly12Cys TGGTGGC
G382D/Y165C 2256 2821G-T GIU941X GGAAAAT 34G-T Gly12Cys TGGTGGC
Y165C/Y165C 1010 3850G-T GIU1284X TGAAGAT WT
1283 Not Screened 34G-T Gly12Cys TGGTGGC
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4.3.2 Somatic KRAS and inactivating APC mutations are not
affected by mono-allelic MUTYH mutation status
In twelve MUTYH heterozygous individuals no KRAS codon 12/13 mutations were
identified (Table 4.2). Four of the seven (-57%) G382D heterozygote individuals
screened had inactivating tumour mutations in the mutation cluster region of APC.
One insertion, two deletions, and one C-T transition leading to a nonsense change
(Table 5.2). One of the five (20%) Y165C heterozygotes had an APC MCR mutation;
a C:G-G:C transversion leading to a nonsense change (Table 4.2). The difference in
the frequency of inactivating mutations occurring within the MCR of the APC gene
in the two heterozygote groups was not significant (p=0.198).
One misense mutation was identified, in the constitutional DNA of patient 2596. A
heterozygous C:G-T:A transition at codon 1129, leading to a Leucine to Serine
amino acid change. The mutation was not present in the tumour DNA. The Leucine
at this position in the APC gene is conserved in Chimp and Mouse, however amino
acid 1129 does not fall within any of APCs' conserved domains. The variant amino
acid has been predicted to be benign using the polyphen program,
http://www.bork.embl-heidelberg.de/PolyPhen/, this program predicts the possible
impact of an amino acid substitution on the structure and function of a human protein
using straightforward physical and comparative considerations. The presence of this
non-pathogenic lesion in the normal, but not the tumour DNA may indicate a loss of
heterozygosity event in the tumour of this patient, although this had not been pursued
further.
Tumour samples from patients 1184 and 1962 both have inactivating APC mutations
within the B1D2 region used to determine mutation frequency in Chapter 3. The
mutation in 1184T occurs approximately halfway through the C1C2 fragment and the
1962T mutation at the end of the B1B2 fragment. The distribution of mutations on
the individual alleles that contained either the mutant stop codon or wild-type
sequence was therefore analysed, and compared with the distribution seen in the
normal sample from the same patient (mutation details are listed in Appendix B). No
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significant differences were observed. One might expect that the presence of an
upstream stop codon would affect the frequency with which mutations occur
downstream. Conceivably, this may arise due to alterations in the mechanisms
controlling sequence fidelity during tumourigenesis. It is likely that due to the small
size of the amplified fragments not enough sequence has been analysed to
definitively determine what the effect is on downstream mutation frequency.
Interestingly, no mutations were observed at KRAS codon 13 in any individual
screened.
In four patients with sporadic colorectal cancer (2486, 2490, 2491 and 2494), and
three with HNPCC (1946, 2116 and 1974), no somatic tumour mutations were
identified in our APC region, or at KRAS codon 12. The difference in the frequency
of inactivating mutations occurring within the MCR of APC between the sporadic
individuals and MUTYH heterozygotes was not significant (p=0.099).
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Table 4.2 Somatic mutations detected in the tumour DNA (none of the mutations are present
in constitutional DNA) of twelve MUTYH heterozygotes.
APC B-J KRAS Codons 12 & 13
Genotype Sample ID Amino-acid Sequence Nucleotide Amino-acid Sequence
Nucleotide Change change Context Change change Context
G382D/WT 1184 2626C-T Arg876X GCGAGGT WT
1677 3921 -3925Del5bp Frameshift1314X ATAAAAGAA WT
2564 ND WT
1574 4248Del 1 bp Frameshift1418X GCATTAT WT
2596 ND WT
2519 4394-4395lns2bp Frameshift1473X AG(AG)TGGAC WT
3603 ND WT
Y165C/WT 3116 ND WT
2009 ND WT





The data presented in this chapter show a direct link between genetic instability and
tumour gene mutations. We present data that indicate that tumour specific mutations
can predict the repair status of BER null patients. In line with previous studies (A1
Tassan et al., 2002;Jones et al., 2002), our results clearly highlight the effect that loss
of BER repair has upon the somatic mutation spectrum of the APC gene during
tumour progression. In unselected patient cohorts transitions are the most common
type of point mutation leading to APC truncation (Luchtenborg et al., 2004). Here we
observe a vastly increased proportion of inactivating G:C-T:A transversions, with
four of seven (57%) cancers in MUTYH homozygote patients harbouring an
inactivating G:C-T:A mutation in the APC region studied. This has been seen in
previous studies of CRC from BER null patients (Lipton et al., 2003). No mutation
hotspots were identified in the APC region studied, although all G:C-T:A
transversions occurred at Glutamate (GAA) residues, and were therefore upstream of
an AA dinucleotide.
The effect of inactivation of MUTYH can clearly be seen at codon 12 of the KRAS
gene, further underlining the causal role played by genetic instability in colorectal
neoplasia. Previous studies in MAP patients have shown 9 of 14 (64%) cancers and
13 of 30 (43%) adenomas to harbour KRAS codon 12 G:C-T:A transversions (Lipton
et al., 2003). Another study of 50 adenomas and 4 carcinomas from 5 MAP patients
detected KRAS codon 12 G:C-T:A transversions in 16.7% of tumours (Jones et al.,
2004). Here we have observed this same mutation, resulting in a glycine-to-cysteine
substitution in 6 of 7 (86%) of our MUTYH homozygote tumours. Jones et al
compiled a database to determine the spectrum of KRAS mutations in sporadic and
FAP adenomas and carcinomas. This revealed a highly significant difference in the
spectrum of mutations occurring in MAP tumours (where only G:C-T:A
transversions are detected) compared to the other cancer types. We have shown that
the genetic instability resulting from MYH deficiency targets both the APC and
KRAS genes, and whilst the APC changes occurred upstream of the AA dinucleotide,
this is not the case at codon 12 of the KRAS gene. It is therefore a possibility that the
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sequence context of the first G residue at codon 12 (TGGT) gives it susceptibility to
hypermutation in the MYH deficient background, as no mutations were detected at
the other 3 G residues at codons 12 or 13. Alternatively, it could be due to the nature
of the mutation at codon 12 that leads it to be selected.
<L-
The question as to whether or not there is a heterozygous effect of having one
inactivated copy of MUTYH is very much still up for debate (Kambara et al.,
2004;Russell et al., 2005;Farrington et al., 2005;Jenkins et al., 2006;Tenesa et al.,
2006), and for this reason we have investigated twelve heterozygote individuals to
determine the spectrum of inactivating APC and activating KRAS mutations.
Kambara et al have shown a higher than expected frequency of G:C-T:A mutations
at KRAS codons 12 and 13, and APC in colorectal cancer cases with mono-allelic
MUTYH mutations, compared to those without MUTYH mutations (Kambara et al.,
2004). 5 of 20 (25%) monoallelic MUTYH patients Vs. 6 of 72 (8%) wild-type
MUTYH patients had KRAS codon 12 or 13 G:C-T:A transversions, and 4 of 20
(20%) Vs. 5 of 72 (7%) in the MCR of APC, suggesting that heterozygote variants of
MUTYH may influence genetic pathways in colorectal cancer. Our results are not in
agreement with this study. We do see a subtle heterozygous effect via our mutation
frequency and spectrum data (Chapter 3), but it indicates a different carcinogenic
pathway compared with bi-allelic inactivation, and indeed the data in this chapter
supports this different effect for mono-allelic MUTYH carriers at the level of somatic
inactivating mutations. None of the 5 APC inactivating tumour mutations observed in
our heterozygote patients was a G:C to T:A transversion. In the KRAS gene, 86% of
the MUTYH homozygote individuals had G:C-T:A transversions at codon 12,
compared with none of the 12 heterozygote individuals studied (p<0.0001), and none
of the 4 sporadic and 3 HNPCC cases with two wild-type copies of MUTYH. The
study by Kambara et al studied 20 colorectal cancers with monoallelic MUTYH
mutations, of these only 2 had a single G382D mutation, the rest were variants of a
more polymorphic nature. It is possible that the contradictory results obtained by the
two studies is due to the different germline MUTYH mutations present in the
Australian population studied by Kambara et al. compared to the Scottish population
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studied here. Alternatively, patients classified as MUTYH heterozygotes by Kambara
et al. may in fact be homozygotes, whose second mutation has not been identified.
APC and KRAS gene mutations are often relatively early events in colorectal
tumourigenesis (Vogelstein et al., 1988). However, interestingly, in this study of 16
sporadic patients (12 with single MUTYH mutations, and 4 with none), none (0%)
had a KRAS mutation at either codon 12 or 13. Kambara et al. report finding 32 of 92
(35%), Hsieh et al, 36.4% and Tortola et al 41% of sporadic colorectal cancers to
have a somatic mutation in KRAS at either codon 12 or 13 (Tortola et al.,
1999;Kambara et al., 2004;Hsieh et al., 2005). The most likely explanation for this
phenomenon is the differences in the populations studied (Spanish, Australian and
Taiwanise, respectively). We did identify 5 (33%) patients who had an APC mutation
in the MCR, and this is line most other studies of sporadic colorectal tumours (Huang
et al., 1996;Diergaarde et al., 2003;Hsieh et al., 2005)
Previous studies have shown that the gene mutations in tumour tissue do not seem to
be effective for the surveillance of colorectal cancer patients (Hsieh et al., 2005).
Likewise, Morrin et al. report that KRAS mutation status does not correlate with
Dukes stage, tumour differentiation or five year survival rate of colorectal cancer
patients (Morrin et al., 1994). However, in our patient series from the Scottish
population we have strong data to suggest that the presence of a G:C-T:A
transversion at codon 12 of the KRAS gene is indicative of bi-allelic inactivation of
the MUTYH gene, although this may not apply to other populations where
heterozygotes show KRAS G:C-T:A mutations. As APC mutation is so important for
colorectal cancer development, one would expect to find APC mutations in all the
tumour samples studied here. We have analysed the entire MCR, approximately 30%
of the total coding region of APC. It is therefore possible that there are further
pathogenic mutations in other areas of the gene, deletions of the whole of, or parts of
APC (as may be the case in patient 2596), or epigenetic alterations such as
methylation (Kondo and Issa, 2004), that have not been detected by our assay. In
individual 2650, both inactivating APC mutations were detected, and confirmed to be
on separate alleles. The Glul554X mutation occurs just downstream of the MCR,
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and leaves 3 of 7 (3-catenin binding repeats intact. The Glul306X mutation is within
the MCR, and causes only 1 P-catenin binding repeat to remain intact. Although two
mutations within the MCR are thought to be the most likely combination of events
leading to APC inactivation, one within and one out with is also highly probable
(Cheadle et al., 2002). Additionally, as has been predicted previously, some (3-
catenin binding activity is likely to remain, despite these inactivating mutations
(Albuquerque et al., 2002).
In this chapter, detailed analysis of a series of tumours has allowed independent
determination of the effect of genetic instability on mutations in two genes known to
be involved in tumourigenesis. We highlight that as well as increasing the overall
genomic mutational load of a cell, the presence of inactivated BER leads to an
increase in the proportion of total transversions (somatic) mutations in the colon. The
susceptibility of the APC and KRAS genes to such mutations is likely due to the
presence of specific target sequences, such as at KRAS codon 12, and this goes some
way to explain why CRC forms part of the MAP tumour spectrum.
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Chapter 5
In Silico Analysis of Genome Mutation Frequencies
5.1 Introduction
In the chapter I have set out to investigate the possibility of instability in the APC
gene sequence using an alternative approach, including number of in silico
techniques, to that presented in Chapter 3.
Instability of the APC gene within the genome might explain the high frequency of
new mutations observed in FAP, (these de novo mutations arise without the usual
pattern of autosomal dominant inheritance, instead germline mutations occur de novo
during oogenesis, spermatogenesis, or early embryogenesis), and the fact that the
majority of colorectal cancers (whether familial, or sporadic) carry APC mutations.
The idea of unstable genes (Frei, 1990;Frei, 1995) and hypermutable regions of the
genome (Strauss, 1998) have been proposed before. It is widely accepted that
genomic instability is required for the initiation and progression of cancer (Cahill et
al., 1999). It has recently been proposed that cellular and clonal diversity are key
parameters driving neoplastic transformation and progression (Maley et al., 2006),
with multi-lineage persistence, rather than sequential selection favouring increased
diversity (Shibata, 2006).
In order to address the APC genomic mutation status on a wider basis, I have
compared the de novo mutation rate ofAPC and other disease genes for which data is
available. This will allow me to determine if the published mutation rate for APC is
indeed higher than for other similarly inherited, similarly sized genes. Using disease
mutation databases I have established where, and by what mechanisms de novo APC
mutations are likely to have occurred from, and how this compares to familial APC
mutations and de novo mutations in other genes. Mutations in the PAX6 gene have
previously been compared to those in the Factor IX gene to ascertain what occurs at
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the mutational level across disease genes (Prosser and vanHeyningen, 1998),
highlighting this as a meaningful and valid technique. From the pattern of mutations
within genes, previous studies have been successful in inferring mechanisms by
which they arise (Kuraguchi et al., 2000;A1 Tassan et al., 2002;Shao et al., 2004),
therefore knowledge of the type and location of de novo APC mutations may be
insightful. Using orthologs I have also determined the degree of conservation of the
APC gene in mouse and chimp, and the degree of polymorphism in APC amongst the
general population. If APC is indeed highly mutable, as the previous experiments
have suggested, then one might expect it to have a reduced degree of evolutionary
conservation, and harbour a larger number of silent polymorphisms compared to
other similar genes, unless there is some constraint mechanism in place for
maintaining the DNA sequence ofAPC constant.
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5.2 Methodological Overview
5.2.1 Comparison of de novo mutation rate in disease genes
As outlined in 2.9.2, Entrez was used to search the Pubmed database
(www.pubmed.gov) to access relevant citations from biomedical literature that had
calculated the de novo mutation rate for an autosomal dominant disease gene.
Original articles were studied to ensure that mutation rates had been calculated in
comparable ways, by the direct method (Vogul and Motulsky, 1986):
Mutation Rate (p) = Number of sporadic (de novo) cases with condition of interest
2 x (Number of individuals examined)
This calculation gives the probability with which a particular mutational event takes
place per generation. This is done by determining the number of new alleles carrying
a de novo mutation within a certain period of time (i.e. individuals born with FAP in
a 30 year period) as a proportion of the total number of all new alleles (2 x the
number of individuals born in same 30 year period). The direct method can be used
for single gene determined traits as well as genomic and chromosome mutations, but
cannot be used for recessive conditions.
5.2.2 Investigation of the type and position of de novo mutations
in disease genes
To address how and where de novo APC mutations occur the latest version of the
APC mutation database (Beroud and Soussi, 1996) was obtained from Thierry Soussi
(personal communication) and manipulated, as outlined in 2.9.1.
2020 APC mutations were listed in the original database, 1000 of which were
classified as 'germline FAP mutations'. The germline FAP mutations were further
classified by referring to the original references cited in the database, and listed in
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Appendix C. A total of 166 original references were analysed to determine the status
of the mutations to which they were referring as 'true familial' (shown to have been
inherited), sporadic (de novo mutation), or unknown (if no data on mutation origin
was available from the original reference). This information was then added to the
database. References containing details of de novo mutations are highlighted in
Appendix C.
In total 708 mutations were classified as 'true familial', and 38 as sporadic/de novo,
for the remaining 1274 no data was available on mutation origin. The Scottish APC
database compiled by Dr Susan Farrington (S. Farrington, personal communication)
was organised in a similar manner. An additional 56 Scottish sporadic/de novo cases
were added to the 38 from the Soussi database. The total of 94 sporadic/cfe novo
germline APC mutations (Appendix C) were then compared with the 708 true
familial germline mutations for mutation position, wild-type and mutant
codon/amino acid, event (i.e. introduction of a stop codon) and mutation type
(transition, transversion, frameshift).
The sporadic/de novo APC mutations were also compared with sporadic/de novo
mutations in the PAX6 and /3-globin genes. The PAX6 mutation database
(http://pax6.hgu.mrc.ac.uk/) was searched for sporadic mutations, and information
was compiled into a similar format as the APC database (Appendix C). The 40
mutations listed in the Stamatoyannopoulos and Nute paper on de novo mutation rate
in /3-globin (Table 6.2), along with 10 /3-globin mutations leading to Hb M disease
were also compiled into database format (Appendix C) (Stamatoyannopoulos and
Nute, 1982). The three sporadic/^*? novo mutation databases were used to perform a
three-way comparison of sporadic germline mutations (mutation type, WT/mutant
codon and mutation position).
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5.2.3 Sequence conservation and polymorphism in APC
Gene sequences and polymorphism data were obtained from the ensembl genome
browser (www.ensembl.org). Gene ID's for the APC gene in human (Homo sapien),
chimpanzee (Pan troglodytes) and mouse (Mus musculus) are listed in Table 6.1.
Table 5.1 Ensembl gene IDs for APC




Pairwise alignments were performed using the 'Needlman & Wunsch' algorithm at
the former UK human genome mapping project resource centre
(www.hgmp.mrc.ac.uk).
The phylogenetic analysis by maximum likelihood (PAML) resource at
(http://abacus.gene.ucl.ac.uk/software/paml.html) was used for the estimation of
synonymous and nonsynonymous substitution rates for both the human-chimp and
human-mouse alignments using the codonml program. This is a maximum likelihood
analysis of protein-coding DNA sequences using codon substitution models
(Goldman and Yang, 1994) for the calculation of codon-usage tables, the estimation
of synonymous and nonsynonymous substitution rates, likelihood ratio testing of
positive selection or relaxed selective constraints along lineages based on the d^/ds
rate ratios, identification of amino acid sites or evolutionary lineages potentially
under positive selection, and the reconstruction of ancestral codon sequences.
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5.3 Results
5.3.1 Published de novo mutation rates in APC and other genes
Every individual born in Denmark with FAP between 1920 to 1949 has been
identified and recruited to the Danish polyposis register (Bulow, 1991). Probands and
family members have been analysed to deduce whether the APC mutation is familial
or sporadic. For the same period (1920 to 1949) the number of births was obtained
from Vital Statistics, Denmark (http://www.dst.dk/HomeUK.aspx). The de novo
mutation rate of APC was calculated by the direct method (5.2.1) to be 9.3 x 10"6
mutations/genome/generation (Bisgaard et al., 1994). In this section this rate has
been compared to the published de novo mutation rates of seven other autosomal
dominant conditions and their responsible genes.
Table 5.2 lists the mutation rate estimates for the seven conditions including FAP.
Inclusion in the table depends upon the reliable determination of true de novo cases,
and population size/birth rate in the same period from which cases were determined.
The following is a brief synopsis of the conditions/genes included in Table 5.2.
Neurofibromatosis (MIM 162200), one of the most common inherited diseases
known to man, is caused by mutations in the tumour suppressor gene Neurofibromin
(NF1, 17ql 1.2); 4.29 x 10"5 mutations/genome/generation. It is a large gene with a
predominant paternal derivation of mutations (Stephens et al., 1992). The condition
is characterised by cafe-au-lait spots, and fibromatous tumours of the skin.
Prader-Willi Syndrome (MIM 176270) is caused by genomic deletions at 15q 11.2-
ql2 in the male germline (maternal genes at this locus are inactive due to
imprinting). The vast majority of cases are de novo interstitial deletion, 2.86 x 10~5
mutations/genome/generation. The condition is characterised by diminished foetal
activity, obesity, muscular hypotonia, mental retardation, short stature and
hypogonadotrophic hypogonadism (Prader, 1956).
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Apert Syndrome (MIM 101200) is caused by mutations in the Fibroblast Growth
Factor Receptor 2 gene (FGFR2, 10q26.13); 7.75 x 10~6
mutations/genome/generation. Most cases are believed to be sporadic, and a paternal
age effect has been reported (Moloney et al, 1996). It is a complex syndrome
consisting of skull malformations, complete distal fusion of the fingers and a
tendency for fusion of the bones.
Von Hippel-Lindau Disease (MIM 193300) is caused by mutations in the tumour
suppressor gene VHL (3p25.3); 5.15 x 10~6 mutations/genome/generation. It is a
cancer syndrome, predisposing to a variety of malignant and benign neoplasms, most
frequently retinal, cerebellar, and spinal hemangioblastoma, renal cell carcinoma,
pheochromocytoma and pancreatic tumours.
Methemoglobinemia Cyanosis (HbM) (MIM 141800) (16p 13.3) is caused by
substitution of critical Histidine residues of the a-globin chain with Tyrosine, 4.3 x
10~8 mutations/genome/generation. HbM causes cyanosis from birth
(Stamatoyannopoulos and Nute, 1982).
Unstable Fib Disease (MIM 141900) (1 lp 15.5) is caused by structural abnormalities
that lead to the introduction of an abnormal charge to the interior of the (3-globin
chain, alterations between subunits, or distortion of the a-helical configuration of the
affected chain (Stamatoyannopoulos and Nute, 1982), 1.32 x 10"8
mutations/genome/generation.
Comparison of the data sets presented in Table 5.2 show that the rate of de novo
mutations arising in the APC gene and leading to FAP, is 4 fold lower than in the
NF1 gene, and 3 fold lower than at the chromosome 15 region associated with
Prader-Willi syndrome. In contrast, the new mutation rate of APC is 1.2 fold greater
than seen in the FGFR2 gene, 1.8 fold greater than seen in the VHL gene, and 234
and 936 fold greater than seen in the j3- and a-globin genes respectively.
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Differences in estimated mutation rates which are deduced from clinical phenotype
presentation may be the result of factors other than the presence of an underlying
difference in germline mutation rate. Most of these will be considered in detail in the
discussion section of this chapter. However, differences in the number of nucleotides
per gene will be examined here. Table 5.3 shows the mutation rates for the seven
genes of interest, corrected for gene size (number of coding base-pairs). By
correcting for gene size, there has been a considerable change in the order of the
mutation rates with respect to the APC gene. The VHL gene now has a mutation rate
over 7 fold greater than APC. Due to its large size, the NF1 gene is no longer the
gene with the highest mutation rate. The mutation rate of NF1 is still around 4 fold
greater than APC, due to the fact that both genes are a similar size (8517 and 8535
coding base-pairs respectively). The mutation rate of FGFR2 is 2 fold greater than
APC when considered per base pair, rather than 1.2 fold less before the correction
was made, however it should be noted that Apert syndrome is caused by specific
missense substitutions involving just two amino acids of FGFR2 that are selected for
in the male germline. For this reason the mutation rate of FGFR2 cannot strictly be
compared with that of APC in this way. Due to the small size of both the a- and /?-
globin genes (438 and 423 base-pairs respectively) the fold difference between their
mutation rates and that of APC has been reduced dramatically to 11 fold less for /?-
globin and 35 fold less for a-globin. The mutation rate determined for Prader-Willi
syndrome cannot be accurately adapted to give a per base pair figure. Whilst the
majority of cases are cle novo, they arise as a result of interstitial deletion affecting a
critical region of chromosome 15, rather than changes in a specific gene. It is
reasonable to assume that when considering mutation rate corrected for gene size this
would result in a relatively low mutation rate, as the critical region is so large. These
corrections take into account gene size, but not other differences that might influence
differences in estimated mutation rate such as sequence specificity, or the influence
of disease biology (see discussion). Thus, with correction for gene size, APC is in the
middle order section when considering de novo mutation rate.
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Table 5.2 Estimates of mutation rates (calculated by the direct method) for 7 autosomal
dominant conditions, including FAP. Data from which rates were calculated; number of new
mutants (de novo cases) and number of births in same period are included. Mutation rates
are expressed as the number of mutations per million gametes per generation for easy
comparison between genes. Genes are listed in order of mutation rate, with the highest rate
appearing at the top of the table.

























Hiroaki et at. 15 262,000 2.86E-05 28.63
APC FAP Bisgaard et at. 39 2,083,366 9.36E-06 9.36










40 464,800,000 4.30E-08 0.04
a-Globin Hbs M Stamatoyannopoulos
and Nute
5 189,700,000 1.32E-08 0.01
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Table 5.3 Estimates of mutation rates (calculated by the direct method) for 7 autosomal
dominant conditions corrected for gene size, therefore representing a per-base-pair, per-
generation rate. Genes are listed in order of mutation rate, with the highest rate appearing at












FGFR2 Apert Syndrome 3.15E-09
APC FAP 1.10E-09
p-Globin Unstable Hb Disease 9.82E-11






5.3.2 Analysis of the type and position of de novo mutations in
disease genes
Few studies have focused on the genetic features of sporadic FAP. In a comparison
of the clinical and genetic characteristics of patients with and without a family
history of FAP, Truta et al. have shown that truncating APC mutations are detected
less frequently in patients without a family history (Truta et al., 2005), however,
screening was not carried out for genomic deletions/re-arrangements. We have
comprehensively screened 51 unrelated individuals, clinically diagnosed with a
multiple polyp phenotype, and without a family history of disease, in whom no
germline APC mutations had been identified, for exonic deletions and duplications
by MLPA, as described in 2.8.1 and 2.8.2. Two deletions were identified (data not
shown), accounting for 4% of cases. An unknown proportion of APC mutation
negative polyposis patients are expected to carry mutations in recessive genes such
as MYH. MAP, as discussed in Chapter 1, can predispose to a similar phenotype to
that seen in FAP. However, in the Scottish population MYH deficiency appears to
play very little role in classical FAP (Susan Farrington, personal communication). As
a recessive condition, MAP may occur in individuals without a previous family
history of colorectal cancer, and therefore appear sporadic. There are also likely to be
other, as yet undiscovered genes involved in colorectal cancer that may explain a
proportion of these cases. For the remaining cases it has been proposed by Truta et
al. that the type of APC mutation may differ between FAP cases with and without a
family history. If this is indeed correct, they propose that sporadic FAP could be
classified as a distinct condition. The techniques used by the Truta et al. study to
detect mutations in FAP (SSCP and PTT) focus upon protein truncating mutations.
Intronic and missense mutations are not readily detected using these techniques. It
has been estimated that germline APC missense variants such as E1317Q account for
-10% of patients with multiple adenomas (Lamlum et al., 2000a). An enrichment of
sporadic FAP cases with these types of mutation (with potentially low penetrance)
could explain why patients without a family history are more often classified as
mutation negative. Data from this laboratory has revealed that 1.12% of controls also
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display heterozygosity at this specific locus (Susan Farrington, personal
communication).
To approach this problem we have used 2 databases of APC mutations causing FAP
to carry out a direct comparison of de novo and familial mutations. These databases
are collections of data from many separate studies that have used a variety of
techniques to detect the mutations.
The majority of APC mutations in both the de novo and familial groups were located
in exon 15; 71/91 (78%) of de novo mutations, 520/708 (73%) of familial mutations.
The remaining mutations were evenly distributed between exons 4 to 14. No
significant differences were found between the two groups of APC mutations when
examined for mutation type, or mutated and mutant codons. Data are shown in
Tables 5.4, 5.5 and 5.6.
123




Transition (Ts) 17 18% 138 19%
Transversion (Tv) 8 9% 63 9%
Frameshift
Splice Site
65 69% 507 72%
1 1% 0 0%
Large deletion 3 3% 0 0%
Table 5.5 Distribution of mutated codon types, shown as percentages, no significant
differences are observed between the de novo and familial APC mutations.
























TAA 5 5.5% 27 4%
TAG 5 5.5% 51 7%
TGA 15 16% 109 15%
Frameshift 69 73% 521 74%
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Although no differences are observed between APC familial and sporadic mutations,
the distribution of de novo mutation types differs significantly between the APC and
the /3-globin genes (Table 5.7). In the /3-globin gene all sporadic disease causing
mutations are missense. In APC 69% of mutations are small insertions or deletions
that cause a frameshift leading to early termination of the protein (Table 5.7). This
difference reflects the fact that missense mutations in APC are largely unreported, as
their phenotype is difficult to determine (Luchtenborg et al, 2004). In unstable Hb,
and Hb M disease missense mutations cause the disease phenotype
(Stamatoyannopoulos and Nute, 1982). However, Stamatoyannopoulos and Nute
looked for all types of haemoglobin disorders and all but one of the de novo cases
caused unstable Hb disease, or Hb M disease, therefore virtually all de novo
mutations in this gene are missense mutations. A scan of literature published since
this initial 1982 report shows that subsequently reported de novo haemoglobin
disease mutations are also virtually all missense. (search using keywords 'de novo
haemoglobin disease' at www.pubmed.gov)
In PAX6 a mixture of missense, nonsense and frameshift mutations are reported with
additional splicing mutations also disrupting normal protein function (Table 5.7).
The lack of reported de novo splicing mutations in APC and /3-globin is likely to be
due to reduced analysis of intronic sequences, and in the case of /3-globin reflect the
fact that it is a much smaller gene (Figure 5.1), with just 3 exons.
Sporadic transition mutations at CpG dinucleotides are presumed to result from
spontaneous deamination of endogenously methylated 5-methylcytosine (Kondo and
Issa, 2004). The data presented here show a significant difference in the proportion
of de novo transition mutations that occur at CpG dinucleotides in our three genes of
interest (x2=21.443, p<0.0001), due to the distribution of CpG and non-CpG
transitions in the /3-globin gene (Table 5.7). 86% of mutations arising in the /3-globin
gene occur at codons coding for Histidine, Leucine, Phenylalanine or Valine. None
of which contains a CpG. Previous reports demonstrate that 28% of all PAX6
mutations are C-T transitions at CpG dinucleotides (Prosser and vanHeyningen,
1998), this analysis has indicated that de novo PAX6 mutations alone show a slight
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decrease in transitions at CpG dinucleotides to 20% (i.e. 22 of the total 112 PAX6
mutations are transitions at CpG) (Table 5.7). Again, no significant difference
between familial and de novo transitions at CpG was observed for APC\ of the 138
transitions seen in familial mutations (Table 5.4) 89 (64%) occurred at a CpG
dinucleotide, compared with 13/17 (76%) of de novo mutations (Table 5.7). All of
these mutations (familial and de novo) occur at CGA Arginine codons, and via a C-T
mutation result in TGA stop codons (Table 5.8). The high rate of de novo mutations
in APC cannot therefore be explained by excessive deamination of 5-methylcytosine
residues, as these only make up 14% of all mutations. However, a significant
proportion of all truncating mutations in APC are likely to have arisen originally as a
result of transition mutations at CpG. In all three genes approximately two thirds of
all sporadic nucleotide substitutions are transitions (Table 5.8).
Taking into account ascertainment bias, and the over-reporting of certain mutations,
comparisons with PAX6 and /7-globin de novo mutations show that APC does not
appear to have an unusual pattern of mutation types that might explain the high rate
of de novo mutations.
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Table 5.7 Types of de novo mutations in three genes of interest
0-globin PAX6 APC
n n n
Ts tota 1 35 70% 41 36.5% 17 18%
76%Ts @ CpG 5 14% 22 54% 13
Ts @ non-CpG 30 86% 19 46% 4 24%
Tv total 15 30% 18 16% 8 9%
Tv @ CpG 0 0% 6 33% 1 12.5%
Tv @ non-CpG 15 100% 12 67% 7 87.5%
Frameshift 0 0% 30 27% 65 69%
In frame insertion/deletion 0 0% 2 2% 0 0%
Splicing mutation 0 0% 21 18.5% 1 1%
Large deletion 0 0% 0 0% 3 3%
Total 150 112 94




A->G 1 2% 8 14% 0 0%
C->T 9 18% 28 47% 17 68%
G->A 5 10% 2 3% 0 0%
T->C 20 40% 3 5% 0 0%
Transversions
A->C 1 2% 0 0% 0 0%
A->T 0 0% 8 14% 1 4%
C->A 3 6% 3 5% 3 12%
C->G 0 0% 1 2% 1 4%
G->C 2 4% 0 0% 0 0%
G->T 1 2% 4 7% 3 12%
T->A 4 8% 0 0% o 0%
T->G 4 8% 2 :3% 0 0%
Total 50 59 25
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As mentioned previously, in /3-globin 60% of mutated codons occur at either
Histidine or Leucine, with the other 40% coding for just 5 other amino acids. This
can be explained partly by the biology of methemoglobinemic cyansosis. HbM
disease is usually produced by the substitution of a proximal or distal Histidine by a
Tyrosine. These Histidine residues are critical for the binding of the heme group,
which is disrupted by changes to the charge of the a-globin chain when replaced by
Tyrosine (Ameri et al., 1999). This accounts for 10 of the 11 Histidine mutated
codons. PAX6 has the widest variety of mutated codons (only Histidine codons
remain unmutated in sporadic cases) although in 26% of mutations, Arginine is the
target, and in 13% the target is Glutamine. In APC the most frequently mutated
codons in sporadic cases are those most easily mutated to a stop codon with just a
single transition or transversion. Table 5.10 shows that all substitution mutations lead
to a stop codon. Selection is therefore likely to be the most significant factor
affecting the distribution of mutated codons, with the FAP phenotype manifesting via
truncating mutations.
Figure 5.1 shows that the APC protein contains an armadillo repeat region at its 5'
end, and a microtubule binding/EBl binding domain at the 3' end. The (3-catenin
regulatory regions are found in the central portion of the gene (containing the
mutation cluster region, amino acids 1286-1513). Armadillo repeats consist of
approximately 40 amino acid repeats, forming a super-helix of helices that is
proposed to mediate interaction with (3-catenin. From the de novo APC mutations, 2
previously reported mutation hot-spots are again detected, at codon 1061 (10% de
novo mutations) and codon 1309 (19% de novo mutations) (Table 5.11). 31% of de
novo mutations are found to lie within the MCR, this does not differ significantly
from the 29% of germline mutations reported previously (Miyaki et al., 1995).
PAX6 contains a conserved 124 amino acid N-terminal paired box domain (residues
42 to 180) of unknown function. The C terminal homeobox domain binds DNA
through a helix-turn-helix (HTH) structure and spans the residues 263 to 319. The
new mutations recorded in the PAX6 database appear fairly uniform throughout the
gene and are not clustered disproportionally in the conserved domains. Clustering of
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mutations in the conserved domains has been reported previously in a study that did
not separate de novo and familial mutations (Prosser and vanHeyningen, 1998). 33%
of the gene constitutes the paired box domain, and 28% of new mutations are found
here, likewise, the homeobox domain covers 13% of the gene, and 17% of mutations
are found within it. The majority of mutations in the homeobox domain occur at a
CpG dinucleotide at codon 240. This is the most frequent PAX6 mutation, accounting
for 12% of all reported mutations (Prosser and vanHeyningen, 1998), but only 6%
(7/113) of de novo mutations (Table 5.11). The (3-globin protein contains a globin
domain from residues 7 to 141 (over 90% of the protein) within which, all but 1 de
novo mutations are contained (Table 5.11).
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Table 5.9 Codons that are targets for mutation in the three genes of interest
p-globin PAX6 APC
n n n
Arg 0 0% 24 27% 17 19%
Asn 0 0% 4 4.5% 4 4.5%
Gin 0 0% 12 13% 11 12.5%
Glu 0 0% 4 4.5% 22 25%
Gly 1 2% 1 1% 1 1%
lie 0 0% 7 8% 2 2%
Lys 1 2% 1 1% 10 11%
Pro 0 0% 4 4.5% 1 1%
Ser 0 0% 7 8% 7 8%
Tyr 0 0% 2 2% 2 2%
Ala 4 8% 3 3% 2 2%
His 11 22% 0 0% 1 1%
Leu 17 34% 2 2% 3 3%
Phe 7 14% 1 1% 1 1%
Val 9 18% 4 4.5% 3 3%
Asp 0 0% 1 1% 3 3%
Cys 0 0% 3 3% 1 1%
Met 0 0% 2 2% 0 0%
Ter 0 0% 6 7% 0 0%
Thr 0 0% 2 2% 0 0%
Trp 0 0% 1 1% 0 0%
Total 50 91 91
Table 5.10 Codons arising as a result of mutation in the three genes of interest
P-glob in PAX6 APC
n n n
Stop 0 0% 33 37% 25 28%
Fr. 0 0% 29 32% 65 72%
In frame 0 0% 2 2% 0 0%
Arg 3 6% 5 5.5% 0 0%
Asp 4 8% 2 2% 0 0%
Gin 2 4% 2 2% 0 0%
Glu 2 4% 0 0% 0 0%
Gly 1 2% 0 0% 0 0%
Leu 1 2% 6 7% 0 0%
Met 5 10% 0 0% 0 0%
Pro 16 32% 1 1% 0 0%
Ser 6 12% 4 4.5% 0 0%
Tyr 9 18% 0 0% 0 0%
Val 1 2% 3 3% 0 0%
Ala 0 0% 1 1% 0 0%
His 0 0% 1 1% 0 0%
lie 0 0% 1 1% 0 0%
Thr 0 0% 1 1% 0 0%
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Codon Mutations Codon Mutations
1 1 170 1
17 174 1




39 1 243 1
40 244 1
















































103 1 722 1
111 753 1
113 1 764 1
118 1 844 1
119 1 868 1
123 1 876
135 932 1
143 1 935 1
150 1 974 1
152 1 1000 1
156 1 1035 1 15aa rpt
167 1 1055 1
180 1 1061
181 1 1062 1
199 1 1063 1
203 1066 1
205 1 1067






1170 1 15aa rpt
247 1 1192 1














283 1 1378 1
292 1 1392 1 20aa rpt 1
297 1396 1 <3
301 1 1397 1 s
317 1398 3
355 1 1450 1 3
S
363 1 1463 1
378 1 1464
381 1 1533 1
384 1 1833 1
391 1 1919 1




5.3.3 Sequence conservation and polymorphism in APC
Due to the high degree of sequence conservation between the human and chimp
genomes (>99%), comparisons between gene sequences can be highly informative in
identifying biologically important changes that have occurred since the two lineages
diverged around 6 million years ago. In this way it is possible to identify genes that
have exhibited accelerated amino acid substitution, relative to other genes, since we
diverged from our most common ancestor. Clark et al. identified accelerated
evolution in genes associated with olfaction and nuclear transport using human-
chimp-mouse orthologous gene trios (Clark et al., 2003).
If sequence context and genomic location influence the rate of mutations observed
within a gene, APC may be located in one of these 'faster' mutating regions.
Comparison of the human and chimp APC sequences has been used to identify
mutations that are fixed in each lineage, and are therefore the product of mutation
rate and positive selection. To identify changes that are specific to the divergence in
each lineage we compared the human-chimp aligned sequence to mouse. We have
additionally compared sequence variants that result in colorectal cancer with amino
acid substitutions that have accumulated since the divergence of humans from
chimps.
The human-chimp aligned cDNA sequences contained exons 1 to 15, excluding the
alternatively spliced exons 9 and 14a that were not present in the chimp sequence. A
gap between contigs AADA01173489 and AADA01178933 in the chimp sequence
at exon 15 missed 63 base pairs of sequence.
In total there are 38 mismatches between human and chimp sequences (Table 5.12),
excluding the alternatively spliced exons, and 63 base pair gap in exon 15. Of these,
29 (76%) were base mismatches, and 9 (24%) were insertions/deletions. The 9
insertion/deletions were all complete codons (i.e. 3 base pairs), 2 codons (6bp) were
deleted from the chimp sequence (in exon 4), and 1 (3bp) inserted into the human
(exon 15).
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sequence) Event AA Change Lineage
123 Del In frame del Chimp
126 Del In frame del Chimp
429 C/A Pro-Gin Human
545 G/A Silent Human
872 T/C Silent Human
940 G/A Silent Chimp
1171 G/A Arg-His Human
1212 T/G Silent Chimp
1243 C/A Pro-Thr Human
1262 T/C Silent Human
1330 C/A Pro-Thr ?
1569 A/G Asp-Gly Chimp
1589 cat Arg-Cys Chimp
1678 G/T Silent Human
1756 T/G Silent Chimp
1761 CAT Silent Human
1822 T/A Val-Asp ?
1933 T/C Silent Human
1960 G/A Silent Human
1978-1979 Ins Asn Human
2060 A/C Asn-His Chimp
2063 CAT His-Tyr Chimp
2073 G/C Gly-Ala Human
2295 T/A Ser-Thr Chimp
2451 C/A Silent Chimp
2468 A/G Silent ?
2603 A/C Glu-Ala Chimp
2620 T/A Phe-lle Human
2690 C/G Ala-Gly Human
2749 A/G Silent Chimp
2782 T/A Silent Human
2786 CAT Silent Chimp
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Two deleted codons (6bp) and 2 base pair mismatches were present at the 5' end of
the gene (exons 1-14) (21% of mismatches), the remaining 27 mismatches, and
single inserted codon (3bp) were seen in exon 15 (79%). Within the mutation cluster
region, only a single mismatch change was observed, at codon 1330; A CCT
(Proline) in human, and an ACT (Threonine) in chimp. The lineage of this change
could not be determined using the mouse sequence, as codon 1330 is a GCT
(Alanine) in the mouse APC gene. At this same position an 8bp deletion, and lbp
insertion have been recorded in an FAP and a hepatoblastoma patient respectively,
highlighting the importance of this region in the APC protein. Threonine is a
hydrophilic amino acid and forms hydrogen bonds, whereas Proline is aliphatic and
hydrophobic. This change (Proline to Threonine) is predicted by Polyphen
(http://www.bork.embl-heidelberg.de/PolyPhen/) to be 'potentially damaging'.
However, alignments used by this program show that the rat and xenopus APC
proteins (P70478 and P70039) also have a Threonine at this position. This suggests
that it is the human sequence that has acquired the change.
From 29 mismatched base pairs (excludes ins/dels), 15 (52%) resulted in a
synonymous/silent change, and 14 (48%) in a nonsynonymous change. Only 2 of the
14 (14%) nonsynonymous changes were present in the APC database as human
mutations, and are therefore probable polymorphisms. At codon 1171, the exact
same change (arginine to histidine, G-A transition at a CpG dinucleotide) was seen in
a patient with gastric cancer. At codon 1822 a Valine to Aspartate change is observed
between chimp and human. Its lineage is unknown. The APC database records three
cases of an Aspartate to Valine change in FAP patients at this position (D1822V),
which is believed to be a polymorphism. Although it is often assumed that a change
observed between human and chimp is unlikely to cause disease, as selection has not
caused its removal, in this case the Valine allele is believed to have a protective
effect against CRC, especially when combined with a low-fat diet (Slattery et al,
2001b).
In total 8 synonymous changes were observed in the human lineage, and 6
synonymous changes in the chimp lineage. 6 non-synonymous changes were
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observed in the human lineage, and 6 non-synonymous changes in the chimp lineage.
The remaining 1 synonymous and 2 non-synonymous changes were of unknown
lineage. KA/KS (number of non-synonymous differences per non-synonymous
site/number of synonymous differences per synonymous site) is a measure of
selection acting upon a sequence. KA/KS <1 is indicative of negative/purifying
selection, >1 indicates positive selection, and ~ 1 indicates neutral evolution. As
Ka/Ks is used as a measure of the rate of protein evolution, after controlling for
mutation rate (Hurst, 2002), it is a useful indicator of selection pressures. Usually,
Ka« Ks and therefore Ka/Ks <1, however in a few instances (i.e. immune system
genes) KA/KS >1, this is strong evidence for positive selection. In the human lineage
Ka/Ks for APC is 0.285, and in the chimp lineage 0.378 (data for number of
synonymous and non-synonymous sites in APC is taken from (Bustamante et al.,
2005). These figures indicate that in both lineages the APC gene is subject to
purifying selection. Since the value of KA/Ks is lower in the human lineage than in
the chimp, there is no evidence of accelerated amino acid substitution in the APC
gene since the divergence of humans from our most common ancestor.
Data on coding single nucleotide polymorphisms in APC was analysed to give a
figure of Pn/Ps (number of non-synonymous polymorphisms per non-synonymous
site/number of synonymous polymorphisms per synonymous site). Using the
randomly found polymorphisms from Bustamante et al. Pn/Ps is 0.378. By
comparing Pn/Ps and KA/KS, inferences can be made about selection acting upon a
sequence, i.e. molecular adaptation in evolutionarily conserved genes, and
differentiation between weak and strong purifying selection. Genome-wide analysis
has shown that the ratio of non-synonymous to synonymous differences is smaller
than the ratio of non-synonymous to synonymous polymorphisms (Bustamante et al.,
2005). This suggests that a large proportion of amino acid variation in the human
genome is slightly to moderately deleterious. From data presented here KA/KS
(0.285) < Pn/Ps (0.378). There is therefore an excess of amino acid variation relative
to divergence. This suggests a weak purifying selection is acting upon mildly
deleterious mutations to increase the proportion of non-synonymous polymorphisms
relative to the proportion of non-synonymous fixed differences.
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We have used the PAML program (default settings) to calculate Ka and Ks for the
APC gene using the mouse orthologous sequence (Table 5.13). This has allowed us
to compare APC with a number of other genes analysed in published articles that
have calculated KA and Ks in the same way.





Smith and Eyre-Walker (Smith and Eyre-Walker, 2003) have calculated KA and Ks
values for disease and non-disease genes using human-mouse alignments (with
PAML default settings). They found that disease genes are evolving faster than non-
disease genes at both synonymous and non-synonymous sites. This is expected to be
due to non-disease gene evolution being more affected by lethal mutations than
disease genes. Disease genes (less affected by lethal mutations) therefore evolve
faster because mutations have a discernible affect on phenotype. From human-mouse
alignments, average values of KA/Ks for non-disease genes and disease genes were
0.0913+0.0022 and 0.1135+0.0052 respectively. These values are higher than 0.089
for the APC gene. Similarly, Chuang and Li have used Ks values to compare
mutation rates in families of genes. Using PAML (default settings) they estimated,
from human-mouse alignments that the genome average for Ks is approximately
0.337, significantly lower than the value we have obtained for APC. Genes in 'Hot'
or rapidly mutating regions of the genome were found to have Ks values of 0.346-
0.468, whilst genes in cold regions had Ks values of 0.220-0.326. Thus, APC would
appear to be within, or an integral part of a rapidly mutating region of the genome.
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5.4 Discussion
In this chapter, a variety of in silico techniques have been used to investigate further
the possibility of instability in the APC gene. The consequence ofAPC instability on
the prevalence of sporadic FAP has been determined by directly comparing the de
novo mutation rate of APC with a number of other disease genes. To determine if
there might be any mutational mechanisms at play, other than sequence instability,
that are influencing the frequency of de novo APC mutations, the mutations of APC
have been analysed alongside de novo mutations arising in other disease genes.
Lastly, the degree of sequence conservation and polymorphism in APC has been
ascertained, as this provides historical evidence of the selection and mutational
influences that APC is under.
To establish and compare de novo mutation rates for a set of genes, the 'direct
method' is the most straightforward. Unlike the 'indirect' method (Vogul and
Motulsky, 1986) there is no need to calculate the average fertility of patients in
relation to the population average. However, establishing the de novo mutation rate
for a gene still requires a large amount of epidemiological data. This includes the
incidence of cases in the population where parents and other family members are
unaffected i.e. sporadic/de novo cases. The number of births in the same time period
must also be obtained. If a condition cannot be identified at birth, then prevalence
data is used. However, if life expectancy is reduced in mutation carriers, then
prevalence figures must be adjusted accordingly, to account for the reduction in
observed prevalence due to death. Despite the importance and significant interest of
determining the mutation rate for a disease gene, as a result of the difficulties
involved in obtaining the necessary data, very few genes have been analysed in this
way.
One of the main difficulties with determining mutation rates by the direct method is
the differences in the number of nucleotides per gene, as was eluded to in 5.3.1. The
analysis of the de novo mutation rate of the APC gene, and its comparison with other
disease genes must be done in the context of a number of other factors that may
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introduce error. Illegitimacy will introduce errors if there are very few sporadic cases
observed amongst a majority of familial ones. In the more recent studies, paternity
will have been confirmed, but this is not always the case in earlier estimations of
mutation rate. If the penetrance of a condition is not 100%, then not all sporadic
cases in a population will be determined. In this comparison all conditions are
believed to have complete, or virtually complete penetrance. Different autosomal
dominant conditions caused by mutations in the same gene will cause an elevated
mutation rate to be recorded if both conditions are considered together. For this
reason only cases of unstable Hb disease and Apert syndrome were used to calculate
the mutation rate of /3-globin and FGFR2 respectively, despite the fact that mutations
in /3-globin and FGFR2 can also cause other conditions. When comparing
differences in mutation rates between genes that lead to disease, selection against a
condition must be strong enough to account for the fraction of sporadic cases among
all cases. If a disease phenotype is so severe that it causes virtually no transmission
of the mutation to the next generation, then almost all cases will arise due to de novo
mutations (this is true for Prader-Willi syndrome). In this situation a high de novo
mutation rate must exist if a condition is to persist (as is seen in Table 5.2). In less
severe diseases, such as FAP, Apert syndrome, Neurofibromatosis, VFIL disease,
HbM and unstable Hb disease, a variably large fraction of cases will be new mutants,
and it will be roughly proportional to the selective disadvantage of the trait. If the
trait has no bearing on reproductive fitness, then only a very low level of de novo
mutations will be required.
In addition to the caveats listed above, it should be noted that mutation rates
determined by observing a phenotype, i.e. the presence or otherwise of a disease,
cannot reveal the true mutability of a gene, because they only consider mutations that
produce a visible phenotype. Silent mutations and embryonic lethal mutations are not
considered. However, mutation rates calculated in this way can provide an indication
of any differences in mutation probability that may exist between genes, especially
when they have been corrected for differences in gene size.
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After correcting for gene size, three genes had mutation rates greater than APC. The
VHL gene had a rate 7 fold greater than APC. The study in which the mutation rate
for VHL was calculated was earned out in East Anglia (Maher et al., 1991). A
relatively small population size from which cases were determined (485,437
compared with over 2 million in the FAP study) may have biased the study to give an
inaccurately high mutation rate. In a small study population the chances of a single
large kindred being responsible for a large number of cases is much more likely.
Additionally, this study was carried out prior to the VHL gene being identified.
Phenotype was used to infer gene mutation, but unlike the FAP study, true mutation
carriage could not be confirmed. Therefore, cases cannot all be definitely attributed
to mutations in VHL. The FGFR2 gene also had a mutation rate greater than APC.
Aperts syndrome is a severe phenotype, and few affected individuals have children.
It appears that the disease is only able to persist because of the high susceptibility of
just two adjacent nucleotides (Cohen, Jr. et al., 1992) (including one at a CpG
dinucleotide) to mutation in the male germline (Moloney et al., 1996). The mutation
rate considered here is therefore only representative of a very small proportion of the
FGFR2 gene. The mutated nucleotides are involved in the interaction between
FGFR2 and its ligand (FGF2), but the possible effect of sequence context on
mutation rate has not been determined.
Of the genes examined here, the NF1 gene is most comparable with APC. NF1 is a
similar sized gene to APC, is also a tumour suppressor gene, and estimates of the
effect on reproductive fitness of being a mutation carrier is around 0.8 for both
conditions (Samuelsson and Akesson, 1988;Bisgaard et al., 1994). The mutation rate
of NF1 from this study is 4 fold greater than in APC, although earlier reports of NF1
mutation rate have given the highest known rate for a human disorder (1 x 10"4)
(Crowe FW et al., 1956).
From these data alone it is not possible to conclude that the de novo mutation rate of
the APC gene is significantly higher than for other genes where relevant data is
available. However, the rate of occurrence of new mutations in APC is comparable
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with that of other similar genes for which high new mutation rates have been
previously proposed.
In a Dutch cohort of sporadic colorectal carcinomas, 61% of mutations were found to
be missense point mutations, and multiple mutations were seen in 55% of cases (52%
of individuals with a truncating mutation also had a missense change) (Miyaki et al.,
1995). This study suggests that missense mutations are under-reported in FAP,
leading to an ascertainment bias. Their relevance in the context of APC is not well
understood. As a result, it has not been possible to accurately determine what
proportion of de novo mutations are missense changes, and what influence, if any,
these have on the de novo mutation frequency of APC. A lack of controls and limited
study populations can also hinder comparisons between databases.
It is unsurprising that there are no observable differences between de novo and
familial mutations in APC, if one considers that all familial mutations were sporadic
mutations when they occurred for the first time. Likewise, sporadic mutations will
become 'familial' if they are inherited. As discussed above, each generation de novo
mutations will replace those familial mutations that have been lost from the gene
pool due to a reduction in reproductive fitness. These de novo mutations are
subsequently passed on to further generations creating new FAP families.
Detailed analysis of the mutations within a gene, with special attention to any biases
in the data can provide information on mutational hotspots, and mechanisms by
which mutations arise. It has been proposed that new germline mutations in APC are
not premeiotic events (because no parental bias is observed in mutation origin), but
instead occur during meiotic division (Ripa et al., 2002). This is an unusual finding,
as most other genes studied are not susceptible to genetic changes at meiosis, with
mutations instead arising during the mitotic divisions preceding meiosis, and
therefore showing parental origin bias. The error rate of mutations occurring during
DNA synthesis is known to be dependent on the DNA sequence being synthesised,
and the polymerase used. Polymerase-8 has been proposed to play a role in
semiconservative DNA synthesis and repair during the early stages of meiosis (Plug
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et al., 1997), whilst polymerase-e is believed to replicate DNA at mitosis. Ripa et al.
propose that errors arising during polymerase-S DNA synthesis might offer an
explanation as to why the locations of somatic and germline mutations differ
significantly within APC (Miyaki et al., 1995;Ripa et al., 2002). It may also provide
a mechanism for the emergence of de novo APC mutations, if the sequence context,
or potentially the genomic region of APC is susceptible to mutation by polymerase-8
during oogenesis or spermatogenesis.
By comparing the types and locations of de novo mutations in the APC, PAX6 and /?-
globin genes, it has been shown that the differences that exist between the three loci
reflect differences in nucleotide sequence, the biology of the conditions caused by
mutations, and the size and structure of the genes. Taking into consideration all of
these factors, it has not been possible to identify any likely underlying mechanism
that might account for the de novo mutations arising in APC. Although, polymerase-
(3 induced errors cannot be ruled out. These comparisons are however an important
tool for further work into understanding what influences de novo mutations.
Research into the genetic basis of de novo FAP may shed light on the genetic basis of
colorectal cancer in general.
Comparisons of the human and chimp APC sequences reveal that evolutionary
pressures on the two lineages since they diverged are likely to have been similar and
purifying. In contrast to this, the value of Ks that has been calculated from the
divergence between human and mouse indicate that APC is mutating at a rate that is
faster than genes in previously designated 'hot' regions of the genome. Hot (genes
under positive selection/high neutral mutation rate) and cold (purifying selection/low
neutral mutation rate) regions of the genome have been proposed by Chuang and Li
to explain the observation of differing neutral mutation rates (Chuang and Li, 2004).
They hypothesise that the observed non-random distribution of gene families offers
the possibility that selection is acting at the level of gene location in the genome.
Neutral mutation rates are often used to determine how fast a sequence is evolving,
since they are not subject to the usual selection pressures present at non-neutral sites.
The Mouse Genome Sequencing Consortium (Waterston et al., 2002) used
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alignments of the mouse and human genomes to study neutral mutation rates,
reporting variation in the substitution rate across the human genome, indicating
'substantial regional fluctuation'.
When APC protein evolution is measured, controlling for this high neutral mutation
rate, the resulting value is lower than previously reported for disease genes (Smith
and Eyre-Walker, 2003b), suggesting a striking increase in selection against non-
synonymous substitutions. Hurst and Smith (Hurst and Smith, 1999) show that
essential genes have significantly lower Ka/Ks ratios than non-essential genes.
Polymorphism data suggests that purifying selection is indeed acting upon APC and
increasing the proportion of non-synonymous polymorphisms relative to the
proportion of non-synonymous fixed differences. These data suggest that APC may
be a highly mutable gene, or lies in a highly mutable region of the genome, but that
purifying selection is acting as a constraint mechanism maintaining the DNA
sequence 'constant'. This increase in mutation rate may stem from local sequence
complexity within the APC gene, or may arise as a result of structural and
conformational features of the DNA in this region of the genome. Differences in
structure and conformation of the DNA may lead to differential mutation rates by
providing different levels of exposure to mutagenic and DNA damaging agents, and
enzymes involved in DNA processing. A possible explanation as to why this affect
has not been detected in the human-chimp comparison is that there is not sufficient
evolutionary time between the two species, unlike the human-mouse comparison.
Although the human and chimp APC genes appear to have been subject to similar
evolutionary pressures, their alignment has highlighted some interesting differences.
Using the context of human-chimp divergence to analyse two amino acid changes
from our alignment that are also present in the APC mutation database, suggests that
both are likely to be human polymorphisms, and not causative in the conditions
(indeed, D1822V is predicted to have a protective effect (Slattery et al., 2001b)).
Amino acid substitutions associated with human disease tend to occur at sites that are
more highly conserved in other organisms (Smith and Eyre-Walker, 2003c), and so
they can give novel insights into the selective relevance of genetic changes.
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Alternatively, as has been proposed by Gao and Zhang, a compensatory mutation
hypothesis might explain the fixation of disease causing mutations in other
organisms (Gao and Zhang, 2003). Within the mutation cluster region, only a single
mismatch change was observed, indicating high conservation at this region, likely
due to the consequences ofmutations that occur here.
Data presented in this chapter provides some in silico evidence to support the
hypothesis of instability in the APC gene sequence that has been investigated in
Chapter 3. By comparing the value of Ks that we have calculated for APC with
figures previously calculated across the genome, we can conclude that the mutation
rate at neutral sites is indeed unusually high. In contrast, polymorphism and Ka
values indicate that APC is subject to purifying selection pressures that eliminate
mutations. If the majority of mutations arising in APC are only mildly deleterious
(i.e. missense changes), they may affect one specific role of APC, and will be
selected against. On the other hand truncating mutations in APC (which can be
assumed to arise occasionally as a consequence of a high mutation rate) may offer a
selective advantage to the cell by disrupting vital roles such as Wnt signalling, and
are therefore likely to be subject to positive selection in the short-term/at the cellular
level.
Possession of a germline truncating mutation in APC is likely to result in a reduction
in reproductive fitness. For this reason the gene must be generating a significant
number of de novo mutations each generation. Our data on the de novo mutation rate
of APC is not conclusive, due to the rarity of suitable data with which to make
comparisons. However, we believe our evidence indicates that there is a high
mutation rate for APC in the germline as well as somatic cells. This is supported by
the lack of specific mutation types amongst de novo mutations compared with
familial mutations, or sequence specificity that might have implicated a particular
process in the generation of new germline HFC mutations.
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Chapter 6
Measurement of DNA Base Excision Repair in Live
Cells
6.1 Introduction
It has recently been shown that loss of DNA base excision repair function leads to
the development of colorectal cancer (Al Tassan et al., 2002;Jones et al.,
2002;Lipton et al., 2003;Cheadle and Sampson, 2003;Farrington et al., 2005).
Current methods for identifying patients harbouring deficient BER involves the
identification of mutations in the genes known to be involved, such as MUTYH and
OGG1 (Sampson et al., 2003;Vandrovcova et al., 2004;Russell et al., 2005). Whilst
these are reliable methods, they provide no information about a mutation's functional
consequence.
Currently, assays for BER activity are technically difficult, time consuming and
expensive. A number of techniques use cell extracts rather than live cells, these
include the 7/z vitro Cleavage Assay' where whole cell extracts are incubated with an
antibody of interest (Parker et al., 2002;Alhopuro et al., 2005), and the highly
complex '2-Photon Fluorescence Cross-Correlation Spectroscopy' where uracil
DNA-glycosylase activity is measured in cell protein extracts (Collini et al., 2005).
An example of an assay that utilises live cells is the 'Host Cell Reactivation Assay'
which is based on the expression of a repair gene and/or repair gene mutants of
interest, alongside a reporter gene (Carreau et al., 1995). The reporter gene is treated
with a DNA damaging agent in vitro, and then introduced into cells by transfection.
Resulting gene expression thus reflects the repair ability of the cells. Whilst this
assay gives quantitative information about the activity of the repair proteins of
interest in vivo, complicated vectors need to be constructed. Clearly, there is an
increasing need for simple and reliable approaches to compare and monitor BER
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capacities in various types of cells, under various physiological and pathological
conditions.
At this time there are reports of three functional assays that utilise the green
fluorescent protein (GFP) to determine DNA repair function. In 1999 Pierce et al.
developed a recombination reporter system to assay chromosomal gene conversion
events in response to double strand breaks (DSBs) (Pierce et al., 1999). A vector
containing the GFP gene with an endonuclease site inserted into it, alongside a gene
coding for the corresponding endonuclease was transfected into cells of interest.
When expressed, the endonuclease cleaved the GFP protein, however, functional
homologous repair using a linked donor GFP fragment could restore GFP expression
and this was quantified by flow cytometry two days after transfection.
BER has been further described by two sub-pathways; 'short patch' BER (SP-BER)
and 'long patch' BER (LP-BER). In SP-BER only a single nucleotide is excised and
replaced, but in LP-BER at least two nucleotides are excised and replaced by gap-
filling (Klungland and Lindahl, 1997). Sattler et al. set out to quantify the proportion
of BER activity that is specifically attributable to LP-BER (Sattler et al., 2003). They
constructed a plasmid that contained a single 8-Oxoguanine residue within an
enhanced GFP (EGFP) gene, close to an inserted stop codon. If 8-OxoG was
corrected, LP-BER would remove the stop codon, and restore EGFP expression, but
SP-BER would not. Cells were incubated for 18 hours following transfection with
the plasmid, and fluorescence was then quantified by flow cytometry.
A novel method has been successfully developed by Lei et al. to examine mismatch
repair activity in a variety of cells with and without known MMR defects (Lei et al.,
2004). A mismatch that knocked out gene expression was introduced into the start
codon of the EGFP gene. Following transfection of cells with this mutant vector,
levels of EGFP protein expression were detected by flow cytometry. The number of
cells repairing the start codon mismatch could then be calculated for each cell line,
giving a measure of mismatch repair activity.
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Data presented in this chapter aims to develop an assay that would be useful for
comparing and monitoring total BER activity in a number of live cells, under a
number of different conditions. To our knowledge there is no assay available to
directly measure total BER activity in live cells at this time. Our approach has been
to make use of a vector carrying the EGFP gene, and use flow cytometry for the
high-throughput analysis of a large number of cells, in a similar fashion as Lei et al.,
2004.
In the development of this assay we were able to take advantage of two primary cell
lines, the colorectal cancer cell line, VAC0425 (Parker et al., 2002) and the
fibroblast cell line, 2630 (See Chapter 3) that are known to be BER null. We also
analyse other MMR null and control colorectal cancer and fibroblast cell lines that




Colorectal cancer cell lines VAC0425 (BER null, see (Parker et al., 2002) and
Chapter 3), HCT116 (MMR null, see (Papadopoulos et al., 1994) and Chapter 3) and
SW480 (BER and MMR proficient, (Leibovitz et al., 1976)), and fibroblast cell lines
2630 (BER null), 825 (MSH2 heterozygote) and 439 (BER and MMR proficient)
(see Chapter 3 and 2.1.1) were maintained as outlined in 2.1.2.
6.2.2 Site Directed Mutagenesis of pEGFP-C1 vector
The 4731 base pair pEGFP-Cl vector (Becton Dickinson Biosciences) encodes an
enhanced GFP (EGFP) gene (nt 613 - nt 1410) under the control of a human CMV
promoter, see Figure 6.1. Site directed mutagenesis (2.6) was used to introduce a stop
codon into the 5' end of the GFP gene. Codon 45 of the EGFP gene (vector position
nt 745 - nt 747) was chosen, as mutation of the wild-type sequence, CTG (Leucine),
to a TGA stop codon, was predicted to disrupt EGFP expression, and gave rise to a G
residue upstream of an AA dinucleotide, the most likely sequence to be mutated in
the presence of deficient BER (Al Tassan et al., 2002) (Figure 6.2, top panel).
Consequently, a G:C-T:A transversion mutation at the codon 45 TGA, stop, would
give rise to a TTA (Leucine) codon, therefore restoring the original amino-acid at
this position, ensuring wild-type EGFP expression.
Primers used to mutate codon 45 are detailed in 2.6.1. Following mutagenesis of
codon 45, 12 colonies were picked using sterile pipette tips. Colonies were stabbed
into a 96 well stock plate containing 200pl L-Broth containing kanamycin
(30pg/ml), and grown with shaking for 8 hours prior to being stored at 4°C. Stock
cultures were miniprepped and sequenced as detailed in 2.2.2 using the primers listed
below, to ensure that the mutation had been successfully inserted, and that no other
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mutations had been introduced to other parts of the vector during the site directed
mutagenesis process:
EGFP-N: CGTCGCCGTCCAGCTCGACCAG (nt 679 to nt 658, to check sequence
upstream of EGFP gene)
EGFP-MUT: GGTGCGCTCCTGGACGTAGCC (nt 906 to nt 886, to ensure
mutation had been successfully inserted)
EGFP-CF: CATGGTCCTGCTGGAGTTCGTG (nt 1266 to nt 1287, to check
sequence downstream of EGFP gene)
EGFP-CR: CACGAACTCCAGCAGGACCATG (nt 1287 to nt 1266, to check
whole EGFP gene, including mutation at codon 45)
Sequencing from these primers provided coverage from nt 4581 to nt 1990,
incorporating approximately 50% of the vector, and the entire EGFP gene. Of the 12
colonies sequenced, 9 had the appropriate TGA sequence at codon 45, with no other
mutations introduced in other areas of the vector. Of these 9, two were picked from
the stock plate and grown in a 5ml overnight culture of L-Broth containing
kanamycin (30pg/ml). This was pelleted at 3000rpm for 5min in a Sorvell RT6000
centrifuge, and resuspended in 0.85ml L-Broth + 0.15ml glycerol to make a glycerol
stock for long-term storage at -80°C.
Glycerol stocks were used to streak agar plates containing Kanamycin, and incubated
overnight at 37°C. A single colony was picked, and plasmid DNA isolated for
transfection by maxiprep (Qiagen).
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Figure 6.2 Schematic diagram of assay to detect BER in live cells. Top panel shows the
codon change resulting from site directed mutagenesis of the pEGFP-C1 vector. Bottom
panel represents the proposed mechanism by which BER null cells might revert the EGFP
mutation, so that expression is restored.
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6.2.3 Transfection of cell lines
On day 1 cells were plated at a density of ~ 2 x 105 in 2 ml media, into 6 well dishes
for transfection (2.5.3). In three parallel experiments 6 well dishes were set up with 3
wells of cells for transfection with mutant plasmid DNA (6.2.2), unmutated (wild-
type) plasmid DNA, and an untransfected control, as described in 2.5.3. Cells
transfected with the mutant and wild-type vectors were co-transfected with 0.6pl
(2.745jug/jo.l) of the pSV-P-Galactosidase control vector (Promega) (2.5.4).
Transfection took place on day 2, followed with a media change on day 3.
6.2.4. FACs analysis of transfected cells
Cells were harvested for FACs analysis on day 5, as outlined in 2.5.5. 50pl aliquots
of cells re-suspended in PBS were then removed, to control for transfection
efficiency by |3-Galactosidase enzyme assay system (2.5.4).
A FACS Caliber cytometer, was used to analyse fluorescence levels in all samples,
as detailed in 2.5.5. FL1 and SSC parameters were adjusted using the untransfected
samples to insure that differences in the amount of auto-fluorescence did not
influence results. Wild-type and mutant transfected cells could then be analysed, with
reference to the un-transfected sample.
6.2.5 Data Analysis
Fluorescence data was analysed for all cells with >10 units of fluorescence, as this
high level of fluorescence was never seen in un-transfected cells, therefore any
transfected cells with this level of fluorescence are assumed to be expressing EGFP.
Total EGFP expression was calculated as a product of N (number of cells with
fluorescence >102 units) and I (mean intensity of fluorescence in these cells), for all
samples. Total EGFP expression was then corrected for transfection efficiency using
levels of (3-Galactosidase enzyme activity. Lastly, the mean levels of fluorescence
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and standard errors were calculated from the three experiments carried out in parallel
(total of 15,000 cells).
Relative EGFP expression was also calculated to determine the proportion of wild-
type expression seen in cells transfected with the mutant plasmid. This was
calculated as (corrected NM x ^/(corrected Nwt x Iwt), where M represents cells
transfected with mutant vector, and WT represents cells transfected with wild-type
vector. Again, the means and standard errors were calculated.
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6.3 Results
6.3.1 Optimisation of the method
The transfection procedure was optimised using the wild-type vector on all 3
fibroblast cell lines (825, 2630 and 439) and the colorectal cancer cell line
VAC0425. It was found that the Lipofectamine™ 2000 (Invitrogen) reagent gave
the highest level of transfection efficiency in all cell types (used according to
manufacturers instructions), when compared directly with the Lipofectamine™
(Invitrogen) reagent. Cell density was also optimised, with plating 2 x 105 cells in 2
mis media, giving approximately 50-60% confluency of cells on day 2 when
transfection took place, and the best transfection efficiency, with approximately 50%
of cells expressing EGFP at some level (determined by fluorescent microscopy).
Higher confluency resulted in a high level of cell death following transfection. As
per manufacturers instructions, 4p,g vector was found to give the best transfection
efficiency, in the 6 well dish format. A media change was introduced on day 3 to
feed cells, this had no effect on transfection efficiency, but reduced cell death
following transfection. Cells transfected on day 2 were analysed for fluorescence on
day 5 by flow cytometry, this 72 hour incubation was included so that the vector
could be replicated, and therefore subjected to DNA repair mechanisms and/or
deficiencies.
It was hypothesised that BER deficient cells would show higher levels of EGFP
expression from mutant constructs than MMR deficient or BER/MMR proficient
cells. The initial optimisation included H202 treatment to induce oxidative damage,
and therefore detect higher levels of EGFP expression from mutant constructs
(Slupphaug et al., 2003). However, during the optimisation of the protocol,
transfected and untransfected cells were treated with 100pM, 200p.M and 400pM
H202 for 24 hours as part of the media change step on day three, but the treatment
was highly toxic to our cells, and resulted in widespread cell death, so was not
pursued further.
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During the initial optimisation experiments, detectable fluorescence from the mutant
vector was only detected in the BER null VAC0425 colorectal cancer cell line. The
other cell lines studied were all of fibroblast origin (including the BER null 2630
line), and it was postulated that this effect might be cell type specific. For this reason,
2 additional colorectal cancer cell lines were added for the final set of experiments
for comparison. These were, SW480 (MMR and BER proficient) and HCT116
(MMR defective).
155
6.3.2 p-Galactosidase enzyme activity reveals higher levels of
transfection efficiency in colorectal cancer cell lines compared
with fibroblast cell lines
To determine the levels of transfection efficiency that could be expected in our six
cell lines of interest, they were co-transfected with the wild-type pEGFP-Cl vector
and the pSV-P-Galactosidase control vector. P-Galactosidase enzyme activity was
then used to correct for differences in transfection efficiencies between the cell lines
(2.5.4). The colorectal cancer cell lines VAC0425, SW480 and HCT116 showed
higher levels of transfection efficiency by P-Galactosidase enzyme assay than the
fibroblast cell lines 439, 825 and 2630 (Table 6.1). The efficiency of DNA uptake by
transfection varied enormously between cell lines, but the cells of fibroblast origin
were all extremely low. In this case it is most likely that differences in proliferation
rate can explain this phenomenon, as the tumour-derived cell lines can be seen to be
multiplying at much higher rates than the primary fibroblast cell lines. Liposomes are
incorporated into cells mainly by endocytosis (Zhou and Huang, 1994;Zabner et al.,
1995). High cell proliferation activity correlates well with cellular endocytotic
activity, therefore transfection of cationic liposomes, such as used in the
lipofectamine 2000 reagent, will be more efficient in highly proliferating cells. This
association has been confirmed via P-Galactosidase enzyme assay in a study of oral
tumour cell lines (Nakase et al., 2005).
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Table 6.1 (3-galactosidase enzyme activity in six cell lines. The colorectal cancer cell lines,
VAC0425, SW480 and HCT116 have increased transfection efficiencies over the other cell
lines. Units are absorbance at 420nm.
Co-transfected Co-transfected








Despite correcting for transfection efficiency, Figure 6.3 shows that average levels of
wild-type EGFP expression in the HCT116 cell line, 72 hours after transfection, were
greatly increased compared with the other five cell lines (around 10-fold), including
the other two colorectal cancer cell lines. However, when disregarding the HCT116
cell line, (3-Galactoidase enzyme activity did effectively control for differences in
transfection rates in the other 5 cell lines. The failure of (3-Galactosidase enzyme
activity to control for the transfection efficiency in HCT116 can be attributed to the
threshold of the (3-Galactosidase enzyme assay being exceeded by high levels of
expression. Figure 6.4 shows a standard curve for (3-Galactosidase enzyme activity
that was calculated subsequent to our EGFP assay. It shows clearly that whilst
absorbance at 420nm increases linearly up to 5 milliunits of (3-Galactosidase activity
(x axis), after this the curve levels off, and absorbance becomes a less accurate
method of determining enzyme activity.
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425 SW480 HCT116 439 825 2630
Figure 6.3 Average total EGFP expression levels in 6 cell lines transfected with the wild-type
pEGFP-C1 vector. Colorectal cancer cell line HCT116 has around a 10 fold higher level of
total fluorescence than the other 5 cell lines. Error bars represent standard errors for three
separate experiments of 5000 cells each (total 15000 cells per cell line). Levels of total
EGFP expression are arbitrary units
Milliunits B-Glactosidase
Figure 6.4 Standard curve for p-Galactosidase enzyme activity. Standards of 0, 1, 2, 3, 4, 5,
20, 40 and 100 x 10"3 units of p-Galactosidase were used.
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6.3.3 VAC0425 cell line shows significantly higher mutant E-GFP
expression than 5 other cell lines
Total fluorescence was calculated as outlined in 6.2.5, as a product of N (number of
cells with fluorescence >10 units) and I (mean intensity of fluorescence in these
cells), this was corrected for transfection efficiency and standard errors from three
experiments were calculated. Figure 7.5 shows typical FACs outputs for all six cell
types when untransfected, transfected with the wild-type pEGFP-Cl vector, and
transfected with the mutant pEGFP-Cl vector.
Figure 6.6 shows the average total fluorescence (level of EGFP expression) from the
mutant pEGFP-Cl vector for each cell line. Despite extremely high levels of EGFP
expression from the wild-type vector in the HCT116 cell line (6.3.2), no expression
was detected from the mutant vector. This provides good evidence that expression of
the EGFP gene, from the mutant pEGFP-Cl vector is not detected in the absence of a
BER defect, even when it is present in a high proportion of cells, and is not
effectively corrected by (3-Galactosidase enzyme activity. In the colorectal cancer
cell line, VAC0425, the average level of fluorescence detected from the mutant
vector was 2707 + 793 arbitrary units. This is 2.5 fold greater than the level of
fluorescence detected in the SW480 CRC cell line (943 + 943 arbitrary units),
however since standard errors pass through zero for SW480, this may not be a real
effect. The level of fluorescence detected in the VAC0425 cell line was more than
2500 fold greater than in the HCT116 cell line, or the three fibroblast cell lines,
where no fluorescence was detected from the mutant vector. This included the 2630





Figure 6.5 Typical FACs data set for each cell line untransfected (top panel), transfected





425 SW480 HCT116 439 825 2630
Figure 6.6 Average total EGFP expression levels in 6 cell lines transfected with the mutant
pEGFP-C1 vector. The BER deficient colorectal cancer cell line VAC0425 has a 2.5 and
2500 fold higher level of total fluorescence than the BER proficient SW480 and HCT116
colorectal cancer cell lines respectively. Error bars represent standard errors for three
separate experiments of 5000 cells each (total 15000 cells per cell line). Levels of total
EGFP expression are arbitrary units.
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6.3.4 Measurement of relative excision repair activity in VAC0425
cell line
Relative fluorescence was calculated as outlined in 6.2.5, as (corrected
NMlivOAcorrected NwtIwt)- 'Relative fluorescence' expresses fluorescence from the
mutant vector as a percentage of fluorescence from the wild-type vector. Figure 6.7
shows that in the VAC0425 cell line, the mutant vector was expressed at 0.1% of the
level seen in the wild-type vector.
From the uncorrected raw data, the average fluorescence intensity of a VAC0425
cell transfected with the wild type vector (Uverage) was 391 units. In the 15,000
VAC0425 cells transfected with the wild-type vector, 559 cells had a level of
fluorescence intensity above the 102 unit cut-off used to determine total EGFP
expression from the wild-type vector (see 6.2.5), this is termed NWt- The uncorrected
total level of fluorescence from the WT vector was therefore NWt x laverage, or
218,569 units. The uncorrected total level of fluorescence from the mutant vector is
therefore 0.1% of the WT level, or 219 units. This is approximately equivalent to 1
cell with a level of fluorescence >102 units, or 0.56 cells with a level of fluorescence
equivalent to Forage (391 units). Therefore, assuming similar transfection efficiencies
from the wild-type and mutant vectors, we have observed between 1 in 559 and 1 in
1000 vectors harbouring a mutation that leads to EGFP expression.
Data presented previously in Chapter 3 for the VAC0425 cell line reveal that across
the APC, TGF/3R2 and GPD1 genes, a total of 127 mutations were detected in a total
of 151.148 Kb sequence analysed, corresponding to a general mutation frequency of
0.84 mutations/Kb. The pEGFP-Cl vector is 4.731 Kb, if we assume that it too is
subject to a mutation frequency of 0.84 mutations/Kb, we would expect ~ 4
mutations per vector when analysed using our cloning and sequencing approach. If
we assume that these 4 mutations occur at random along the sequence of the vector,
then 1 in 1184 vectors would be mutated at the critical G residue of codon 45 (4731 /
4). If the G were mutated to a T or a C, then expression of EGFP would be restored,
if G were mutated to an A, codon 45 would still code for a stop codon. Therefore,
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based on a mutation frequency of 0.84 mutations/Kb we would expect 1 in 1775
vectors to harbour a mutation that leads to EGFP expression.
The observed frequency of EGFP expression from the mutant vector is between 1.7
and 3 fold greater than expected to arise by chance due to the mutation frequency
observed previously in the VAC0425 cells. This suggests that our assay is indeed
able to detect the increase in G:C-T:A transversions expected in the presence of BER




















Figure 6.7 Expression of the mutant pEGFP-C1 vector in each cell line is represented as a
percentage of the expression seen from the wild-type pEGFP-C1 vector. Expression of
EGFP from the mutant pEGFP-C1 vector in the BER deficient colorectal cancer cell line
VAC0425 is 0.1% of the level detected from the wild-type pEGFP-C1 vector. In the BER
proficient SW480 cell line mutant expression is 0.04% of that seen from the wild-type vector.
In the other 4 cell lines, including the BER null 2630 cell line, no EGFP expression is
detectable from the mutant vector. Error bars show the standard errors of the mean. Levels
of total EGFP expression are arbitrary units.
I.
425 SW480 HCT116 439 825 2630
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6.4 Discussion
Data presented in this chapter demonstrates that by using a mutant EGFP reporter
gene, our assay is able to detect a BER deficiency present in live colorectal cancer
cells.
Precise analysis of BER activity in the genomic context would be ideal, however,
this is hampered by a lack of techniques that can reliably introduce a single lesion at
a defined position on chromosomal DNA. Therefore, the use of plasmids has been
developed to probe the pathway indirectly. Our assay aims to measure oxidative
DNA damage that remains un-repaired due to deficient BER. The ability of the assay
to detect differences in repair activity between different cell types is therefore
dependent upon endogenous oxidative damage. In contrast to the assay described in
this chapter, a number of previously developed assays for BER activity depend upon
the repair of damage that is artificially introduced into the plasmid. Importantly, this
has provided evidence that damaged plasmid DNA is processed in the same way as
endogenous DNA (Le Page et al., 1998;Le Page et al., 2000), however, these assays
have used resistance to restriction enzymes as a non-quantitative method of
determining if BER repair of introduced 8-OxoG lesions has occurred. The assay
described by Sattler et al. introduced an 8-OxoG lesion coupled to a stop codon
within the EGFP gene, but is specific for LP-BER, so is unsuitable for assaying total
BER activity, as was the aim here.
The introduction of a TGA stop codon containing an 8-OxoG residue in place of a
normal G, into the EGFP gene might have allowed us to bypass the initial step in our
assay that is dependent upon endogenous oxidative damage taking place. This would
produce a more sensitive assay, at the expense of simulating the real situation. Once
replication had taken place, mis-pairing of an A with the inserted 8-OxoG lesion
(assuming that repair had not occurred) would result in EGFP expression. Another
alternative would be to introduce an 8-OxoG lesion directly onto the transcribed
(template) strand, rather than onto the untranscribed (coding) strand, that would not
disrupt EGFP expression i.e. opposite a TCA serine residue or a TAC tyrosine
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residue. Following replication, and in the absence of BER, a G:C-T:A transversion
would result in a stop codon (TAA in both cases), and EGFP expression would be
halted. However, reports indicate that during transcription RNA Polymerase II stalls
at 8-OxoG lesions, but is also able to bypass them, and may insert either a correct C
or an incorrect A residue in its place to ensure transcription continues (Kuraoka et
al., 2003). For the purposes of our assay, the introduction of 8-OxoG onto the
transcribed (template) strand rather than the untranscribed (coding) strand would
therefore not be useful, as any transcription taking place prior to replication of the
vector, may result in the introduction of a stop codon, even in the presence of
functional BER, due to mis-reading of 8-OxoG by RNA Polymerase II. Additionally,
there are likely to be more technical difficulties associated with detecting rare events
that result in loss of EGFP expression rather than rare events resulting in gain of
EGFP expression.
During the development of this assay, one of our aims was that it should be able to
analyse BER activity in a variety of different cell types, this is, in theory possible,
however, we have shown that the assay is very prone to differences in cell growth
and transfection efficiency. This is due to its dependency upon vector replication
following endogenous oxidative DNA damage. During the optimisation stage, up to
50% of cells could be seen to have some level of fluorescence from the wild-type
vector, 24 hours after transfection (6.3.1). Many less cells had levels >10" units of
fluorescence when analysed by flow cytometry 72 hours after transfection, indicating
that a number of cells had lost the vector following replication. Although we have
detected a significant increase in the fluorescence levels of the mutant vector in the
VAC0425 CRC cell line compared with the other cell lines, our stringent cut-off for
fluorescence levels (>102 units) coupled with the loss of the vector from a large
number of cells 72 hours after transfection is likely to be under estimating the rate at
which G:C-T:A transversions are occurring in BER deficient CRC cells. Using non-
replicating plasmids to assay for repair kinetics, Le Page et al. have shown that the
repair of 8-OxoG:C lesions takes place within 12 hours of transfection (Le Page et
al., 1998) suggesting that in our rapidly dividing CRC cell lines it may be possible to
reduce the incubation time between transfection and flow cytometry analysis. This
166
may help to reduce the number of cells that have lost the vector containing the EGFP
gene.
The effect of a BER defect causing EGFP expression from the mutant vector appears
to be specific to CRC cells, as it is not detected in the BER null 2630 fibroblast cell
line. This may be due to the higher proliferation rate in CRC cells compared with
fibroblast cells. Firstly, high cell proliferation activity is correlated with cellular
endocytotic activity, and transfection will therefore be more efficient in highly
proliferating cells (Nakase et al., 2005), whilst this was corrected for using (3-
galactosidase enzyme activity, the more cells that contain the mutant vector, the
more likely it is that an effect from deficient BER will be detected. Additionally, the
chance of a BER defect being observed in highly proliferating cells may also be
more likely. Reactive oxygen species are generated endogenously by cellular
metabolism, therefore, cells that have a higher rate of cellular metabolism, such as
tumour cells, may generate more endogenous oxidative damage (Brozmanova et al.,
2001). For further optimisation of the assay it will be useful to investigate alternative
transfection strategies that may not be so sensitive to cell proliferation rates. These
include physical methods such as electroporation and sonoporation. A high rate of
cell proliferation may go some way to explaining the results from the SW480 cell
line, where we observed a detectable, but non-significant level of fluorescence from
the mutant vector in the absence of a BER defect. However, despite the high level of
wild-type EGFP expression observed in the HCT116 cell line, which was not
effectively corrected for by (3-galactosidase enzyme activity, no fluorescence was
observed from the mutant vector, even when it is, presumably, present in a high
proportion of cells, providing good evidence that expression of the EGFP gene, from
the mutant pEGFP-Cl vector is not detected in the absence of a BER defect.
The colon is believed to be inherently more prone to cancer, due to rapid cell
division, and exposure to DNA (including oxidative) damage via dietary toxins
(Leedham et al., 2005). This goes some way to explaining why patients with MYH
associated polyposis, where MYH is bi-allelically inactivated, develop colorectal
cancer specifically, rather than cancers in other tissues, i.e. fibroblast cells. As well
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as the origin of the cells, the nature of the BER defects in the cells studied in this
chapter could be influencing how they perform in our assay. The 2630 fibroblast cell
line has been shown to harbour bi-allelic inactivating mutations of MUTYH, and
whilst the direct effects of these mutations on this cell line have not yet been
determined specifically, a study that included a lymphoblastoid cell line with the
same G382D/Y165C genotype revealed significantly reduced expression of MYH
and reduced levels of 8-OxoG:A repair (Parker et al., 2005a). Likewise, the
VAC0425 CRC cell line has been characterised as having a 20 fold increase in
genomic 8-OxoG, and a 15 fold reduction in repair activity of 8-OxoG:A, compared
with SW480 cells. This is presumed to be due to inactivation of MUTYH, as reduced
levels of mRNA and protein were detected compared with control cell lines, although
specific MUTYH mutations have not been determined (Parker et al., 2002).
The tumour suppressor gene p53, is involved in several DNA repair pathways, either
via transactivation of p53-dependent genes or by direct involvement with the p53
protein (Offer et al., 1999;Offer et al., 2001). Whilst the HCT116 CRC cell line is
wild-type for p53, SW480 cells have been shown to harbour a G-A mutation at
codon 273 resulting in an Arginine to Histidine substitution (Liu and Bodmer, 2006).
The effect of a variety of p53 mutations, including the SW480 273R/H mutation
were determined by Offer et al. in p53 knock-out cells. Along with deletions of the
C-terminus, the 273R/H mutation failed to augment BER activity when compared
with the wild-type p53 protein. BER activity was therefore concluded to be
dependent on a wild-type core domain (amino acids 100 to 300), and an intact C-
terminus domain (amino acids 363 to 393), but not an intact N-terminal domain.
These findings have implications for our assay, as the detection of fluorescence from
the mutant vector in SW480 cells, whilst not statistically significant, may signify a
BER deficiency in these cells caused by abrogation of p53 function. Further work is
warranted to determine if these cells do indeed contain a BER defect, despite being
characterised as largely wild-type for genomic 8-OxoG levels, 8-OxoG:A repair, and
levels of MYH mRNA and protein (Parker et al., 2002). Initial western blot analysis
has been carried out, and reveals WT levels of p53 protein in the SW480 cell line
(data not shown). This is not unexpected, as the 273R/H mutation affects p53's
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ability to augment BER, rather than decreasing overall levels of the protein.
Interestingly however, significantly reduced levels of p53 were observed in both the
VAC0425 and HCT116 cell lines (data not shown). The p53 protein has been
reported at WT levels in HCT116 (Liu and Bodmer, 2006) so this finding suggests
that our cell line may have acquired additional pathogenic mutations or inactivating
events. However, the results from our EGFP assay do not suggest that reduced levels
of p53 are affecting detectable BER activity. Reduced levels of p53 protein in the
VAC0425 cell line may provide another means, alongside absent MYH, by which
these cells are deficient for BER.
In this chapter we have begun to develop an assay that is able to detect BER
deficiency in colorectal cancer cell lines. At this preliminary stage we have obtained
some exciting results that indicate that the occurrence of G:C-T:A transversion
mutations in cells with a known BER defect may be as much as three times greater
than would be expected from the underlying mutation frequency of the cells. To
further improve the assay it will be important to test a wider variety of cell lines
known to have BER defects, to see if it is possible to replicate what is seen in
VAC0425, and determine if the assay will be useful for other cell types. Another
important aspect of the assay that requires further investigation is the manipulation of
the physiological conditions of the cell lines. We were unsuccessful with initial H2O2
treatments since they were toxic to the cells, however sublethal concentrations of
other reactive oxygen species (such as superoxide, 6-hydroxydopamine and heme)
should be investigated. Increasing oxidative damage within cells should increase the
number of mutant vectors that express EGFP when BER is deficient, improving the
reliability of the assay. A reasonably straightforward proof-of-principle experiment
would be to co-transfect the VAC0425 cell line with a vector containing the mutant
EGFP gene alongside a WT MUTYH gene. Transfection of MUTYH deficient cell
lines with exogenous WT MUTYH has partially corrected MYH activity in a
previous study (Parker et al., 2005b). Therefore, if the vector containing WT
MUTYH abolishes fluorescence from the mutant EGFP gene, there would be strong
evidence that fluorescence is directly due to dysfunctional MYH protein, resulting
from bi-allelic MUTYH mutations. Lastly, it would be interesting to trial vectors with
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an 8-OxoG lesion directly inserted, this should reduce the complexity of the assay, as





The main aim of this thesis was to investigate our hypothesis of inherent instability
in the APC gene. This was approached in a number of different ways, including
attempting to determine the underlying frequency with which mutations arise in the
APC gene in both the in vivo (patient samples) and in vitro (cell lines) situations.
Subsequently, the mutations that are ultimately selected for during the tumourigenic
process were also determined. Alongside this comparison of mutation frequencies,
types and spectra, in silico techniques were used to establish how inherent instability
ofAPC might contribute to tumour initiation and progression.
As cancers with DNA repair defects influence genetic alterations, elucidation of how
they exert this effect may provide new insight into the contribution of DNA repair
defects in colon carcinogenesis. Therefore, throughout this project the influence that
DNA repair plays on the APC gene, and how the presence or absence of DNA repair
affects mutations in individual cells and genetic alterations in whole tumours has
been investigated.
Lastly, with the aim of ascertaining the effect of loosing DNA repair on cellular
mutation frequency, a novel assay has begun to be optimised.
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7.1 Mutation frequency at the APC gene in normal lymphoblastoid
cell lines
Work in this thesis has utilised two normal lymphoblastoid cell lines, from patients
devoid of cancer and without a family history of cancer. As they are derived from
non-tumourous tissue, these cells are not subject to selection pressures for mutations
that provide the cell with a growth advantage, and which result in successive waves
of clonal evolution. Whilst these cell lines have been EBV transformed, previous
work from the lab has indicated that this is unlikely to have an effect on mutation
frequency (Bacon et al., 200If). In these normal cells, factors biasing the observable
mutation frequency (such as mutations in DNA repair genes) are minimised, and
therefore it was proposed that the presence of inherent instability at given sequences
would be effectively "unmasked". It was believed that because these cell lines are
not cancer derived, any detection of excess mutations would indicate that the APC
gene sequence is inherently unstable, adding further strength to support the
importance of an inherent mutation rate in tumourigenesis (Loeb, 2001a).
In both normal control cell lines (ConC and ConA) there were no significant
differences between the mutation frequencies observed in the two control genes
(TGF/3R2 and GPD1), suggesting that this low level of mutation (0-0.2
mutations/Kb) represents a basal level with which mutations arise in most genes.
Previous estimations of the underlying mutation frequency of the genome have been
estimated using the HPRT reporter gene. In T-lymphocytes the mutation frequency
of this 43Kb gene has been estimated to be ~5 x 10"6 in healthy 20 year old subjects
(Robinson et al., 1994). This equates to -2.15 x 10"4 mutations/Kb, approximately
1000 times less than the estimation from our assay. Even though the method used to
determine mutation frequency at the HPRT reporter gene requires the selection of
individual cells that have lost HPRT function, which is likely to result in an
underestimation of the true frequency with which mutations arise, this comparison
suggests that our assay is grossly over-estimating mutation frequency.
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As discussed in section 3.4, the expansion of mutant clones within a population of
cells would result in an estimation of mutation frequency that is highly variable and
include many overestimates (Lea and Coulson, 1949). However, the results detected
in this thesis, using a PCR/cloning assay are remarkably consistent from clone to
clone. This observation, alongside the high frequency of mutations observed in all
cell lines is well explained by the bulk of mutations having arisen during PCR
amplification. Therefore, it is not possible to conclude that instability of the APC
gene has been uncovered in these normal lymphoblastoid cell lines.
Two areas of future work, important for more detailed investigation of the possible
instability in the APC gene include the examination of the normal in vivo situation.
At this time ethical approval has not been obtained for the collection of colonic
mucosa from healthy individuals without a family history of colorectal cancer. The
ability to determine whether normal colonic mucosa behaves in a similar way to
normal lymphoblastoid cells will be advantageous, although it should be considered
that instability at the APC gene may well be masked by tissue specific selective
pressures in such samples.
Hypermutability of the APC gene sequence would provide a mechanism to explain
the high frequency of mutations that occur early in the carcinogenic process.
However, the elevated frequencies of mutations that have been observed are likely to
be due to the PCR/cloning assay used, and therefore the data do not support this
hypothesis. Infact, the data are consistent with the APC gene being normal with
respect to mutagenesis and the observed mutation frequency being due to selection
pressure acting on cells with advantageous mutations, due to the key gatekeeper role
ofAPC.
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7.2 In silico analysis of APC mutation frequency
The in silico work presented in Chapter 5 was carried out with the aim of providing a
greater insight into the proposed instability of the APC gene. Previous studies have
used the footprint ofmutations left behind by a defective DNA polymerase or repair
system to identify the source of mutation (Kuraguchi et al., 2000c;Al Tassan et al.,
2002a;Shao et al., 2004b). However, similar work carried out here has not been able
to offer a viable and constant alternative explanation to explain the frequency ofAPC
mutations seen in CRC. At this stage three possible explanations include inherent
instability of the APC gene sequence that may act alongside clonal selection,
undetected mutational mechanisms and selection pressure acting on APC allowing
advantageous mutations to become fixed. Evidence to support the theory of
instability in APC is highlighted by the high value of Ks obtained from the human-
mouse alignment in silico work, suggesting that the APC gene is likely to be subject
to a high neutral mutation rate.
There are two main scenarios from which inherent instability of the APC gene
sequence could arise, both of which warrant further investigation. Firstly, the APC
gene may be located in a faster mutating region of the genome compared with the
two control genes analysed, or secondly, it might be that it is the gene sequence itself
that is susceptible to mutation.
Despite extensive analysis of de novo mutations, we have so far been unable to
identify any aspect of the APC gene sequence that might make it more susceptible to
mutation, although further investigation into the role played by polymerase 5 in
contributing to de novo mutations will be important (Ripa et al., 2002e).
If the APC gene is in fact located in a fast mutating region of the genome then it
might be the conformation, or local environment of the DNA that is affecting
mutation frequency. Additional features, such as the structure and/or conformation of
the DNA surrounding APC may lead to the differential mutation frequencies
observed, as they can provide different exposure to mutagenic agents or DNA
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processing enzymes, and their features warrant further investigation. A similar
hypothesis has previously been proposed, suggesting that chromatin structure may
affect the susceptibility of regions of DNA to mutation (Hsu, 1975). Although,
whether genes in open or closed chromatin are the most susceptible to mutation is
still debated (Gazave et al., 2005). The chromatin structure of the DNA surrounding
the three genes studied here has been determined (James Prendergast, personal
communication). The APC gene overlaps a clone in very closed chromatin, TGF/3R2
is in marginally closed chromatin, and GPD1 is believed to be in average chromatin,
based on the nearest available clones (Gilbert et al., 2005). Therefore, the chromatin
environment surrounding APC is not significantly different to the two control genes.
At this stage, with the role played by chromatin environment in susceptibility to
mutation still under debate, it is not possible to determine accurately if this is
contributing to the increase in APC mutation frequency that we have observed.
Nevertheless, it does underline the importance of considering factors such as DNA
conformation and environment.
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7.3 DNA repair mechanisms may influence the spectrum of
mutations arising in the APC gene
The data presented in this thesis on the analysis of APC 'instability' in a variety of
DNA repair backgrounds using our 'snap-shot' technique produced a large amount of
information. As has been discussed previously in Chapter 3, much of this data
appears likely to have arisen as a result of PCR error, however some of the mutation
spectrum data may well be pointing towards a novel influence of defective DNA
repair in the APC gene and across the genome.
The use of cell lines lbl-1260 and lbl-1261, derived from normal tissue, but with
deficient MMR, has previously revealed mutations that specifically arise as a result
of absent MMR, but with a reduced bias of selection pressures and clonal advantage
that tumourigenic cells are subject to (Bacon et al., 2001 g). For this reason we have
used these cell lines to investigate the relationship between MMR and APC
instability, and directly compare the results with those obtained in the two control
cell lines. However, due to the non-repetitive sequence that was analysed in this
study it is likely that alongside mutation frequencies being potentially influenced by
the expansion ofmutant clones in cell culture, errors from PCR have also had a large
impact on our results.
It was expected that selection pressures present in colorectal cancer cell lines would
bias the observable mutation frequency, making the dissection of events dependent
solely on APC instability more difficult in the HCT116 MMR defective colorectal
cancer cell line. The trend in mutation frequencies and spectra across all three genes
studied in this cell line were indistinguishable from that in the MMR defective
lymphoblastoid cell line, lbl-1261. Also, our two BER defective cell lines, although
being of different origin (fibroblast and colorectal cancer) gave indistinguishable
results across all three genes. This evidence strongly suggests that the observed
mutation frequency and spectra were indeed greatly influenced by factors other than
instability in the APC gene sequence.
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In tumour samples a greater proportion of transversions is observed than in normal
mucosa samples. We have considered the possibility that these transversion
mutations may be appearing above the 'noise' of transition mutations (possibly
caused by PCR error), and may represent true mutations occurring in the tumour
DNA. We have not been able to identify a possible mechanism to explain how
inactive MUTYH causes an increase in general transversion mutations. However, an
increase in transversion mutations arising, compared with transition mutations,
significantly increases the likelihood of a coding amino acid becoming a STOP
codon. In heterozygote MUTYH tumours the increase in transversion mutations
compared with sporadic tumours suggest a distinct mechanism by which these
individuals are predisposed to colorectal cancer, and may provide insights to the
mechanism of tumourigenesis in these cancers, and also supports the evidence of a
heterozygous effect in susceptibility to the disease. Currently, the contribution, or
otherwise, made by heterozygous MUTYH mutations to CRC susceptibility is still
under debate (Croitoru et al., 2004a;Farrington et al., 2005d;Tenesa et al.,
2006c;Jenkins et al., 2006c). Our work suggests that whilst the characteristic
inactivating G:C-T:A transversion mutations observed in the APC and KRAS genes
of MAP individuals are not selected for in the same way in heterozygotes (Chapter
4), the presence of a single MUTYH mutation appears to influence their tumour
DNA, causing it to contain more transversion mutations than that of tumours without
anyMUTYHmutations. This alteration of the mutation spectrum may point towards a
mechanism by which the susceptibility ofMUTYH heterozygotes to developing CRC
is increased over individuals with completely wild-type MUTYH. It will be
interesting to look in more detail at the interactions of MYH with other proteins, to
deduce if any of these could be responsible for the MUTYH heterozygous
phenomenon observed.
Maley et al. suggest that an increase in clonal diversity predicts incipient
transformation (Maley et al., 2006e). Nevertheless, using our assay normal mucosa
samples did not generally have lower levels of diversity than tumour samples, as
would be expected. If a truly normal in vivo sample had been available to us, it
would have been interesting to see if reduced cellular diversity in truly normal
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samples could in fact be detected using our assay. It seems that this would be
unlikely however, because if the vast differences in mutation frequency observed
between in vivo samples (7.3.2) were due to clonal expansion in some tumours
reducing the diversity in the tumour tissue compared to the normal mucosal sample,
this would have produced evidence to support the efficacy of our assay, and this was
rarely seen.
The majority of mutations identified in all samples were transitions. A propensity for
transition mutations in individual cells from cell lines and in vivo samples with MMR
gene mutations, has been reported previously in T cells derived from mice (Shao et
al., 2002;Shao et al., 2004c). At the Aprt reporter gene, all single base substitutions
from both an Mlhl '' and a Pmsl'' mouse were transition mutations, inline with our
findings. However, the distribution of transition mutations observed was
considerably different to what has been observed in this thesis. Again, this indicates
that our assay may be influenced by PCR error. In addition, in the studies of Shao et
al. no increased mutational load was detected in Mlhl+/~ T cells at the Aprt reporter
gene, despite an increase being detected in Mlhl''' cells. Our assay clearly indicates
that MMR heterozygote cells can have an increased mutational load at three different
gene loci.
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7.4 Further characterisation of the influence played by DNA repair
mechanisms is important for the understanding of tumourigenesis
What has become clear during the work undertaken for this thesis is that an
understanding of DNA repair is of fundamental importance for unravelling the
complex process of carcinogenesis. To this end, I have begun to develop a more
reliable molecular tool for clinical and research purposes that accurately measures
DNA BER.
At the present time, despite a variety of tools being available to measure BER, they
tend to be technically difficult, time consuming and/or expensive. A number use
whole cell extracts, rather than live cells, that are either incubated with an antibody
of interest (Parker et al., 2002g;Alhopuro et al., 2005a), or used to measure uracil
DNA-glycosylase activity (Collini et al., 2005). Live cell assays tend to require
complicated vectors (Carreau et al., 1995b). Whilst an assay does already exist that
utilises EGFP expression (Sattler et al., 2003b), only LP-BER, and not SP-BER
could be measured. Therefore, there is clearly a need for simple and reliable
approaches to compare and monitor BER capacities in various types of cells, under
various physiological and pathological conditions.
As discussed in detail in section 6.4, the development of an assay that could be used
in a clinical setting was undertaken. During the optimisation process a detectable
increase in mutation rate was observed in BER null cells. This assay, although in its
early stages of development has the potential to be used in high-throughput screens
of cells from a variety of origins.
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7.5 Summary
Work presented in this thesis has focused on determining the frequency with which
mutations spontaneously arise in the APC gene. Central to this has been investigating
the role played by DNA repair mechanisms in influencing APC mutation frequency
and spectrum.
In two wild-type lymphoblastoid cell lines an elevation in mutation frequency in a
region of APC exon 15 was detected (Chapter 3), whilst this may have indicated
inherent instability of gene sequences even when DNA repair mechanisms are intact,
further work is required to address the problems in our experimental approach.
Polymorphism and evolutionary data (Chapter 5), shows that the APC gene is subject
to a high neutral mutation rate and purifying selection. However, the effect of
selection acting to remove non-synonymous changes is likely to be modest. In
addition, analysis of the type and location of de novo APC mutations has provided no
alternative mechanism to explain how these mutations arise.
The influence of DNA repair mechanisms on APC mutation frequency and spectrum
has been investigated using a significant number of cell lines and patient samples.
There is an effect on the spectrum of mutations observed in the tumour samples of
patients carrying MUTYH mutations (Chapter 3). Furthermore, the influence of bi-
allelic inactivation of MUTYH can be clearly seen on APC and KRAS somatic
inactivating mutations in the Scottish population (Chapter 4).
To further characterise the influence of DNA repair mechanisms in carcinogenesis a
novel technique has begun to be developed for directly measuring and comparing the
effect ofBER deficiency on the mutation frequency of live cells (Chapter 6).
In conclusion, data presented here are largely consistent with the APC gene being
normal with respect to mutagenesis. However, the contribution played by levels of
DNA repair deficiency on the type ofmutations that arise adds further complexity to
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the situation of tumour formation. This research has added to the understanding of
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ConC E12 A-G 274 827 ApA
F8 A-G 719 975 ApA
E6 A-G 729 979 ApA
E6 A-G 758 988 ApA
H4 A-G 829 1012 ApA
C7 A-G 531 913 ApC
A8 A-G 170 792 ApG
A5 A-G 355 854 ApG
B10 A-G 665 957 ApG
A10 A-G 677 961 ApT
C2 A-G 839 1015 ApT
G6 A-G 860 1022 ApT
C10 C-T 590 932 CpA
B2 C-T 289 832 CpC
E8 C-T 804 1004 CpC
B8 C-T 810 100 CpC
C6 C-T 363 857 CpG
A7 C-T 326 844 CpT
G4 C-T 572 926 CpT
A9 G-A 432 880 GpA
B10 G-A 745 984 GpA
F2 G-A 838 1015 GpA
F1 G-A 293 833 GpC
H11 G-A 574 927 GpC
H2 T-C 181 796 TpA
F7 T-C 582 930 TpA
D8 T-C 874 1027 TpA
B10 T-C 226 811 TpC
C5 T-C 304 837 TpC
C10 T-C 493 900 TpC
C4 T-C 695 967 TpC
E6 T-C 754 987 TpC
C3 T-C 756 988 TpG
C10 T-C 849 1019 TpG
A3 T-C 316 841 TpT
B5 T-C 348 852 TpT
B12 T-C 684 964 TpT
G2 T-C 685 964 TpT
ConA 65 A-G 58 755 ApG
53 A-G 58 755 ApG
14 A-G 62 756 ApA
46 A-G 78 761 ApG
28 A-G 125 777 ApC
4 A-G 174 793 ApA
56 A-G 264 823 ApC
5 A-G 307 838 ApG
6 A-G 335 847 ApA
27 A-G 401 869 ApT
13 A-G 505 904 ApG
5 A-G 545 917 ApT
26 A-G 721 976 ApG
32 A-G 735 980 ApC
27 A-G 913 1040 ApG
3 C-T 522 909 CpA
54 G-A 563 923 GpA
50 G-A 782 996 GpT
61 T-C 27 744 TpT
26 T-C 30 745 TpG
6 T-C 46 751 TpC
46 T-C 100 769 TpT
14 T-C 286 831 TpT
37 T-C 301 836 TpC
6 T-C 486 897 TpC
14 T-C 546 917 TpG
42 T-C 605 937 TpC
44 T-C 613 940 TpC
11 T-C 639 948 TpA
24 T-C 670 959 TpC
62 T-C 673 960 TpC
23 T-C 717 974 TpA
67 T-C 748 985 TpC
67 T-C 843 1016 TpA
70 T-C 888 1031 TpT
58 T-C 888 1031 TpT
32 T-C 907 1038 TpC
56 T-C 921 1042 TpC
69 T-G 93 766 TpC
lbl-1261 G3 A-G 337 848 ApA
C6 A-G 339 849 ApG
E10 A-G 359 855 ApA
8 A-G 37 748 ApG
56 A-G 62 756 ApA









ConC E9 A-G 190 202 ApC
C5 A-G 265 227 ApG
B9 A-G 265 227 ApG
C9 A-G 323 246 ApC
F11 A-G 620 345 ApC
F11 A-G 620 345 ApC
F1 A-G 691 369 ApG
C1 C-T 72 162 CpA
C4 C-T 567 327 CpG
E1 C-T 803 406 CpT
E11 T-C 26 147 TpT
F3 T-C 605 340 TpC
ConA A5 A-G 400 272 ApC
G4 G-A 405 273 GpG
C5 G-A 744 386 GpA
lbl-1261 G2 A-G 495 303 ApC
B1 A-G 530 315 ApG
F10 A-G 571 329 ApA
B3 C-T 144 186 CpT
D7 C-T 294 236 CpA
G2 C-T 324 246 CpA
B8 C-T 565 327 CpA
C4 G-A 832 416 GpG
B5 T-C 142 186 TpA
A11 T-C 665 360 TpC
HCT116 A4 C-T 234 216 CpA
B6 C-T 252 222 CpC
lbl-1260 G8 A-G 197 204 ApG
B7 A-G 452 289 ApG
F9 A-G 610 342 ApG
F9 A-G 746 387 ApG
C8 C-T 292 236 CpA
C8 C-T 312 242 CpA
F9 C-T 326 247 CpC
A9 C-T 649 355 CpG
A10 C-T 720 378 CpC
C9 G-A 378 264 GpA
E9 T-C 117 177 TpG
A7 T-C 856 424 TpA
2630 A4 A-G 69 161 ApG
H6 A-G 170 195 ApG
F2 A-G 337 251 ApA
A2 A-G 353 256 ApG
G4 A-G 488 301 ApG
B2 A-G 490 302 ApA
E5 A-G 587 334 ApG
E6 A-G 719 378 ApC
H6 C-T 150 188 CpT
H6 C-T 411 275 CpA
B2 G-A 213 209 GpG
C3 G-A 451 289 GpA
C3 G-A 469 295 GpA
G4 G-A 635 350 GpC
B2 T-C 242 219 TpG
A1 T-C 268 228 TpC
E5 T-C 433 283 TpA
C6 T-C 463 293 TpT
D2 T-C 843 419 TpT
VAC0425 B11 A-G 38 151 ApA
D3 A-G 53 156 ApT
G10 A-G 80 165 ApA
A2 A-G 108 174 ApC
C8 A-G 302 239 ApG
C5 A-G 446 287 ApG
A8 A-G 452 289 ApG
A1 A-G 515 310 ApG
G10 A-G 553 323 ApT
A1 A-G 691 369 ApG
E1 A-G 749 388 ApC
B3 C-T 659 358 CpT
B12 G-A 118 178 GpC
D9 G-A 254 223 GpC
B11 G-A 519 311 GpC
D9 G-A 751 389 GpA
B3 G-A 761 392 GpC
E10 T-C 61 159 TpT
A8 T-C 68 161 TpA
D8 T-C 242 219 TpG
D3 T-C 356 257 TpC
B1 T-C 371 262 TpG
G1 T-C 665 360 TpC






cont D10 C-T 49 752 CpT
31 C-T 265 824 CpC
49 C-T 421 876 CpG
12 G-A 934 1047 GpA
16 G-A 577 928 GpC
29 G-A 124 777 GpA
49 G-A 351 852 GpG
72 G-A 658 955 GpA
101 G-A 930 1045 GpA
A10 T-C 25 744 TpC
G8 T-C 260 822 TpT
E10 T-C 436 881 TpC
E8 T-C 539 915 TpG
F10 T-C 539 915 TpG
E3 T-C 881 1029 TpT
F8 T-C 901 1036 TpT
30 T-C 775 944 TpT
85 T-C 775 944 TpC
HCT116 84 A-G 140 782 ApG
84 A-G 161 789 ApG
59 A-G 360 855 ApC
28 A-G 419 875 ApG
86 A-G 447 884 ApG
3 A-G 69 758 ApG
10 A-G 250 819 ApT
22 A-G 719 975 ApA
33 C-T 437 881 CpC
94 C-T 483 896 CpA
61 C-T 820 1009 CpA
44 C-T 449 885 CpC
59 C-T 578 928 CpC
22 C-T 740 982 CpG
2 G-A 544 917 GpA
16 T-C 145 784 TpC
1 T-C 145 784 TpC
23 T-C 493 900 TpC
78 T-C 613 940 TpC
76 T-C 765 990 TpG
lbl-1260 93 A-G 19 742 ApT
56 A-G 37 748 ApG
39 A-G 62 756 ApA
59 A-G 69 758 ApG
25 A-G 75 760 ApG
H3 A-G 78 762 ApG
59 A-G 78 761 ApG
C6 A-G 102 770 ApT
C5 A-G 125 777 ApC
12 A-G 125 777 ApC
46 A-G 163 790 ApG
63 A-G 165 790 ApC
95 A-G 175 794 ApG
85 A-G 215 807 ApT
9 A-G 218 808 ApT
1 A-G 220 809 ApA
C1 A-G 241 816 ApC
93 A-G 253 820 ApC
E8 A-G 267 825 ApT
E7 A-G 341 849 ApT
59 A-G 341 849 ApT
26 A-G 419 875 ApG
70 A-G 497 901 ApG
15 A-G 533 913 ApT
16 A-G 583 930 ApC
G3 A-G 631 946 ApC
17 A-G 700 696 ApG
50 A-G 703 970 ApG
65 A-G 707 971 ApT
57 A-G 803 1003 ApC
C12 A-G 875 1027 ApT
10 A-G 913 1040 ApG
44 C-T 80 762 CpA
70 C-T 80 762 CpA
E2 C-T 302 836 CpA
C3 C-T 315 841 CpT
H5 C-T 416 874 CpA
G4 C-T 496 901 CpA
D12 C-T 557 921 CpA
F11 C-T 623 943 CpA
21 C-T 804 1003 CpC
22 G-A 314 840 GpC
6 G-A 666 957 GpA
H5 G-A 692 966 GpC
C12 G-T 942 1050 GpG






ConA G5 A-G 201 236 ApG
E8 T-C 182 230 TpG
D11 T-C 264 257 TpG
E7 T-C 264 257 TpG
B3 T-C 563 283 TpC
lbl-1260 F9 A-G 175 228 ApT
F9 T-C 130 213 TpT
A3 T-C 182 230 TpG
H8 T-C 182 230 TpG
C6 T-C 576 287 TpG
2630 H2 A-G 290 266 ApT
E4 A-G 290 266 ApT
G1 A-G 309 272 ApG
G11 C-T 125 211 CpT
G12 T-C 247 252 TpT
B2 T-C 248 252 TpC
B1 T-C 248 252 TpC
E7 T-C 251 253 TpG
F6 T-C 266 258 TpT
VAC0425 G4 A-G 111 206 ApG
F5 A-G 158 222 ApC
F12 A-G 196 235 ApT
A4 A-G 212 240 ApG
A7 A-G 212 240 ApG
E8 A-G 212 240 ApG
H8 A-G 256 255 ApG
F10 A-G 277 262 ApT
C3 A-G 294 267 ApG
D6 A-G 307 272 ApA
D7 A-G 336 281 ApA
E4 C-T 153 220 CpG
G1 G-A 112 207 GpT
F3 G-A 300 269 GpA
C11 G-A 318 275 GpG
D6 T-C 108 205 TpG
D2 T-C 110 206 TpA
H11 T-C 119 209 TpG
G11 T-C 119 209 TpG
B12 T-C 131 213 TpC
H3 T-C 143 217 TpG
C5 T-C 197 235 TpG
G8 T-C 205 238 TpT
D9 T-C 238 249 TpC
D5 T-C 247 252 TpT
B9 T-C 261 256 TpG





lbl-1260 22 T-C 260 822 TpT
cont 50 T-C 295 834 TpC
93 T-C 316 841 TpT
39 T-C 324 843 TpT
F3 T-C 325 844 TpC
13 T-C 330 845 TpT
19 T-C 387 864 TpC
76 T-C 387 864 TpC
91 T-C 414 873 TpT
63 T-C 444 883 TpG
84 T-C 455 887 TpT
76 T-C 485 897 TpT
16 T-C 588 931 TpT
61 T-C 622 943 TpC
B9 T-C 639 949 TpA
50 T-C 645 950 TpT
74 T-C 645 950 TpT
32 T-C 693 966 TpT
43 T-C 753 986 TpT
95 T-C 756 987 TpG
73 T-C 786 997 TpG
2 T-C 813 1006 TpA
24 T-C 831 1012 TpC
2 T-C 879 1028 TpC
37 T-C 888 1031 TpT
37 T-C 909 1038 TpG
2630 B12 A-C 545 917 ApT
C9 A-G 63 757 ApC
E12 A-G 109 772 ApC
B1 A-G 116 774 ApC
E9 A-G 125 777 ApC
E3 A-G 128 778 ApT
H8 A-G 128 778 ApT
F6 A-G 158 788 ApG
E7 A-G 206 804 ApT
F7 A-G 206 804 ApT
F5 A-G 210 806 ApC
E4 A-G 221 809 ApT
G3 A-G 230 812 ApC
E5 A-G 239 815 ApT
B1 A-G 346 851 ApG
F7 A-G 346 851 ApG
E8 A-G 353 853 ApG
B11 A-G 355 854 ApG
B9 A-G 359 855 ApA
F1 A-G 367 858 ApT
E5 A-G 399 869 ApA
G12 A-G 401 869 ApT
C1 A-G 419 875 ApG
H11 A-G 431 879 ApG
H3 A-G 550 919 ApG
F2 A-G 552 920 ApA
F6 A-G 554 920 ApT
A8 A-G 568 925 ApG
G1 A-G 568 925 ApG
E7 A-G 585 931 ApC
A5 A-G 619 942 ApA
C12 A-G 660 956 ApT
F10 A-G 669 959 ApT
G5 A-G 677 961 ApT
D2 A-G 759 989 ApG
G2 A-G 767 991 ApA
F10 A-G 769 992 ApG
G6 A-G 867 1025 ApA
F7 A-G 927 1045 ApC
G5 C-T 373 860 CpT
G8 G-A 70 759 GpC
F11 G-A 134 780 GpT
D12 G-A 319 842 GpA
G1 G-A 351 853 GpG
D1 G-A 352 853 GpA
F12 G-A 445 884 GpC
D9 T-C 27 745 TpC
A10 T-C 34 747 TpC
H4 T-C 54 854 TpG
A7 T-C 56 754 TpT
B7 T-C 56 754 TpT
E2 T-C 145 784 TpC
H3 T-C 194 800 TpT
A3 T-C 260 822 TpT
B7 T-C 260 822 TpT
A5 T-C 279 829 TpA
B5 T-C 287 831 TpA
D6 T-C 301 836 TpC





2630 C5 T-C 330 846 TpT
cont E8 T-C 374 860 TpA
B10 T-C 382 863 TpA
B11 T-C 414 874 TpT
A2 T-C 476 894 TpG
H6 T-C 476 894 TpG
C3 T-C 571 926 TpC
D2 T-C 582 930 TpA
D12 T-C 582 930 TpA
D6 T-C 604 937 TpT
G12 T-C 673 960 TpC
H5 T-C 754 987 TpC
H9 T-C 783 997 TpT
D1 T-C 836 1014 TpG
H5 T-C 857 1021 TpA
A1 T-C 873 1027 TpT
B5 T-C 879 1029 TpC
F5 T-C 879 1029 TpC
E8 T-C 881 1029 TpT
H2 T-C 907 1038 TpC
B8 T-C 921 1043 TpC
D11 T-G 30 746 TpG
B8 T-G 374 860 TpA
VAC0425 H1 A-C 447 885 ApG
G9 A-G 45 751 ApT
F2 A-G 58 755 ApG
C6 A-G 63 757 ApC
F10 A-G 102 770 ApT
C4 A-G 139 782 ApA
C2 A-G 140 782 ApG
D12 A-G 163 790 ApG
G5 A-G 167 791 ApC
D2 A-G 228 812 ApG
F12 A-G 264 824 ApC
G8 A-G 303 837 ApT
D11 A-G 309 839 ApG
A11 A-G 312 840 ApA
F9 A-G 339 849 ApG
D7 A-G 346 851 ApG
A7 A-G 357 855 ApG
F1 A-G 390 866 ApG
D11 A-G 394 867 ApC
D12 A-G 401 869 ApT
G9 A-G 433 880 ApT
C11 A-G 447 885 ApG
F5 A-G 473 893 ApA
E9 A-G 480 896 ApG
F4 A-G 501 903 ApG
H3 A-G 501 903 ApG
C9 A-G 505 904 ApG
A7 A-G 548 918 ApG
H1 A-G 564 924 ApA
B1 A-G 567 925 ApA
C12 A-G 659 955 ApA
H11 A-G 669 959 ApT
A2 A-G 723 977 ApG
G11 A-G 734 980 ApA
H1 A-G 764 990 ApT
B10 A-G 768 992 ApA
B4 A-G 798 1002 ApG
D2 A-G 803 1003 ApC
H8 A-G 803 1003 ApC
C7 A-G 848 1018 ApT
H5 A-G 896 1034 ApG
H1 C-T 328 845 CpG
F2 C-T 737 981 CpC
A2 G-A 184 797 GpG
G7 G-A 453 887 GpA
A7 G-A 515 907 GpG
A5 G-A 716 974 GpT
H4 G-A 838 1015 GpA
G7 T-A 183 797 TpG
G12 T-C 48 752 TpC
A8 T-C 50 752 TpT
G6 T-C 103 770 TpC
G10 T-C 103 770 TpC
C11 T-C 111 773 TpT
A2 T-C 255 821 TpG
D5 T-C 279 829 TpA
H9 T-C 321 843 TpA
H4 T-C 330 846 TpT
A1 T-C 331 846 TpC
D10 T-C 372 860 TpC
C9 T-C 434 880 TpC





VAC0425 E4 T-C 493 900 TpC
cont G4 T-C 576 928 TpG
A2 T-C 582 930 TpA
G3 T-C 613 940 TpC
A11 T-C 645 951 TpT
H11 T-C 670 959 TpC
G2 T-C 684 964 TpT
H3 T-C 708 972 TpG
E10 T-C 726 978 TpC
E6 T-C 756 988 TpG
C2 T-C 822 1010 TpA
C12 T-C 876 1028 TpA
B7 T-C 881 1029 TpT










2256N C5 A-G 62 756 ApA
A4 A-G 288 831 ApC
A5 A-G 380 862 ApC
H1 A-G 165 790 ApC
E5 A-G 339 848 ApG
E5 A-G 419 875 ApG
E5 A-G 501 902 ApG
G4 A-G 355 854 ApG
C7 A-G 823 1010 ApG
E7 A-G 913 1040 ApG
A6 C-T 99 768 CpT
H10 G-A 502 903 GpA
G1 G-A 134 780 GpT
A5 T-C 478 895 TpC
B3 T-C 907 1038 TpC
F12 T-C 748 985 TpC
A8 T-C 753 986 TpT
2256T A4 A-G 552 919 ApA
B3 A-G 626 944 ApA
E7 A-G 62 756 ApA
E7 A-G 220 809 ApA
F2 A-G 62 756 ApA
F2 A-G 220 809 ApA
B12 A-G 927 1044 ApC
D12 A-G 631 946 ApC
F11 A-G 503 903 ApC
G5 A-G 503 903 ApC
A11 A-G 735 980 ApC
A2 A-G 355 854 ApG
B2 A-G 667 958 ApG
B4 A-G 462 889 ApG
C3 A-G 78 761 ApG
D3 A-G 355 854 ApG
G2 A-G 339 848 ApG
H5 A-G 355 854 ApG
B2 A-G 223 810 ApG
C1 A-G 471 892 ApG
C3 A-G 896 1034 ApG
A9 A-G 218 808 ApT
C7 A-G 221 809 ApT
E6 A-G 218 808 ApT
E10 A-G 303 836 ApT
F8 A-G 218 808 ApT
F8 A-G 221 809 ApT
G12 A-G 212 806 ApT
H3 A-G 102 769 ApT
H3 A-G 533 913 ApT
A2 A-G 792 999 ApT
A4 A-G 660 955 ApT
A6 C-T 727 978 CpA
E5 C-T 524 910 CpT
B11 G-A 549 918 GpA
H7 G-A 841 1016 GpA
A1 G-A 841 1016 GpA
A4 G-A 715 974 GpG
B8 G-A 715 974 GpG
C3 G-A 715 974 GpG
C6 G-A 715 974 GpG
C8 G-A 715 974 GpG
C9 G-A 715 974 GpG
B2 G-A 710 972 GpT
E10 G-A 193 800 GpT
C10 G-A 710 972 GpT
B12 T-C 822 1009 TpA
F10 T-C 382 863 TpA
H4 T-C 519 908 TpA
C4 T-C 571 926 TpC
D7 T-C 325 844 TpC
E10 T-C 295 834 TpC
A11 T-C 907 1038 TpC
A4 T-C 573 926 TpG
B12 T-C 444 883 TpG
C8 T-C 186 797 TpG
B1 T-C 50 752 TpT
C3 T-C 414 873 TpT
E5 T-C 286 831 TpT









2256N C5 G-A 115 208 GpC
D2 G-A 169 226 GpC
2256T G4 A-G 290 266 ApT
C10 C-T 229 246 CpC
D1 C-T 303 270 CpC
D9 C-T 203 237 CpC
F2 C-T 203 237 CpC
H6 C-T 284 264 CpC
F7 C-T 326 278 CpG
A4 C-T 214 241 CpT
H3 C-T 142 217 CpT
A5 G-A 136 215 GpA
D2 G-A 198 235 GpA
F4 G-A 109 206 GpT
C5 T-C 248 252 TpC
G2 T-C 215 241 TpC
F4 T-C 270 259 TpG
E5 T-C 143 217 TpG
G6 T-C 148 219 TpT
2630N A8 A-G 307 272 ApA
D7 A-G 272 260 ApC
B2 C-T 281 263 CpT
G2 G-A 305 271 GpG
B8 T-C 108 205 TpG
E7 T-C 217 242 TpT
F12 T-C 266 258 TpT
2630T F7 A-C 294 267 ApG
G8 C-T 279 262 CpA
D6 C-T 167 225 CpG
C1 G-A 268 259 GpC
E12 T-C 206 238 TpC
D12 T-C 138 215 TpG
G11 T-A 225 244 TpG
F2 T-C 322 277 TpT
2574N G8 A-G 331 280 ApC
E4 G-A 134 214 GpT
E3 T-C 176 228 TpC
F4 T-C 215 241 TpC
F11 T-C 248 252 TpC
E3 T-C 126 211 TpG
2574T D1 G-A 339 282 ApG
C12 G-A 226 245 GpG
2650N B9 A-G 211 240 ApA
B11 A-G 309 272 ApG
E6 A-G 309 272 ApG
E10 A-G 111 206 ApG
E9 A-G 254 254 ApG
H5 A-G 338 282 ApG
H2 A-G 196 235 ApT
C7 C-T 242 250 CpC
D7 C-T 242 250 CpC
B3 C-T 207 238 CpG
F1 C-T 207 238 CpG
F7 C-A 239 249 CpT
G3 T-G 275 261 CpT
H9 C-T 288 265 CpT
D9 G-A 185 231 GpA
G7 G-A 185 231 GpA
D4 G-A 139 216 GpG
F9 G-A 260 256 GpT
E11 T-C 215 241 TpC
D11 T-C 215 241 TpC
F8 T-C 251 253 TpG
G2 T-C 119 209 TpG
A2 T-C 148 219 TpT
G9 T-C 205 238 TpT
2650T G4 A-G 137 215 ApT
A7 G-A 140 216 GpC
D2 G-A 192 233 GpG
D10 G-A 127 212 GpG
D10 G-A 265 258 GpT
D11 G-A 112 207 GpT
B9 T-G 110 206 TpA
G3 T-C 286 265 TpG
B2 T-C 148 219 TpT
E9 T-C 130 213 TpT








2256T E5 A-G 735 980 ApC
Continued F4 A-G 230 812 ApC
F10 A-G 735 980 ApC
F8 A-G 792 999 ApT
E1 C-T 727 978 CpA
E5 C-T 524 910 CpT
F2 G-A 340 849 GpA
G4 G-A 841 1016 GpA
E5 G-A 715 974 GpG
F10 G-A 715 974 GpG
G1 G-A 715 974 GpG
E7 G-A 824 1010 GpT
G10 G-A 710 972 GpT
D2 T-C 879 1028 TpC
H2 T-C 879 1028 TpC
D9 T-C 762 989 TpG
E6 T-C 775 994 TpT
2630N B10 A-G 107 771 ApA
B10 A-G 527 911 ApA
E4 A-G 567 924 ApA
F6 A-G 62 756 ApA
C9 A-G 659 955 ApA
C12 A-G 400 869 ApA
D5 A-G 829 1012 ApA
D8 A-G 767 991 ApA
A9 A-G 593 933 ApC
E1 A-G 277 828 ApC
G1 A-G 585 930 ApC
G12 A-G 98 768 ApC
G1 A-G 599 935 ApC
B10 A-G 501 902 ApG
C9 A-G 548 918 ApG
D4 A-G 313 840 ApG
D4 A-G 343 850 ApG
E2 A-G 419 875 ApG
F10 A-G 105 770 ApG
F11 A-G 105 770 ApG
G11 A-G 105 770 ApG
H1 A-G 899 1035 ApG
E11 A-G 84 763 ApT
B12 A-G 885 1030 ApT
E5 A-G 887 1031 ApT
E7 C-T 302 836 CpA
E12 C-T 522 909 CpA
E12 C-T 804 1003 CpC
A9 C-T 33 746 CpT
B10 G-A 499 902 GpA
A6 G-C 91 766 GpC
B3 G-A 808 1005 GpC
B1 T-C 699 968 TpA
F2 T-C 702 969 TpA
C1 T-C 257 821 TpC
F8 T-C 304 837 TpC
G10 T-C 726 977 TpC
G12 T-C 907 1038 TpC
B4 T-C 183 796 TpG
D11 T-C 255 820 TpG
C4 T-C 111 772 TpT
B8 T-C 645 950 TpT
C1 T-C 711 972 TpT
E9 T-C 684 963 TpT
2630T C9 A-G 108 771 ApA
C11 A-G 417 874 ApA
B12 A-G 280 829 ApC
A9 A-C 158 788 ApG
B3 A-G 431 879 ApG
E7 A-G 53 753 ApT
C3 C-T 178 795 CpT
C11 C-T 49 752 CpT
D3 C-T 596 934 CpT
D3 G-A 352 853 GpA
E5 G-A 499 902 GpA
A7 G-A 347 851 GpT
C9 T-C 279 828 TpA
A7 T-C 243 816 TpG
C10 T-C 198 801 TpG







2650T C9 A-G 336 281 ApA
Continued D9 G-A 185 231 GpA
G9 G-A 185 231 GpA
H6 G-A 226 245 GpG
D9 T-C 110 206 TpA
F10 T-C 133 214 TpG
H10 T-C 251 253 TpG
101ON D2 C-T 303 270 CpC
E12 C-T 177 228 CpC
G9 C-T 303 270 CpC
B11 C-T 246 251 CpT
D8 G-A 253 254 GpA
F6 G-A 154 221 GpA
D2 G-A 202 237 GpC
E11 G-A 115 208 GpC
F2 G-A 319 276 GpC
C1 G-A 339 282 GpG
E10 G-A 312 273 GpG
F9 G-A 172 227 GpT
G2 T-C 289 266 TpA
B3 T-C 235 248 TpC
E12 T-C 215 241 TpC
G3 T-C 135 214 TpG
1010T B11 A-G 163 224 ApA
G11 C-T 162 223 CpA
G12 C-T 156 221 CpA
F7 C-T 228 245 CpC
H3 C-G 228 245 CpC
B8 C-T 178 229 CpG
C2 G-A 316 275 GpA
A4 G-A 120 209 GpG
C8 G-A 145 218 GpG
B9 G-A 263 257 GpT
B5 T-C 131 213 TpC
2564N G4 C-T 279 262 CpA
C3 T-C 248 252 TpC
2564T B6 C-T 273 260 CpC
G4 C-T 167 225 CpG
D3 C-T 187 232 CpT
B11 G-A 253 254 GpA
D6 G-A 185 231 GpA
E12 G-A 174 227 GpA
G10 G-A 306 271 GpA
B11 G-A 202 237 GpC
C6 G-A 227 245 GpC
E12 G-A 268 259 GpC
G10 G-A 146 218 GpC
E9 G-A 183 230 GpG
E9 G-A 265 258 GpT
D6 T-C 188 232 TpC
1184T D6 A-G 254 254 ApG
G5 C-T 279 262 CpA
H8 C-T 237 248 CpT
E1 G-A 257 255 GpC
H2 G-A 262 257 GpG
1962N A3 A-G 111 206 ApG
B7 A-G 333 280 ApG
H11 G-A 306 271 GpA
D1 G-A 335 281 GpC
D2 T-C 205 238 TpT
1962T D4 A-G 194 234 ApG
C11 A-G 194 234 ApG
H11 C-T 320 276 CpC
H11 C-T 249 252 CpT
E2 G-A 185 231 GpA
F9 G-A 136 215 GpA
D5 G-A 313 274 GpC
G9 G-A 213 240 GpC
G11 G-A 221 243 GpC
A3 G-A 183 230 GpG
D4 G-A 139 216 GpG
C5 G-A 260 256 GpT
D2 G-A 263 257 GpT
E2 T-C 173 227 TpG
G5 T-C 143 217 TpG
G7 TDEL 324 277 TpG








2630T F12 A-G 338 848 ApA
Continued G12 A-G 68 758 ApA
D6 A-G 733 980 ApA
D8 A-G 733 980 ApA
G4 A-G 720 975 ApA
A1 A-G 593 933 ApC
A12 A-G 864 1023 ApC
B11 A-G 864 1023 ApC
F11 A-G 471 892 ApG
G10 A-G 550 919 ApG
H3 A-G 480 895 ApG
H7 A-C 355 854 ApG
G10 A-G 769 992 ApG
G12 A-G 913 1040 ApG
H6 A-G 929 1045 ApG
A5 A-G 833 1013 ApT
A12 A-G 689 965 ApT
B11 A-G 689 965 ApT
F12 A-G 845 1017 ApT
F11 C-T 451 886 CpA
E12 C-T 606 937 CpA
E12 C-T 294 833 CpT
B10 C-T 738 981 CpT
G12 G-T 115 774 GpA
G12 G-A 245 817 GpC
F9 G-A 615 940 GpG
H8 T-C 333 846 TpG
B12 T-C 100 769 TpT
G12 T-C 672 959 TpT
2395N DB10 A-G 618 941 ApA
DC5 A-G 867 1024 ApA
DD5 A-G 733 980 ApA
DD9 A-G 904 1037 ApA
DF12 A-G 854 1020 ApA
DA2 A-G 733 980 ApA
DF5 A-G 854 1020 ApA
BE1 A-G 68 758 ApA
BF4 A-G 167 791 ApC
BB9 A-G 109 772 ApC
BE8 A-G 292 833 ApG
BB7 A-G 95 767 ApG
DA9 A-G 885 1030 ApT
DB12 A-G 707 971 ApT
DC2 A-G 680 962 ApT
DC12 A-G 677 961 ApT
DE3 A-G 640 949 ApT
DF3 A-C 689 965 ApT
DG12 A-G 842 1016 ApT
DH11 A-G 677 961 ApT
BF1 A-G 144 783 ApT
BF9 A-G 267 824 ApT
DF12 C-T 736 981 CpC
DC2 G-A 757 988 GpA
DC5 G-A 895 1034 GpA
DF5 G-A 802 1003 GpA
BA1 G-A 229 812 GpA
DE11 G-A 642 949 GpC
DA11 T-C 627 944 TpA
DC2 T-C 699 968 TpA
BD9 T-C 122 776 TpA
BD9 T-C 190 799 TpA
BF2 T-C 262 823 TpC
BB9 T-C 194 800 TpT
2395T DC5 A-G 653 953 ApA
DC7 A-G 867 1024 ApA
DF12 A-G 867 1024 ApA
DA5 A-G 723 976 ApG
DC2 A-G 858 1021 ApG
DC5 A-G 723 976 ApG
DE10 A-G 852 1019 ApG
DE6 A-G 848 1018 ApT
DF8 G-A 851 1019 GpA
DF9 G-A 851 1019 GpA
DB2 G-T 774 993 GpT
DC2 G-T 774 993 GpT
DC12 G-T 774 993 GpT
DD5 G-T 774 993 GpT








1962T F5 C-T 162 223 CpA
Continued H11 C-T 326 278 CpG
1184T D6 A-G 254 254 ApG
G5 C-T 279 262 CpA
H8 C-T 237 248 CpT
E1 G-A 257 255 GpC
H2 G-A 262 257 GpG
533N C4 A-G 336 281 ApA
D10 A-G 317 275 ApG
E8 A-G 223 244 ApG
G7 A-G 137 215 ApT
B2 G-A 257 255 GpC
C7 G-A 180 229 GpC
F3 G-A 179 229 GpG
D4 T-C 311 273 TpG
F5 T-C 135 214 TpG
D2 T-C 205 238 TpT
533T B8 A-G 307 272 ApA
B3 A-G 272 260 ApC
H9 A-G 302 270 ApC
A3 A-G 309 272 ApG
C8 A-G 294 267 ApG
H9 A-G 111 206 ApG
C7 C-T 125 211 CpT
D8 C-T 321 276 CpT
A4 G-A 327 278 GpC
A1 G-A 305 271 GpG
B7 T-C 188 232 TpC
B9 T-C 215 241 TpC
C9 T-C 238 249 TpC
G4 T-C 270 259 TpG
F2 T-C 220 243 TpG
2494N E7 A-G 573 360 ApG
C6 C-T 153 220 CpG
E10 C-T 216 241 CpT
D10 G-A 241 250 GpC
G4 G-A 180 229 GpC
C12 G-A 598 369 GpC
H3 T-C 176 228 TpC
A3 T-C 231 246 TpG
C6 T-C 150 219 TpG
G5 T-C 148 219 TpT
2494T H2 C-T 632 380 CpT
A3 T-C 215 241 TpC
E7 T-C 248 252 TpC
G12 T-C 645 384 TpC
D10 T-C 225 244 TpG
2486N F2 A-G 636 381 ApC
F9 A-G 223 244 ApG
E4 C-T 650 386 CpA
G11 C-T 667 392 CpA
E6 C-T 298 269 CpG
F11 G-A 166 225 GpC
H5 G-A 168 225 GpG
B1 T-C 250 253 TpT
2486T D5 C-A 288 265 CpT
2491N G7 A-G 666 391 ApC
C3 A-G 254 254 ApG
E11 A-G 290 266 ApT
F8 C-T 298 269 CpG
A6 C-T 230 246 CpT
F12 G-A 193 234 GpA
B4 G-A 139 216 GpG
F8 T-C 238 249 TpC
B12 T-C 311 273 TpG
D11 T-C 291 266 TpG
D7 T-C 266 258 TpT
2490N A10 A-G 317 275 ApG
C3 A-G 201 236 ApG
B3 C-T 616 375 CpG
A10 G-A 185 231 GpA
A11 G-A 169 226 GpC
H3 T-C 215 241 TpC
H9 T-C 235 248 TpC
C5 T-C 275 261 TpG
C11 T-C 264 257 TpG
E10 T-C 225 244 TpG








2395T DH6 A-G 680 962 ApT
Continued DG7 G-T 774 993 GpT
DH10 G-T 774 993 GpT
DB10 T-C 889 1032 TpC
DG12 T-C 881 1029 TpT
2574N D8 A-G 65 757 ApA
F11 A-G 447 884 ApG
B3 A-G 543 916 ApG
C9 A-G 858 1021 ApG
F12 A-G 554 920 ApT
B7 A-G 792 999 ApT
F1 A-G 554 920 ApT
G6 A-G 842 1016 ApT
G8 A-G 401 869 ApT
A9 C-T 211 806 CpA
D2 C-T 148 785 CpA
F8 C-T 810 1005 CpC
D1 C-T 180 795 CpT
D11 C-T 180 795 CpT
B11 G-A 124 777 GpA
H9 G-A 124 777 GpA
A3 G-A 171 792 GpC
C8 G-A 283 830 GpT
G12 G-A 477 894 GpT
C9 T-C 717 974 TpA
D7 T-C 476 894 TpG
2574T BH5 A-G 118 775 ApA
DD12 A-G 626 944 ApA
BD6 A-G 125 777 ApC
BA11 A-G 280 829 ApC
DF5 A-G 803 1003 ApC
BD1 A-G 170 792 ApG
DA8 A-G 899 1035 ApG
DE8 A-G 913 1040 ApG
DG12 A-G 721 976 ApG
DH2 A-T 667 958 ApG
DH10 A-G 721 976 ApG
CA10 A-G 562 923 ApG
CF1 A-G 431 879 ApG
CF10 A-G 322 843 ApG
CF12 A-G 505 904 ApG
BA7 A-G 89 765 ApT
DD8 A-G 654 953 ApT
DC2 A-G 792 999 ApT
DF2 A-G 792 999 ApT
CA5 A-G 484 897 ApT
BC7 C-T 246 817 CpA
BA10 C-T 99 768 CpT
BH8 C-T 92 766 CpT
DD11 G-T 732 979 GpA
DH7 G-A 895 1034 GpA
BE8 G-A 38 748 GpC
DG3 G-A 629 945 GpG
BA7 G-A 152 786 GpT
BC10 T-C 101 769 TpA
BG5 T-C 147 784 TpC
BH2 T-C 93 766 TpC
DA7 T-C 879 1028 TpC
DA9 T-C 879 1028 TpC
DC6 T-C 879 1028 TpC
DD6 T-C 879 1028 TpC
BC12 T-C 41 749 TpG
DF12 T-C 648 951 TpG
CF12 T-C 537 914 TpG
CH9 T-C 428 878 TpG
BD10 T-C 195 800 TpT
BH3 T-C 130 779 TpT
BH9 T-C 194 800 TpT
BD11 T-C 300 835 TpT
DC5 T-C 888 1031 TpT
DE11 T-C 775 994 TpT
CA5 T-C 510 905 TpT
CE6 T-C 414 873 TpT
2650N BB12 C-T 136 781 CpC
BB5 C-T 99 768 CpT
BA11 G-A 91 766 GpC
BA5 T-C 57 754 TpA







2490N H6 G-A 617 375 GpA








2650N BD7 A-G 312 839 ApA
Continued CE12 A-G 345 850 ApA
DB3 A-G 772 993 ApA
DB8 A-G 854 1020 ApA
DG10 A-G 768 991 ApA
DG10 A-G 719 975 ApA
DB7 A-G 854 1020 ApA
BC8 A-G 98 768 ApC
BD7 A-G 165 790 ApC
CB6 A-G 583 930 ApC
CE6 A-G 383 863 ApC
CF6 A-G 490 899 ApC
DD10 A-G 803 1003 ApC
DE11 A-G 803 1003 ApC
DF4 A-G 803 1003 ApC
BE10 A-G 163 790 ApG
BD4 A-G 154 787 ApG
BD9 A-G 307 838 ApG
CA2 A-G 501 902 ApG
CB9 A-G 390 865 ApG
CE11 A-G 390 865 ApG
DB3 A-G 721 976 ApG
DE8 A-G 691 966 ApG
DE10 A-G 313 840 ApG
DF7 A-G 703 970 ApG
DB1 A-G 660 955 ApT
DB12 A-G 602 936 ApT
DD2 A-G 669 958 ApT
DE2 A-G 821 1009 ApT
DF1 A-G 875 1027 ApT
DF9 A-G 792 999 ApT
DF9 A-G 842 1016 ApT
DG8 A-C 792 999 ApT
DB5 A-G 835 1014 ApT
DC3 A-G 640 949 ApT
DC4 A-G 932 1046 ApT
BC8 C-T 166 791 CpA
CC6 C-T 395 867 CpA
CH10 C-T 395 867 CpA
DB2 C-T 800 1002 CpC
BF10 C-T 294 833 CpT
DA7 C-T 750 985 CpT
DE2 C-T 750 985 CpT
BD2 G-A 273 826 GpA
BG6 G-A 124 777 GpA
DC11 G-A 859 1022 GpA
CB6 G-A 481 896 GpC
DE10 G-A 914 1040 GpG
DF6 G-A 914 1040 GpG
DD10 G-A 694 967 GpT
BD3 T-C 181 796 TpA
BF11 T-C 101 769 TpA
BE8 T-C 321 842 TpA
DG9 A-G 690 965 TpA
DG10 T-C 834 1013 TpA
CF3 T-C 517 908 TpC
DE2 T-C 748 985 TpC
DF3 T-C 889 1032 TpC
DG2 T-C 613 940 TpC
DH1 T-C 622 943 TpC
BC8 T-G 243 816 TpG
BG5 T-C 90 765 TpG
CA1 T-C 576 927 TpG
CA2 T-C 576 927 TpG
CE8 T-C 539 915 TpG
CE9 T-C 573 926 TpG
CG7 T-C 555 920 TpG
CH8 T-C 476 894 TpG
DE1 T-C 648 951 TpG
DE12 T-C 705 970 TpG
DF5 T-C 648 951 TpG
DF7 T-C 714 973 TpG
BA5 T-C 234 813 TpT
CB9 T-C 414 873 TpT
CD7 T-C 411 872 TpT
CE11 T-C 414 873 TpT
DH8 T-C 743 983 TpT








2650N DE8 A-G 733 980 ApA
Continued DF5 A-G 803 1003 ApC
DF12 A-G 794 1000 ApC
DD9 A-G 660 955 ApT
DF9 G-A 914 1040 GpG
DD9 T-C 634 947 TpG
DC10 T-C 901 1036 TpT
DG7 T-C 881 1029 TpT
2650T CF12 A-G 552 919 ApA
DA1 A-G 720 975 ApA
DB2 A-G 734 980 ApA
DB6 A-G 676 961 ApA
DE8 A-G 688 965 ApA
BE4 A-G 165 790 ApC
BE11 A-G 288 831 ApC
CF9 A-G 541 916 ApC
CH2 A-G 541 916 ApC
DB6 A-G 864 1023 ApC
BE1 A-G 170 792 ApG
BH4 A-G 170 792 ApG
CA4 A-G 562 923 ApG
CA8 A-G 452 886 ApG
CF12 A-G 396 867 ApG
CH4 A-G 462 889 ApG
CH9 A-G 505 904 ApG
DG11 A-G 769 992 ApG
DE2 A-G 759 988 ApG
DE5 A-G 723 976 ApG
BD10 AT-GC 269/270 825 ApT
BB7 A-G 239 815 ApT
CC3 A-G 341 849 ApT
DB7 A-G 812 1006 ApT
DD6 A-G 654 953 ApT
DF4 A-G 633 946 ApT
DG12 A-G 640 949 ApT
DG12 A-G 761 989 ApT
DB5 A-G 817 1008 ApT
DB5 A-G 885 1030 ApT
DG11 A-G 640 949 ApT
BD10 C-A 204 803 CpA
BG3 C-T 263 823 CpA
BC9 C-T 265 824 CpC
CH3 C-T 450 885 CpC
CG8 C-T 494 900 CpT
BB8 G-A 115 774 GpA
CG11 G-A 356 854 GpA
DG12 G-A 897 1034 GpC
BD1 G-A 256 821 GpT
DG5 G-A 698 968 GpT
CA2 T-C 519 908 TpA
CC6 T-C 382 863 TpA
DA1 T-C 639 948 TpA
DA6 T-C 886 1031 TpA
DC11 T-C 857 1021 TpA
DF6 T-C 712 973 TpA
DG2 T-C 699 968 TpA
BF3 T-C 147 784 TpC
CC9 T-C 434 880 TpC
CD7 T-C 327 844 TpC
CF5 T-C 517 908 TpC
CF11 T-C 434 880 TpC
DB3 T-C 695 967 TpC
DE1 T-C 748 985 TpC
DE8 T-C 921 1042 TpC
DH8 T-C 726 977 TpC
DA6 T-C 889 1032 TpC
DD7 T-C 925 1044 TpC
BA4 T-C 213 806 TpG
CA6 T-C 467 891 TpG
CB4 T-C 573 926 TpG
DB8 T-C 762 989 TpG
DC1 T-C 825 1010 TpG
DE1 T-C 693 966 TpG
DF8 T-C 744 983 TpG
BF8 T-C 261 822 TpT
CD9 T-C 348 851 TpT
DA8 T-C 783 996 TpT
DC6 T-C 753 986 TpT





2650T Cont. DH1 CINS 738-739 981 CpT
DD8 T-C 603 936 TpT
101 ON BF9 A-G 127 778 ApA
CA5 A-G 418 875 ApA
CA6 A-G 400 869 ApA
CA10 A-G 418 875 ApA
CC2 A-G 400 869 ApA
DD6 A-G 719 975 ApA
DE6 A-G 664 957 ApA
BA1 A-G 230 812 ApC
BB6 A-G 63 756 ApC
BD3 A-G 165 790 ApC
DH4 A-G 862 1023 ApC
BB2 A-G 140 782 ApG
BC4 A-G 307 838 ApG
BG3 A-G 78 761 ApG
BH9 A-G 313 840 ApG
BC2 A-G 163 790 ApG
BD4 A-G 69 758 ApG
DB7 A-G 919 1042 ApG
DE6 A-G 691 966 ApG
DE8 A-G 852 1019 ApG
DG5 A-G 852 1019 ApG
BA9 A-G 267 824 ApT
BF9 A-G 89 765 ApT
BH9 A-G 250 819 ApT
DA7 A-G 689 965 ApT
DD12 A-G 730 979 ApT
BA2 C-T 201 802 CpA
BF11 C-T 305 837 CpA
BH1 C-T 138 781 CpA
BH1 C-T 43 750 CpC
BE12 C-T 137 781 CpC
CA9 C-T 578 928 CpC
BA8 C-T 33 746 CpT
BF2 C-T 73 760 CpT
BH2 G-A 214 807 GpA
BB8 G-A 209 805 GpA
CA10 G-A 469 892 GpA
CA10 G-A 469 892 GpA
CC5 G-A 365 857 GpA
DA4 G-A 838 1015 GpA
DA6 G-A 741 982 GpA
BB6 G-A 32 746 GpC
BG3 G-A 314 840 GpC
BC2 G-A 244 817 GpG
BF1 G-A 141 782 GpG
DA5 G-A 629 945 GpG
DB9 G-A 724 977 GpG
DG5 G-A 715 974 GpG
BF9 G-A 225 810 GpT
DB2 G-A 694 967 GpT
DE11 G-A 694 967 GpT
DH10 G-A 710 972 GpT
DH10 G-T 774 993 GpT
BC3 T-C 57 754 TpA
DF11 T-C 751 986 TpA
DH2 T-C 712 973 TpA
BA8 T-C 226 811 TpC
BG1 T-C 295 834 TpC
DE7 T-C 637 948 TpC
DE8 T-C 673 960 TpC
CB12 T-C 539 915 TpG
DB4 T-C 693 966 TpG
DE6 T-C 648 951 TpG
DF2 T-C 641 949 TpG
DH6 T-C 756 987 TpG
BC9 T-C 300 835 TpT
DA10 T-C 645 950 TpT
DH2 T-C 603 936 TpT
1010T BD5 A-G 139 782 ApA
BB2 A-G 264 823 ApC
BC5 A-G 288 831 ApC
BD2 A-G 133 780 ApG
BA11 A-G 119 775 ApT
BA5 C-T 43 750 CpC
BD5 C-T 297 834 CpT








1010T CH9 A-G 553 920 ApA
Continued DA8 A-G 931 1046 ApA
DB7 A-G 729 978 ApA
DB12 A-G 871 1026 ApA
DC2 A-G 733 980 ApA
DC10 A-G 617 941 ApA
DE1 A-G 624 943 ApA
DG10 A-C 653 953 ApA
DG10 A-G 688 965 ApA
DB2 A-G 734 980 ApA
CE5 A-G 568 925 ApG
CG2 A-G 353 853 ApG
CG4 A-G 447 884 ApG
CG12 A-T 452 886 ApG
DC10 A-G 697 968 ApG
DE4 A-G 665 957 ApG
DE12 A-G 877 1028 ApG
DF12 A-G 665 957 ApG
DG9 A-G 759 988 ApG
DC9 A-G 773 993 ApG
DC7 A-G 669 958 ApT
DE9 A-G 640 949 ApT
DG9 A-G 689 965 ApT
CE3 C-T 580 929 CpA
CF9 C-T 590 932 CpA
DD5 C-T 606 937 CpA
CE3 C-T 443 883 CpT
DE2 C-T 755 987 CpT
DH8 C-T 110 772 CpT
CD12 G-A 354 853 GpA
DF4 G-A 679 962 GpA
CD2 G-A 448 885 GpC
CD5 G-A 391 866 GpC
CG2 G-A 448 885 GpC
CD6 G-A 538 915 GpT
DA2 G-A 694 967 GpT
DB12 G-A 725 977 GpT
BG5 T-C 48 751 TpC
CH5 T-C 412 873 TpC
CH9 T-C 327 844 TpC
DB4 T-C 925 1044 TpC
CE1 T-C 573 926 TpG
CD10 T-C 368 858 TpT
CE6 T-C 324 843 TpT
CG2 T-C 560 922 TpT
DG11 T-C 711 972 TpT
1299N BB3 A-G 108 771 ApA
BB6 A-G 157 788 ApA
BB8 A-T 77 761 ApA
BB9 A-G 108 771 ApA
DA6 A-G 829 1012 ApA
DB5 A-G 599 935 ApC
BB6 A-G 69 758 ApG
BB4 C-T 94 767 CpA
BD3 C-T 94 767 CpA
DA6 C-T 898 1035 CpA
BB4 C-T 137 781 CpC
BD1 C-T 110 772 CpT
BD2 C-T 99 768 CpT
BD3 C-T 99 768 CpT
BD1 G-A 60 755 GpA
DB8 G-A 630 945 GpA
DC10 G-A 630 945 GpA
DA3 G-A 782 996 GpT
DC1 G-A 698 968 GpT
DC11 G-A 716 974 GpT
DA6 T-C 598 935 TpA
DB8 T-C 879 1028 TpC
DC4 T-C 879 1028 TpC
DC10 T-C 879 1028 TpC
DA6 T-C 705 970 TpG
DC6 T-C 783 996 TpT
DB2 T-C 672 959 TpT
DB2 T-C 645 950 TpT
1299T BF3 A-G 264 823 ApC
BF6 A-G 264 823 ApC
BE5 A-G 215 807 ApT








1299T BG7 A-G 139 782 ApA
Continued DF4 A-G 854 1020 ApA
DF5 A-G 619 942 ApA
DG3 A-G 854 1020 ApA
BG3 A-G 69 758 ApG
BG4 A-G 228 811 ApG
DE7 A-G 703 970 ApG
DF8 A-G 703 970 ApG
DG3 A-G 852 1019 ApG
DE2 A-G 860 1022 ApT
DE8 A-G 669 958 ApT
DF4 A-G 932 1046 ApT
DG3 A-G 932 1046 ApT
DH6 A-G 860 1022 ApT
DG7 A-G 835 1014 ApT
BG4 C-T 281 829 CpA
BG2 C-G 305 837 CpA
DF11 C-T 866 1024 CpA
DG6 C-T 866 1024 CpA
DG5 C-G 650 952 CpC
DF1 C-T 856 1021 CpT
DF2 C-T 856 1021 CpT
DG11 C-T 856 1021 CpT
BG7 G-A 187 798 GpA
DE8 T-C 861 1022 TpA
BE1 T-C 179 795 TpC
BG7 T-C 135 780 TpC
DG2 T-C 695 967 TpC
DF3 T-C 756 987 TpG
DG10 T-C 756 987 TpG
2564N C9 A-G 400 869 ApA
E7 A-T 345 850 ApA
F5 A-G 400 869 ApA
A2 A-G 439 882 ApC
A8 A-G 490 899 ApC
B5 A-G 583 930 ApC
C6 A-G 523 910 ApC
E2 A-G 116 774 ApC
D5 A-G 123 776 ApG
D9 A-G 396 867 ApG
E5 A-G 357 854 ApG
H10 A-G 628 945 ApG
H6 A-G 554 920 ApT
D12 C-T 866 1024 CpA
F1 C-T 137 781 CpC
G4 C-T 203 803 CpC
H3 C-T 71 759 CpC
G10 C-T 361 856 CpG
D2 G-A 365 857 GpA
F8 G-A 314 840 GpC
C8 G-A 709 972 GpG
B7 G-A 477 894 GpT
B8 G-A 536 914 GpT
G3 G-A 329 845 GpT
F3 G-A 770 992 GpT
D6 T-C 51 752 TpC
F7 T-C 789 998 TpC
H8 T-C 613 940 TpC
C3 T-C 535 914 TpG
B2 T-C 714 973 TpG
B1 T-C 20 742 TpT
F8 T-C 50 752 TpT
F10 T-C 300 835 TpT
H9 T-C 510 905 TpT
G4 T-C 645 950 TpT
H4 T-C 775 994 TpT
2564T DA3 A-G 883 1030 ApA
DA7 A-G 798 1001 ApG
DA11 A-G 759 988 ApG
DB2 A-G 769 992 ApG
DB4 A-G 628 945 ApG
DC2 A-G 697 968 ApG
DD3 A-G 700 969 ApG
DD10 A-G 798 1001 ApG
DE1 A-G 703 970 ApG
DB10 C-T 865 1024 CpC
DC11 G-A 716 974 GpT








2564T DF7 A-G 828 1011 ApA
Continued DH4 A-G 618 941 ApA
BB8 A-G 67 758 ApA
CB6 A-C 470 892 ApA
CD2 A-G 473 893 ApA
DH3 A-G 552 919 ApA
BD1 A-G 200 802 ApC
DG1 A-G 769 992 ApG
DG6 A-G 769 992 ApG
DG7 A-G 759 988 ApG
DA2 A-G 759 988 ApG
DD3 A-G 700 969 ApG
BB4 A-G 75 760 ApG
BA1 A-G 170 792 ApG
DC10 A-G 419 875 ApG
DH3 A-G 309 838 ApG
DH9 A-G 501 902 ApG
DG7 A-C 689 965 ApT
DA2 A-C 689 965 ApT
DH1 C-T 898 1035 CpA
BF4 C-T 302 836 CpA
BG8 C-T 231 812 CpA
CD8 C-T 522 909 CpA
DC9 C-T 522 909 CpA
CA3 C-T 578 928 CpC
CB5 C-T 578 928 CpC
BA5 G-A 319 842 GpA
BA11 G-A 164 790 GpA
BB4 G-T 344 850 GpA
BE8 G-C 106 771 GpA
CB4 GADEL 358-359 855 GpA
DH4 G-A 788 998 GpT
CE2 G-A 329 845 GpT
DH1 T-C 598 935 TpA
DE3 T-C 909 1038 TpG
DE3 T-C 909 1038 TpG
BG1 T-C 251 819 TpG
BG7 T-C 183 796 TpG
DD7 T-C 888 1031 TpT
DH6 T-C 888 1031 TpT
BF5 T-C 111 772 TpT
BH7 T-C 236 814 TpT
CE4 T-C 597 934 TpT
1184N CE6 A-G 379 862 ApA
DA1 A-G 617 941 ApA
DD4 A-G 844 1017 ApA
DF4 A-G 768 991 ApA
DB1 A-G 855 1020 ApC
DF4 A-G 864 1023 ApC
BE6 A-G 163 790 ApG
BH4 A-G 78 761 ApG
CC2 A-G 355 854 ApG
CC8 A-G 497 901 ApG
CE3 A-G 423 876 ApG
DB4 A-G 773 993 ApG
DC9 A-G 852 1019 ApG
DF2 A-G 858 1021 ApG
DF11 A-G 665 957 ApG
DA8 A-G 872 1026 ApT
DC8 A-G 669 958 ApT
DE4 A-G 689 965 ApT
DE12 A-G 932 1046 ApT
BA1 C-T 281 829 CpA
DC2 C-T 696 967 CpA
DF9 C-T 727 978 CpA
DB7 C-T 638 948 CpT
DE2 C-T 638 948 CpT
CE4 G-A 556 921 GpC
CC11 G-A 514 907 GpG
CF10 G-A 514 907 GpG
CA3 T-C 374 860 TpA
DE5 T-C 806 1004 TpA
DE10 T-C 717 974 TpA
DD7 T-C 921 1042 TpC
BA1 T-C 186 797 TpG
CC9 T-C 455 887 TpT
CG7 T-C 455 887 TpT








1184N DE12 T-C 901 1036 TpT
Continued DG6 G-A 629 945 GpG
DB6 T-C 925 1044 TpC
DD4 T-C 695 967 TpC
1184T BA11 A-G 174 793 ApA
BE4 A-G 174 793 ApA
DC1 A-G 625 944 ApA
DC1 A-G 728 978 ApA
DD4 A-G 626 944 ApA
DE12 A-G 854 1020 ApA
DE12 A-G 918 1041 ApA
BA5 A-G 264 823 ApC
BA11 A-G 280 829 ApC
BE4 A-G 280 829 ApC
DC12 A-T 631 946 ApC
BD2 A-G 123 776 ApG
BD9 A-G 175 794 ApG
BE8 A-G 140 782 ApG
CB4 A-G 550 919 ApG
CD12 A-G 565 924 ApG
CG4 A-G 452 886 ApG
CG4 A-G 497 901 ApG
CH10 A-G 505 904 ApG
DD1 A-G 665 957 ApG
DD2 A-G 852 1019 ApG
DE12 A-G 929 1045 ApG
DG5 A-G 781 996 ApG
DD8 A-G 835 1014 ApT
DE3 A-G 835 1014 ApT
DG5 A-G 677 961 ApT
CE4 C-T 479 895 CpA
CE4 C-T 496 901 CpA
DH4 C-T 632 946 CpA
DF8 C-T 650 952 CpC
DA11 G-A 851 1019 GpA
DB1 G-A 679 962 GpA
CD12 G-A 391 866 GpC
CD3 G-A 468 891 GpG
CG4 G-A 364 857 GpG
DD11 T-C 656 954 TpA
DE10 T-C 639 948 TpA
CH1 T-G 495 900 TpC
DB5 T-C 637 948 TpC
DC10 T-C 726 977 TpC
DG1 T-C 726 977 TpC
DG9 T-C 879 1028 TpC
CG4 T-C 576 927 TpG
DC5 T-C 744 983 TpG
DH1 T-A 778 995 TpG
BE1 T-C 100 769 TpT
CB4 T-C 485 897 TpT
CD12 T-C 427 878 TpT
DD1 T-C 645 950 TpT
DF9 T-C 888 1031 TpT
DH8 T-C 597 934 TpT
3603N BD7 A-G 169 792 ApA
CA3 A-G 564 923 ApA
BC4 A-G 264 823 ApC
BC8 A-G 288 831 ApC
BC8 A-G 264 823 ApC
BD3 A-G 200 802 ApC
BE6 A-G 253 820 ApC
BC8 A-G 264 823 ApC
BC1 A-G 163 790 ApG
BD7 A-G 69 758 ApG
BD12 A-G 154 787 ApG
CB1 A-G 353 853 ApG
BF5 A-G 218 808 ApT
BA8 C-T 203 803 CpC
BD1 C-T 29 745 CpT
CD3 G-A 340 849 GpA
BA5 G-A 42 749 GpC
CB3 G-A 457 888 GpC
CD2 G-A 370 859 GpG
CB10 T-C 582 929 TpA
BH9 T-C 226 811 TpC
CA10 T-C 464 890 TpC








3603N CB6 A-G 553 920 ApA
Continued DB3 A-G 733 980 ApA
DE12 A-G 676 961 ApA
CG7 A-G 523 910 ApC
DA8 A-G 735 980 ApC
CB6 A-G 547 918 ApG
DA9 A-G 773 993 ApG
DC9 A-G 723 976 ApG
DG10 A-G 700 969 ApG
DE2 A-G 835 1014 ApT
DF5 A-G 792 999 ApT
DH7 A-G 932 1046 ApT
CE2 C-T 465 890 CpA
DE7 C-T 790 999 CpA
DG9 C-T 922 1043 CpC
DC12 C-T 755 987 CpT
DB6 C-T 908 1038 CpT
CG8 G-A 352 853 GpA
DB10 G-A 838 1015 GpA
DB5 G-A 903 1036 GpA
DE9 G-A 895 1034 GpA
CD8 G-A 362 856 GpC
DE9 G-A 779 995 GpC
CE4 G-A 370 859 GpG
DD12 G-A 715 974 GpG
CH6 T-C 519 908 TpA
CD3 T-C 372 859 TpC
CB6 T-C 571 926 TpC
DA7 T-C 613 940 TpC
DD12 T-C 754 987 TpC
DE5 T-C 849 1018 TpG
CC1 T-C 597 934 TpT
DC6 T-C 924 1043 TpT
DG5 T-C 603 936 TpT
3603T CF10 A-G 338 848 ApA
CH6 A-G 417 874 ApA
DD3 G-A 917 1041 ApA
DD8 A-G 746 984 ApA
CC9 A-G 541 916 ApC
CE5 A-G 360 855 ApC
CH2 A-G 360 855 ApC
CH6 A-G 439 882 ApC
DD8 A-G 631 946 ApC
DF7 A-G 927 1044 ApC
CC12 A-G 419 875 ApG
CF10 A-G 550 919 ApG
DC6 A-G 665 957 ApG
DE2 A-G 721 976 ApG
DF3 A-G 723 976 ApG
CA9 A-G 587 931 ApT
DA7 A-C 860 1022 ApT
DA9 A-G 713 973 ApT
DC2 A-G 860 1022 ApT
DD12 A-G 792 999 ApT
DG6 A-G 660 955 ApT
DG8 A-G 707 971 ApT
DF8 C-T 810 1005 CpC
CC9 C-T 326 844 CpT
CC6 G-A 566 924 GpA
CD10 G-A 422 876 GpA
DC9 G-A 642 949 GpC
CF11 G-A 498 901 GpG
DB9 G-A 782 996 GpT
DD12 G-A 878 1028 GpT
CC11 T-C 372 859 TpC
DH8 T-C 748 985 TpC
CE3 T-C 539 915 TpG
CC6 T-C 411 872 TpT
DE5 T-C 645 950 TpT
1962N BB5 A-G 170 792 ApG
BB10 A-G 318 841 ApG
CA9 A-G 353 853 ApG
CA10 A-G 346 851 ApG
CA5 A-G 367 858 ApT
BA12 C-T 265 824 CpC
BB9 T-C 321 842 TpA
CA1 T-C 374 860 TpA








1962N DG10 A-G 768 991 ApA
Continued CC8 A-G 405 870 ApG
DG4 A-G 665 957 ApG
CB5 G-A 515 907 GpG
DG5 T-C 748 985 TpC
BB7 T-C 316 841 TpT
CC10 T-C 414 873 TpT
1962T BF9 A-T 169 792 ApA
CG3 A-G 500 902 ApA
DB10 A-G 734 980 ApA
DD10 A-G 768 991 ApA
CG8 A-G 380 862 ApC
DC4 A-G 662 956 ApC
BF10 A-G 292 833 ApG
BH1 A-G 154 787 ApG
BE9 C-T 64 757 CpA
DA9 C-T 696 967 CpA
DA12 C-T 827 1011 CpA
DB9 C-T 827 1011 CpA
DC3 C-T 916 1041 CpA
BH8 C-T 137 781 CpC
CG2 C-T 413 873 CpT
DC8 G-A 808 1005 GpC
BG7 G-A 244 817 GpG
DD8 G-A 715 974 GpG
BF3 G-A 185 797 GpT
DB11 G-A 774 993 GpT
DD8 G-A 701 969 GpT
DE8 G-A 635 947 GpT
BH1 T-C 219 808 TpA
DC2 T-C 784 997 TpA
DD6 T-C 857 1021 TpA
DE4 T-C 771 992 TpA
BE9 T-G 298 835 TpC
CF6 T-C 535 914 TpG
DC4 T-C 902 1036 TpG
DC5 T-C 634 947 TpG
DC5 T-C 648 951 TpG
DC12 T-C 762 989 TpG
BF11 T-C 189 798 TpT
BG5 T-C 85 764 TpT
BG5 T-C 261 822 TpT
DA9 T-G 924 1043 TpT
DD7 T-C 636 947 TpT
3116N DB7 A-G 653 953 ApA
DF1 A-G 205 804 ApA
DG5 A-G 844 1017 ApA
DH10 A-G 931 1046 ApA
DC9 A-G 652 953 ApA
DE8 A-G 662 956 ApC
DB8 A-G 667 958 ApG
DE8 A-G 697 968 ApG
DG2 A-G 697 968 ApG
DH6 A-G 721 976 ApG
DB2 A-G 807 1004 ApG
DD5 A-G 852 1019 ApG
DA1 A-G 860 1022 ApT
DF8 A-G 817 1008 ApT
DC9 A-G 893 1033 ApT
DG9 A-G 893 1033 ApT
DD1 C-T 906 1037 CpT
CA11 G-A 376 861 GpG
DD8 G-A 850 1019 GpG
DA10 G-A 782 996 GpT
DA2 T-C 857 1021 TpA
DG1 T-C 751 986 TpA
DH1 T-C 699 968 TpA
DA8 T-C 695 967 TpC
DE3 T-C 831 1012 TpC
DH11 T-C 695 967 TpC
DB2 T-C 846 1017 TpG
DE5 T-C 775 994 TpT
3116T BB8 A-G 109 772 ApC
BB8 C-T 242 816 CpT
BD12 G-A 308 838 GpA
BF4 G-A 31 746 GpG
BF7 T-C 284 830 TpG








3116T BF7 T-G 260 822 TpT
Continued CB9 A-G 552 919 ApA
CF6 A-G 359 855 ApA
CG4 A-G 500 902 ApA
DA7 A-G 734 980 ApA
DH9 A-G 734 980 ApA
DD5 A-G 854 1020 ApA
DB5 A-G 927 1044 ApC
DG3 A-G 864 1023 ApC
DD11 A-G 735 980 ApC
CB6 A-G 355 854 ApG
CG6 A-G 423 876 ApG
DA9 A-G 929 1045 ApG
DH6 A-G 899 1035 ApG
DA7 A-G 680 962 ApT
BH9 C-T 160 789 CpA
DC8 C-T 632 946 CpA
DE5 C-T 832 1013 CpA
DH9 C-T 928 1045 CpA
CD6 C-T 450 885 CpC
CH7 C-T 449 885 CpC
CG4 C-T 361 856 CpG
BH10 C-T 99 768 CpT
CD9 G-A 547 918 GpA
CG6 G-A 472 893 GpA
DB11 G-A 763 990 GpA
DF6 G-A 930 1045 GpA
DG6 G-A 930 1045 GpA
DC9 G-A 892 1033 GpA
CB10 G-A 556 921 GpC
DD4 G-A 724 977 GpG
DB10 G-A 704 970 GpT
DE12 G-A 701 969 GpT
DG8 G-A 704 970 GpT
DA2 T-C 806 1004 TpA
DB12 T-C 861 1022 TpA
DC12 T-C 726 977 TpC
CG2 T-C 533 913 TpG
BH10 T-C 271 826 TpT
CH9 T-C 427 878 TpT
DG10 T-C 636 947 TpT
DD11 T-C 783 996 TpT
1974N BA3 A-G 253 820 ApC
BA5 A-G 78 761 ApG
BA5 A-G 307 838 ApG
BB4 A-G 128 778 ApT
BE1 A-G 102 769 ApT
BB6 C-T 246 817 CpA
BG5 C-T 151 786 CpG
BG7 C-T 297 834 CpT
BH3 T-C 255 820 TpG
CC2 T-C 444 883 TpG
BB6 T-C 194 800 TpT
1974T BD4 A-G 66 757 ApA
DE10 A-G 619 942 ApA
DG3 A-G 719 975 ApA
DH11 A-G 719 975 ApA
BB8 A-G 75 760 ApG
BC3 A-G 75 760 ApG
BC10 A-G 75 760 ApG
BD1 A-G 75 760 ApG
BD4 A-G 81 762 ApG
BG12 A-G 81 762 ApG
DE2 A-G 677 961 ApT
DF8 A-G 792 999 ApT
BC4 C-T 47 751 CpT
BD6 C-T 47 751 CpT
BA7 G-A 214 807 GpA
DH4 G-A 694 967 GpT
BB4 T-G 181 796 TpA
BH11 T-C 27 744 TpC
BH5 T-C 30 745 TpG
533N A1 A-G 417 874 ApA
B8 A-G 169 792 ApA
B3 A-G 140 782 ApG
A7 A-G 581 929 ApT
B5 C-T 430 879 CpA








533N G9 A-G 359 855 ApA
Continued G10 A-G 169 792 ApA
H6 A-G 68 758 ApA
D1 A-G 280 829 ApC
D2 A-G 230 812 ApC
G9 A-G 202 803 ApC
C8 A-G 69 758 ApG
D1 A-G 405 870 ApG
D3 A-G 339 848 ApG
A9 A-G 508 905 ApG
D11 A-G 89 765 ApT
C4 A-G 669 958 ApT
C7 C-T 168 791 CpA
H8 C-T 363 856 CpG
H1 C-T 805 1004 CpT
G3 G-A 162 789 GpA
C1 G-A 741 982 GpA
D9 G-A 799 1002 GpC
A1 G-A 224 810 GpG
G5 G-A 283 830 GpT
G9 T-C 639 948 TpA
C1 T-C 50 752 TpT
533T B4 A-G 552 919 ApA
C10 A-G 66 757 ApA
C2 A-G 230 812 ApC
C2 A-G 631 946 ApC
D7 A-G 864 1023 ApC
B3 A-G 81 762 ApG
B7 A-G 95 767 ApG
D1 A-G 95 767 ApG
F10 A-G 896 1034 ApG
D4 A-G 554 920 ApT
B2 C-T 43 750 CpC
D7 C-T 738 981 CpT
E3 G-A 124 777 GpA
H9 G-A 164 790 GpA
G5 C-T 802 1003 GpA
C2 G-A 425 877 GpT
A7 T-C 699 968 TpA
E5 T-C 387 864 TpC
A10 T-C 748 985 TpC
G2 T-C 889 1032 TpC
2494N A7 A-G 64 757 ApA
E2 A-G 312 839 ApA
H8 A-G 393 866 ApA
H8 A-G 393 866 ApA
ME10 A-G 758 988 ApA
A7 A-G 864 1023 ApC
MB10 A-G 523 910 ApC
MA10 A-G 548 918 ApG
F9 A-G 89 765 ApT
MF10 A-G 341 849 ApT
B6 C-T 35 747 CpA
B9 C-T 201 802 CpA
A9 G-A 422 876 GpA
MH9 G-A 837 1014 GpG
A7 G-A 425 877 GpT
A9 G-A 716 974 GpT
B6 T-C 135 780 TpC
C10 T-C 493 900 TpC
A10 T-C 748 985 TpC
B6 T-C 573 926 TpG
B9 T-C 243 816 TpG
E10 T-C 30 745 TpG
F12 T-C 443 883 TpG
F12 T-C 444 883 TpG
D5 T-C 316 841 TpT
E9 T-C 411 872 TpT
2494T C8 A-G 624 943 ApA
C2 A-G 380 862 ApC
D7 A-G 531 912 ApC
B7 A-G 471 892 ApG
C2 A-G 161 789 ApG
B5 A-G 119 775 ApT
B7 A-G 341 849 ApT
C12 A-G 119 775 ApT
C1 C-T 395 867 CpA








2494T B10 A-G 733 980 ApA
Continued D8 A-G 733 980 ApA
F10 A-G 733 980 ApA
G4 A-G 380 862 ApC
F2 A-G 346 851 ApG
G4 A-G 161 789 ApG
H3 A-G 161 789 ApG
B7 A-G 767 991 ApG
B1 A-G 833 1013 ApT
C8 A-G 761 989 ApT
D1 A-G 640 949 ApT
C4 C-T 290 832 CpC
D8 C-T 482 896 CpC
H4 C-T 290 832 CpC
A2 C-T 880 1029 CpT
H9 G-A 377 861 GpC
F11 T-C 34 747 TpC
B1 T-C 726 977 TpC
E8 T-C 213 806 TpG
H4 T-C 714 973 TpG
C4 T-C 714 973 TpG
D6 T-C 756 987 TpG
2486N C8 A-G 118 775 ApA
MH1 A-G 68 758 ApA
A2 A-G 125 777 ApC
C3 A-G 125 777 ApC
E10 A-G 125 777 ApC
G4 A-G 607 938 ApC
G8 A-G 607 938 ApC
H6 A-G 607 938 ApC
D10 A-G 607 938 ApC
G12 A-G 607 938 ApC
A1 A-G 405 870 ApG
A11 A-G 405 870 ApG
B8 A-G 405 870 ApG
B11 A-G 81 762 ApG
D4 A-G 161 789 ApG
D10 A-G 339 848 ApG
E11 A-G 405 870 ApG
G4 A-G 339 848 ApG
G8 A-G 339 848 ApG
H6 A-G 339 848 ApG
C12 A-G 405 870 ApG
C10 C-T 315 840 CpT
E3 C-T 315 840 CpT
E4 C-T 373 860 CpT
H8 C-T 315 840 CpT
B12 G-A 577 928 GpC
A5 T-C 789 998 TpC
C10 T-C 426 877 TpT
E3 T-C 426 877 TpT
H8 T-C 426 877 TpT
C10 T-C 775 994 TpT
2486T E7 A-G 759 988 ApA
E3 A-G 116 774 ApC
H6 A-G 541 916 ApC
A8 A-G 462 889 ApG
H3 A-G 341 849 ApT
B3 A-G 484 897 ApT
G3 C-T 385 864 CpA
D7 G-A 106 771 GpA
E7 G-A 285 830 GpT
F2 T-C 103 770 TpC
A8 T-G 539 915 TpG
A8 T-C 348 851 TpT
2491N A7 A-G 734 980 ApA
A3 A-G 660 955 ApT
C10 A-G 587 931 ApT
C11 C-T 512 906 CpT
A2 G-A 526 911 GpA
B6 G-A 642 949 GpC
C10 T-C 876 1027 TpA
D10 T-C 754 987 TpC
A4 T-C 546 917 TpG
C3 T-C 576 927 TpG
A4 T-C 330 845 TpT
A9 T-C 672 959 TpT








2491N MC8 A-C 791 999 ApA
Continued F2 A-G 541 916 ApC
F6 A-G 864 1023 ApC
F2 A-G 431 879 ApG
F6 A-G 665 957 ApG
ME7 A-G 565 924 ApG
G7 A-G 660 955 ApT
G8 A-G 554 920 ApT
H12 A-G 660 955 ApT
MA8 C-T 80 762 CpA
F6 G-A 787 998 GpG
E7 T-C 295 834 TpC
E10 T-C 754 987 TpC
E6 T-C 576 927 TpG
G12 T-C 546 917 TpG
H8 T-C 546 917 TpG
D4 T-C 330 845 TpT
E6 T-C 330 845 TpT
F4 T-C 672 959 TpT
G12 T-C 330 845 TpT
H8 T-C 330 845 TpT
2491T A8 A-G 398 868 ApA
D6 A-G 625 944 ApA
D10 A-G 65 757 ApA
A8 A-G 759 988 ApA
H6 A-G 735 980 ApC
A8 A-G 353 853 ApG
A9 A-G 568 925 ApG
A10 A-G 292 833 ApG
B5 A-G 611 939 ApG
D9 A-G 223 810 ApG
E8 A-G 309 838 ApG
B5 A-G 545 917 ApT
H10 A-G 932 1046 ApT
H1 C-T 644 950 CpT
G1 G-A 930 1045 GpA
A11 G-A 370 859 GpG
G6 G-A 536 914 GpT
H4 T-C 279 828 TpA
A2 T-C 325 844 TpC
B9 T-C 695 967 TpC
H8 T-C 135 780 TpC
H6 T-C 605 937 TpC
B12 T-C 41 749 TpG
B12 T-C 634 947 TpG
C9 T-C 537 914 TpG
A7 T-C 756 987 TpG
A10 A-G 840 1015 TpG
B3 T-C 825 1010 TpG
D1 T-C 894 1033 TpG
D10 T-C 634 947 TpG
F1 T-C 634 947 TpG
F9 T-C 555 920 TpG
G3 T-C 825 1010 TpG
H6 A-G 539 915 TpG
B2 T-C 684 963 TpT
D7 T-C 348 851 TpT
B7 T-C 775 994 TpT
E8 T-C 316 841 TpT
H3 T-C 645 950 TpT
2490N A4 A-G 345 850 ApA
F4 A-G 157 788 ApA
G3 A-G 65 757 ApA
G6 A-G 83 763 ApA
D7 A-G 380 862 ApC
E3 A-G 277 828 ApC
D11 A-G 543 916 ApG
E7 A-G 119 775 ApT
D3 C-T 296 834 CpC
D11 C-T 363 856 CpG
D7 C-T 299 835 CpT
G7 G-A 124 777 GpA
B6 G-A 760 989 GpA
D11 T-C 641 949 TpG
F4 T-C 714 973 TpG
F6 T-C 902 1036 TpG
D6 T-C 196 801 TpT








2490N MC6 A-G 552 919 ApA
Continued MC6 A-G 202 803 ApC
ME5 A-G 523 910 ApC
H3 A-G 913 1040 ApG
H9 A-G 313 840 ApG
MA6 A-G 346 851 ApG
MC6 A-G 667 958 ApG
F10 A-G 320 842 ApT
F10 A-G 660 955 ApT
G5 T-C 806 1004 TpA
MF6 T-C 295 834 TpC
G6 T-C 765 990 TpG
MA6 T-C 444 883 TpG
F5 T-C 901 1036 TpT
2490T A8 A-G 62 756 ApA
B9 A-G 816 1007 ApA
G5 A-G 631 946 ApC
A4 A-G 905 1037 ApC
A8 A-G 794 1000 ApC
A11 A-G 503 903 ApC
C9 A-G 548 918 ApG
D1 A-G 105 770 ApG
E2 A-G 508 905 ApG
F6 A-G 81 762 ApG
D3 A-G 723 976 ApG
D4 A-G 913 1040 ApG
E11 A-G 919 1042 ApG
B9 A-G 554 920 ApT
C12 A-G 454 887 ApT
B10 A-G 764 990 ApT
D3 C-T 532 913 CpA
A5 G-A 826 1011 GpC
B8 G-A 915 1040 GpC
B1 T-C 101 769 TpA
A1 T-C 325 844 TpC
B6 T-C 372 859 TpC
B6 T-G 486 897 TpC
D8 T-C 325 844 TpC
A9 T-C 739 982 TpC
B10 T-C 333 846 TpG
B9 T-C 825 1010 TpG
D3 T-C 427 878 TpT
E4 T-C 40 749 TpT
B11 T-C 924 1043 TpT














APC 4 529 170 GAT del4b stop Fr. Asp Fr. MD
APC 4 529 170 GAT del4b stop Fr. Asp Fr. MD
APC 4 541 174 TTA ins2b stop Fr. Leu Fr. MD
APC 4 550 177 AAT dellb stop Fr. Asn Fr. MD
APC 5 561 181 CAA TAA C->T Ts. no Gin stop MD
APC 6 666 216 CGA TGA C->T Ts. yes Arg stop MD
APC 6 666 216 CGA TGA C->T Ts. yes Arg stop MD
APC 6 714 232 CGA TGA C->T Ts. yes Arg stop MD
APC 6 749 243 GAG ins2c ? ? Glu ? MD
APC 6 757 232 CGA TGA C->T Ts Yes Arg Stop 81
APC 7 793 244 AGG del2a Stop at
250
Fr. Arg Fr. 8
APC 8 926 302 CGA TGA C->T Ts. yes Arg stop MD
APC 10 1374 452 GTT del2a stop Fr. Val Fr. MD
APC 15 1465 482 GAC inslb stop Fr. Asp Fr. MD
APC 11 1480 473 CAG della Stop at
497
Fr. Gin Fr. 25
APC 11 1555 498 AGA dell Stop at
2844
Fr. Arg Fr. 81
APC 12 1579 520 TGC TGA C->A Tv. yes Cys stop MD
APC 13 1680 554 CGA TGA C->T Ts. yes Arg stop MD
APC 13 1680 554 CGA TGA C->T Ts. yes Arg stop MD
APC 14 1773 585 CTC della stop Fr. Leu Fr. MD
APC 14 1773 591 GCC dellc stop Fr. Ala Fr. MD
APC 14 1895 625 CAG del4c stop Fr. Gin Fr. MD
APC 14 1968 650 GAG TAG G->T Tv. no Glu stop MD
APC 15 2035 658 GAG del2c Stop at
672
Fr. Glu Fr. 153
APC 15 2186 722 AGT dellc stop Fr. Ser Fr. MD
APC 15 2277 753 CAT insla stop Fr. His Fr. MD
APC 15 2312 764 TTA Inslc stop Fr. Leu Fr. MD
APC 15 2593 844 TCT della Stop at
860
Fr. Ser Fr. 2
APC 15 2622 868 GAA TAA G->T Tv. no Gin stop MD
APC 15 2646 876 CGA TGA C->T Ts. yes Arg stop MD
APC 15 2646 876 CGA TGA C->T Ts. yes Arg stop MD
APC 15 2689 876 CGA TGA C->T Ts Yes Arg Stop 84
APC 15 2815 932 TCA TGA C->G Tv. no Ser stop MD
APC 15 2825 935 TAC dellc stop Fr. Tyr Fr. MD
APC 15 2983 974 GGT inslc Stop at
984
Fr. Gly Fr. 153
APC 15 3063 1000 TAC TAA C->A Tv No Tyr Stop 153
APC 15 3123 1035 CAG TAG C->T Ts. yes Gin stop MD












APC 15 3203 1061 AAA del5c stop Fr. Lys Fr. MD
APC 15 3203 1061 AAA del5c stop Fr. Lys Fr. MD
APC 15 3209 3209 AGT del4c stop Fr. Ser Fr. MD
APC 15 3220 1067 CAA del2b stop Fr. Gin Fr. MD
APC 15 3226 1055 ATA del5b Stop at
1057
Fr. lie Fr. 101
APC 15 3244 1061 AAA del5a Stop at
1062
Fr. Lys Fr. 7
APC 15 3244 1061 AAA del5a Stop at
1062
Fr. Lys Fr. 7
APC 15 3244 1061 AAA del5a Stop at
1062
Fr. Lys Fr. 10
APC 15 3244 1061 AAA del5a Stop at
1062
Fr. Lys Fr. 13
APC 15 3244 1061 AAA del5a Stop at
1062
Fr. Lys Fr. 25
APC 15 3244 1061 AAA del5a Stop at
1062
Fr. Lys Fr. 100
APC 15 3247 1062 CAA del4a Stop at
1124
Fr. Gin Fr. 81
APC 15 3250 1063 AGT del4b Stop at
1124
Fr. Ser Fr. 19
APC 15 3259 1066 AGA del2c Stop at
1079
Fr. Arg Fr. 12
APC 15 3262 1067 CAA TAA C->T Ts No Gin Stop 153
APC 15 3360 1114 CGA TGA C->T Ts. yes Arg stop MD
APC 15 3394 1125 GTA inslb stop Fr. Val Fr. MD
APC 15 3394 1125 GTA inslb stop Fr. Val Fr. MD
APC 15 3571 1170 AAA ins1 Ins Fr. Lys Fr. 84
APC 15 3595 1192 AAA del4b stop Fr. Asn Fr. MD
APC 15 3598 1193 CAG dellb stop Fr. Gin Fr. MD
APC 15 3838 1259 ATA del2c Stop at
1274
Fr. lie Fr. 12
APC 15 3946 1309 GAA del5b stop Fr. Glu Fr. MD
APC 15 3946 1309 GAA del5b stop Fr. Glu Fr. MD
APC 15 3946 1309 GAA del5b stop Fr. Glu Fr. MD
APC 15 3946 1309 GAA del5b stop Fr. Glu Fr. MD
APC 15 3946 1309 GAA del5b stop Fr. Glu Fr. MD
APC 15 3946 1309 GAA del5b stop Fr. Glu Fr. MD
APC 15 3988 1309 GAA del5 Stop at
2844
Fr. Glu Fr. 2
APC 15 3988 1309 GAA de!5 Stop at
2844
Fr. Glu Fr. 7
APC 15 3988 1309 GAA del5 Stop at
2844
Fr. Glu Fr. 13
APC 15 3988 1309 GAA de!5 Stop at
2844












APC 15 3988 1309 GAA del5 Stop at
2844
Fr. Glu Fr. 25
APC 15 3988 1309 GAA del5 Stop at
2844
Fr. Glu Fr. 25
APC 15 3988 1309 GAA del5 Stop at
2844
Fr. Glu Fr. 100
APC 15 3988 1309 GAA del5 Stop at
2844
Fr. Glu Fr. 100
APC 15 3988 1309 GAA del5 Stop at
2844
Fr. Glu Fr. 100
APC 15 3988 1309 GAA del5 Stop at
2844
Fr. Glu Fr. 100
APC 15 3988 1309 GAA del5 Stop at
2844
Fr. Glu Fr. 100
APC 15 4033 1324 CCA dell Stop at
2844
Fr. Pro Fr. 81
APC 15 4152 1378 CAG TAG C->T Ts. no Gin stop MD
APC 15 4162 1367 CAG TAG C->T Ts No Gin Stop 100
APC 15 4206 1396 TTT della stop Fr. Phe Fr. MD
APC 15 4210 1398 AGT della stop Fr. Ser Fr. MD
APC 15 4211 1397 GAG TAG G->T Tv. no Glu stop MD
APC 15 4238 1392 TCA TAA C->A Tv No Ser Stop 153
APC 15 4368 1450 CGA TGA C->T Ts. yes Arg stop MD
APC 15 4408 1463 AGA del2a stop Fr. Arg Fr. MD
APC 15 4417 1366 GCT del4b stop Fr. Ala Fr. MD
APC 15 4453 1464 GAG del2a Stop at
1467
Fr. Glu Fr. 100
APC 15 4660 1533 AAT insla Stop at
1536
Fr. Asn Fr. 96
APC 15 5519 1833 AGA TGA A->T Tv. no Arg stop MD
APC 15 5777 1919 AAT del16c stop Fr. Asn Fr. MD
PAX6 In7 -108 dell 78 167
PAX6 In7 -108 del178 167
PAX6 ln5-2 -19 G->C 167
PAX6 In9 -16 de!21 167
PAX6 In8 -6 T->A Tv 167
PAX6 In11 -2 A->G Ts 167
PAX6 In11 -2 A->G Ts 167
PAX6 in5-2 -2 A->G 167
PAX6 In8 -2 C->A Tv 167
PAX6 In9 -1 G->A Ts 167
PAX6 In10 1 G->C Tv 167
PAX6 In6 1 G->A Ts 167
PAX6 In6 1 G->A Ts 167
PAX6 In6 1 G->A Ts 167
PAX6 In6 1 G->C Tv 167












PAX6 In6 1 G->T Tv 167
PAX6 In10 2 T->G Tv 167
PAX6 In5-1 2 T->C 167
PAX6 In6 2 Ins1 Ins 167
PAX6 In6 2 Ins1 Ins 167
PAX6 Ex5a 20 7 GTC GAC T->A Tv Val Asp 167
PAX6 Ex4 363 1 ATG GTG A->G Ts No Arg Val 167
PAX6 Ex5 412 17 AAC AGC A->G Ts No Asn Ser 167







PAX6 Ex5 447 29 ATT GTT A->G Ts No Arg Val 167
PAX6 Ex5 448 29 ATT AGT T->G Tv No lie Ser 167
PAX6 Ex5 468 35 AGC dell Fr. Ser Fr. 167
PAX6 Ex5 471 37 GCC del9 Fr. Ala Fr. 167
PAX6 Ex5 472 37 GCC ins31 Ins Fr. Ala Fr. 167
PAX6 Ex5 479 39 CGT del970 Fr. Arg Fr. 167
PAX6 Ex5 482 40 TGC ins41 Ins Fr. Cys Fr. 167
PAX6 Ex5 482 40 GCG CAG C->A Tv yes Cys Gin 167
PAX6 Ex5 482 40 TGC TGA C->A Tv yes Arg Stop 167
PAX6 Ex5 493 44 CGA CAA G->A Ts yes Arg Gin 167
PAX6 Ex5 502 47 CAG CGG A->G Ts No Gin Arg 167
PAX6 Ex6 520 53 GTG del2 Stop at 54 Fr. Val Fr. 167
PAX6 Ex6 526 55 AAA del7 Fr. Lys Fr. 167
PAX6 Ex6 529 56 ATT ACT T->C Ts No Arg Thr 167
PAX6 Ex6 530 56 ATT dell Fr. Tyr Fr. 167
PAX6 Ex6 545 61 TAC TAA C->A Tv yes Arg Stop 167
PAX6 Ex6 561 67 AGA TGA A->T Tv No Pro Ser 167
PAX6 Ex6 564 68 CCC TCC C->T Ts No Gly Asp 167
PAX6 Ex6 580 73 GGT GAT G->A Ts No lie Arg 167
PAX6 Ex6 622 87 ATA AGA T->G Tv No Arg 167






PAX6 Ex6 646 95 CCG ins1 Stop at
116
Fr. Pro Fr. 167
PAX6 Ex6 669 103 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex6 693 111 CTC ins1 Ins Fr. Leu Fr. 167
PAX6 Ex6 693 111 CTC dell Stop at
124
Fr. Leu Fr. 167
PAX6 Ex6 700 113 ACC ins19 Ins Fr. Thr Fr. 167
PAX6 Ex6 715 118 CCA ins5 Ins Fr. Pro Fr. 167
PAX6 Ex6 719 119 AGC AGG C->G Tv yes Ser Arg 167
PAX6 Ex7 729 123 ATA Ins7 Stop at
132
Fr. lie Fr. 167
PAX6 Ex7 765 135 CAA TAA C->T Ts No Arg Stop 167
PAX6 Ex7 765 135 CAA TAA C->T Ts No Arg Stop 167












PAX6 Ex7 812 150 AAC dell Stop at
186
Fr. Asn Fr. 167
PAX6 Ex7 816 152 CAG TAG C->T Ts No Arg Stop 167
PAX6 Ex7 829 156 TGG dell Stop at
206
Fr. Trp Fr. 167
PAX6 Ex7 862 167 TCG TGA CG->GA yes Arg Stop 167
PAX6 Ex8 901 180 CAG dell Stop Fr. Glu Fr. 167
PAX6 Ex8 903 181 GAA TAA G->T Tv No Arg Stop 167
PAX6 Ex8 957 199 GAG TAG G->T Tv No Arg Stop 167
PAX6 Ex8 969 203 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex8 969 203 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex8 969 203 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex8 969 203 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex8 975 205 CAG TAG C->T Ts No Arg Stop 167
PAX6 Ex9 1051 230 GAG dell Stop at
244
Fr. Glu Fr. 167
PAX6 Ex9 1071 237 GTG del2 Stop at
251
Fr. Val Fr. 167
PAX6 Ex9 1072 237 GTG del2 Stop Fr. Val Fr. 167
PAX6 Ex9 1080 240 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex9 1080 240 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex9 1080 240 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex9 1080 240 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex9 1080 240 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex9 1080 240 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex9 1080 240 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex9 1103 247 ATA dell 1 Stop Fr. lie Fr. 167
PAX6 Ex9 1127 255 CAG G->T Tv No Gin His 167
PAX6 Ex10 1135 258 TTT TCT T->C Ts No Phe Ser 167
PAX6 Ex10 1143 261 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex10 1143 261 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex10 1143 261 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex10 1143 261 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex10 1161 267 AGA TGA A->T Tv yes Arg Stop 167
PAX6 Ex10 1180 273 AAT ins1 Stop Fr. Asn Fr. 167
PAX6 Ex10 1201 280 AAC dell Stop Fr. Asn Fr. 167
PAX6 Ex10 1210 283 AGT ins2 Stop at
317
Fr. Ser Fr. 167
PAX6 Ex10 1237 292 AGC ATC G->T Tv yes Ser lie 167
PAX6 Ex10 1251 297 CAA TAA C->T Ts No Arg Stop 167
PAX6 Ex10 1252 297 CAA dell Stop Fr. Gin Fr. 167
PAX6 Ex10 1263 301 CAA TAA C->T Ts No Arg Stop 167
PAX6 Ex11 1311 317 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex11 1311 317 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex11 1311 317 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex11 1311 317 CGA TGA C->T Ts yes Arg Stop 167
PAX6 Ex11 1311 317 CGA TGA C->T Ts yes Arg Stop 167
Mutation WT Mutant WT Mutant
Gene Exon position Codon codon codon Event Type CpG AA AA Ref
PAX6 Ex12 1426 355 TCC ins5 Stop Fr. Ser Fr. 167
PAX6 Ex12 1449 363 TCG CCG T->C Ts No Ser Pro 167
PAX6 Ex12 1495 378 CAG CGG A->G Ts No Gin Arg 167
PAX6 Ex12 1503 381 ATG GTG A->G Ts No Arg Val 167
PAX6 Ex12 1513 384 CAG del4 Stop Fr. Gin Fr. 167
PAX6 Ex12 1533 391 ACC GCC A->G Ts No Thr Ala 167
PAX6 Ex13 1601 413 GAT dell Stop Fr. Asp Fr. 167
PAX6 Ex13 1627 422 CAG CGG A->G Ts No Gin Arg 167
PAX6 Ex13 1630 423 TAA TTA A->T Tv No Ter Leu 167
PAX6 Ex13 1630 423 TAA TTA A->T Tv No Ter Leu 167
PAX6 Ex13 1630 423 TAA TTA A->T Tv No Ter Leu 167
PAX6 Ex13 1630 423 TAA TTA A->T Tv No Ter Leu 167
PAX6 Ex13 1630 423 TAA TTA A->T Tv No Ter Leu 167
PAX6 Ex13 1630 423 TAA TTA A->T Tv No Ter Leu 167
HBB 1 125 25 GGT GTT G->T Tv No Gly Val 168
HBB 1 134 28 GCC GAC C->A Tv No Ala Asp 168
HBB 1 134 28 GCC GAC C->A Tv No Ala Asp 168
HBB 1 137 29 CTG CAG T->A Tv No Leu Gin 168
HBB 1 137 29 CTG CCG T->C Ts No Leu Pro 168
HBB 1 137 29 CTG CCG T->C Ts No Leu Pro 168
HBB 1 137 29 CTG CCG T->C Ts No leu Pro 168
HBB 2 149 33 CTG CGG T->G Tv No Leu Arg 168
HBB 2 149 33 CTG CCG T->C Ts No Leu Pro 168
HBB 2 149 33 CTG CCG T->C Ts No Leu Pro 168
HBB 2 178 43 TTT CTT T->C Ts No Phe Leu 168
HBB 2 179 43 TTT TCT T->C Ts No Phe Ser 168
HBB 2 179 43 TTT TCT T->C Ts No Phe Ser 168
HBB 2 179 43 TTT TCT T->C Ts No Phe Ser 168
HBB 2 179 43 TTT TCT T->C Ts No Phe Ser 168
HBB 2 241 64 CAT TAT C->T Ts No His Tyr 168
HBB 2 241 64 CAT TAT C->T Ts No His Tyr 168
HBB 2 241 64 CAT TAT C->T Ts No His Tyr 168
HBB 2 241 64 CAT TAT C->T Ts No His Tyr 168
HBB 2 241 64 CAT TAT C->T Ts No His Tyr 168
HBB 2 241 64 CAT TAT C->T Ts No His Tyr 168
HBB 2 241 64 CAT TAT C->T Ts No His Tyr 168
HBB 2 242 64 CAT CCT A->C Tv No His Pro 168
HBB 2 247 99 GTG GGG T->G Tv No Val Gly 168
HBB 2 250 67 AAA GAA A->G Ts No Lys Glu 168
HBB 2 254 68 GTG GAG T->A Tv No Val Asp 168
HBB 2 254 68 GTG CAG T->A Tv No Val Asp 168
HBB 2 254 68 GTG GAG T->A Tv No Val Glu 168
HBB 2 257 69 CTC CCC T->C Ts No Leu Pro 168
HBB 2 266 72 TTT TCT T->C Ts No Phe Ser 168
HBB 2 296 82 CTC CGC T->G Tv No Leu Arg 168
HBB 2 308 86 TTT TCT T->C Ts No Phe Ser 168
HBB 2 317 89 CTG CCG T->C Ts No Leu Pro 168
Mutation WT Mutant WT Mutant
Gene Exon position Codon codon codon Event Type CpG AA AA Ret
HBB 2 317 89 CTG CCG T->C Ts No Leu Pro 168
HBB 2 326 92 CTG CCG T->C Ts No Leu Pro 168
HBB 2 328 93 CAC TAC C->T Ts No His Tyr 168
HBB 2 328 93 CAC TAC C->T Ts No His h- 168
HBB 2 330 93 CAC CAG/A C->A/G Tv No His Gin 168
HBB 2 346 99 GTG ATG G->A Ts Yes Val Met 168
HBB 2 346 99 GTG ATG G->A Ts Yes Val Met 168
HBB 2 346 99 GTG ATG G->A Ts Yes Val Met 168
HBB 2 346 99 GTG ATG G->A Ts Yes Val Met 168
HBB 2 346 99 GTG ATG G->A Ts Yes Val Met 168
HBB 3 371 107 CTG CCG T->C Ts No Leu Pro 168
HBB 3 371 107 CTG CCG T->C Ts No Leu Pro 168
HBB 3 371 107 CTG CCG T->C Ts No Leu Pro 168
HBB 3 371 107 CTG CCG T->C Ts No Leu Pro 168
HBB 3 397 116 GCC CCC G->C Tv No Ala Pro 168
HBB 3 476 142 CTG CGG T->G Tv No Leu Arg 168
HBB 3 478 143 GCC CCC G->C Tv No Ala Pro 168
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